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ABSTRACT 
The transforming growth factor beta (TGF) pathway has been conserved 
throughout evolution and plays important roles in tissue homeostasis. 
Dysregulation of the TGF pathway has been implicated in a number of 
disorders, including cancer, fibrosis, and vascular conditions. The signalling 
potential of the TGF pathway is regulated by the route of internalization of its 
cell-surface receptors: Receptors internalized by clathrin-mediated endocytosis 
propagate signal transduction while those internalized by membrane rafts are 
targeted for degradation. Given the importance of trafficking of the TGF 
receptors to signal propagation, this thesis focuses on evaluating proteins which 
direct TGF receptor internalization and trafficking. Initial work in this thesis 
shows that the extracellular domain of the type II TGF receptor (TRII) and the 
glycosylation state of the cell are important factors in permitting membrane-raft 
localization of TRII. Using this information I assessed the ability of TRIII, a 
glycosylated cell surface protein, to direct TRII internalization. I found that 
TRIII increases membrane-raft independent internalization of TRII, increases 
TRII/TRI complex half-life, and basal TGF signalling. I next assessed the role 
of arrestin2, a protein which interacts with TRIII, in regulating TRII trafficking 
and signalling. I show that arrestin2 interacts with TRII and traffics with TRII 
to the early endosome to increase Smad-dependent signalling. Also, I show that 
depletion of arrestin2 increases Smad-independent signal transduction. In the 
last data chapter of this thesis, I evaluate the role of TGF1 and TGF3 to direct 
TGF trafficking and signalling. I found that TGF3 is less potent than TGF1 at 
propagating TGF signalling. I also show that TGF3 induces a different binding 
ratio of TRII/TRI cell-surface complexes, which could explain its decreased 
potency. Overall my studies highlight the role of receptor-interacting proteins in 
directing TGF receptor trafficking and signal transduction. Since this pathway is 
dysregulated in a number of pathologies, my studies suggest that TGF receptor 
trafficking is an important avenue to modifying TGF signal transduction. 
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1 Introduction 
1.1 TGFOverview 
 The transforming growth factor beta (TGF) signalling pathway is 
essential for numerous cell functions and was thought to arise with the 
development of metazoans. In development TGFplays numerous roles, 
including induction of  epithelial-to-mesenchymal transition (EMT) in endocardial 
cells which is necessary for normal heart development (1). TGFalso has 
several roles in normal tissue homeostasis, regulating such diverse functions as 
cellular differentiation, apoptosis, cell-cycle arrest, extracellular matrix production, 
and cellular migration. Partly owing to its pleiotropic effects in numerous cell-
types, TGFhas also been implicated in several pathologies including cancer 
and fibrosis. In cancer, TGFappears to have a dual role: On one hand, it is a 
tumour-suppressor, promoting cell-cycle arrest and apoptosis; on the other hand, 
TGFcan increase cancer cell migration, invasion, and immune evasion (2). In 
wound healing, TGFpromotes wound closure and resolution through the 
production of extracellular matrix (ECM) proteins and inhibition of matrix 
metalloproteinases. However, in fibrotic diseases, excessive TGFproduction 
and signalling promotes extensive tissue fibrosis which can compromise normal 
tissue function (3).  Given the numerous roles of TGFin both homeostasis and 
pathology, understanding the regulation of this pathway is critical. 
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1.1.1 TGF Cytokines 
The TGF superfamily consists of structurally and functionally related 
cytokines that interact with serine/threonine kinase receptors to mediate 
downstream transcriptional events. The TGF superfamily contains over 30 
ligands, including the TGF/Activin/Nodal subfamily and the bone morphogenetic 
protein (BMP)/growth and differentiation factor (GDF)/ Müellerian inhibiting 
substance (MIS) subfamily (4).  
In the canonical TGFsignalling cascade, there are three TGF cytokines 
which have been conserved throughout evolution- TGF1, TGF2 and TGF3; 
indeed, orthologs to human TGF can be found in D. melanogaster and X. laevis 
(reviewed in (1)). The three TGFligands are produced by a number of different 
cell types and the production of all three occurs during development, although 
TGF1 is the predominant type in adults (5,6). Each TGF ligand has relatively 
specific, non-overlapping functions in vivo. The TGF ligands share significant 
sequence homology; together they have greater than 76% identity in their active 
domains (7).  
TGF ligands are secreted as inactive, homodimeric pro-proteins (8). The 
activation of TGF1 is the best characterized of the three ligands, and latent 
TGF1 is found in one of three forms: a small latent complex, a large latent 
complex, or a form that is associated with 2-macroglobulin (9). In its small 
complex form TGFis synthesized as a pro-protein dimer, which is cleaved 
intracellularly by furin convertase and then associates with two precursor chains, 
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the latency associated peptides (LAPs) (9,10) (Figure 1.1). The large complex 
also consists of latency associated peptides, dimerized TGFand a third protein, 
the latent TGFbinding protein (LTBP), which is essential for proper secretion of 
TGF(11)In the extracellular matrix TGFis activated by molecules, such as 
matrix metalloproteinase 2, thrombospondin-1, plasmin or in vitro in acidic 
conditions (12-14).  It has been shown that TGF2 and TGF3 also exist in latent 
complexes (15,16), which suggests that the activation of TGFin the 
extracellular matrix may represent an important regulatory mechanism. In their 
active form, all three TGF ligands are homodimers stabilized by disulfide 
bridges and hydrophobic interactions when in their active form (17).  
Despite structural similarities, TGF ligands have distinct affinities for 
TGF receptors. The type II TGF receptor (TRII) is able to bind both TGF1 
and TGF3, with slightly higher affinity for TGF3 (18,19).  TGF2 on the other 
hand, requires betaglycan (TRIII) in order to bind to TRII (20). Furthermore, 
mice containing deletions of the genes encoding the three TGF ligands illustrate 
that these ligands have non-overlapping functions. Tgfb1-/- mice develop 
significant problems in utero including vasculogenic and hematopoietic defects 
(21). Mice that survive gestation develop a severe wasting inflammatory 
syndrome (21).  Tgfb2-/- mice have a myriad of developmental defects, including 
skeletal, cardiovascular, pulmonary and visual problems (22). Interestingly,  
 
Figure 1.1 Latent and active forms of TGFligand 
TGFcan be found in active and inactive forms. In order for proper secretion of TGF1 
to occur, it must associate with latent TGFbinding protein (LTBP) (A), and this, along 
with two latency associated peptides (LAPs) forms the large latent complex. In its small 
latent complex form (B) TGFexists as a homodimer following its cleavage by furin 
convertase, and is associated with two latency associated peptide proteins (furin 
convertase cleavage site indicated by *). TGFis converted to its active form following 
secretion into the extracellular matrix by proteases or acidic conditions (C) 
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Tgfb3-/- null mice have the least defects and die after birth due to an inability to 
suckle caused by cleft palate (23).  
Similar to their non-redundant roles in development, the TGFligands 
have different effects in various disease states. For example, in the wound 
microenvironment, there are a large variety of growth factors that promote 
production of extracellular matrix and wound-closure.  In adults, TGF1 is found 
at very high levels in the wound microenvironment and promotes myofibroblast 
differentiation, extracellular matrix production, and fibroblast chemotaxis 
(reviewed in (24)). Overall, TGF1 promotes the formation of a scar during adult 
wound healing. Surprisingly, injuries obtained in utero heal scar-free.This may be 
due to the relative ratios of TGF1 vs. TGF3. It has been shown that the 
embryonic wound microenvironment contains high levels of TGF3 and low 
levels of TGF1 (24). Furthermore, adding exogenous TGF3 to an adult wound 
also promotes scar-free healing in rats, possibly through decreasing inflammation 
(25). Currently, a topical cream, called Avotermin, containing TGF3 as its active 
ingredient is being promoted as a therapy for the improvement of scar 
appearance in humans (26).  
In tumourigenesis, TGF1 is well-established as playing a dual role in 
cancer progression: in pre-malignant states TGF1 is anti-tumourigenic and 
induces cell-cycle arrest and apoptosis; in advanced tumours TGF1 correlates 
with a more aggressive phenotype and induces EMT, migration, and invasion of 
tumour cells (27). Similarly, it has been shown that TGF2 is highly over-
7 
 
 
 
expressed in malignant gliomas and correlates with advanced disease state (5). 
Inhibitors of TGF2, such as the antisense oligonucleotide AP 12009, have been 
shown to decrease glioma and pancreatic cancer cell migration (5,28).  However, 
there is a lack of information regarding the role of TGF3 in the tumour 
microenvironment. Studies have illustrated that TGF3 is highly expressed in 
breast cancer samples (29), and other studies have shown that high levels of 
TGF3 are associated with good prognosis in breast cancer (30). Overall, many 
of the roles of TGF3 in the tumour microenvironment are assumed to be the 
same as TGF1. If one were to consider that the tumour microenvironment has 
many of the same cellular players as the wound microenvironment, and TGF1 
and TGF3 have vastly different outcomes in the wound microenvironment, it is 
unlikely that these two ligands share the same function in tumour growth. 
 1.1.2 TGF Receptors 
There are three principal receptor subtypes in the classical TGF 
pathway: TGF receptor I (TRI), TGFreceptor II (TRII) and TGFreceptor III 
(TRIII). TGF receptor I (TRI) and TGF receptor II (TRII) are structurally 
related glycoproteins which contain serine-threonine kinase domains, whereas 
TRIII is a large, membrane-bound proteoglycan lacking kinase activity (17) 
(Figure 1.2). Together, these receptors function to activate cell-type specific 
signalling programmes through the activation of a family of transcription factors 
called the Smads. TGFsignalling can also activate non-Smad mediated 
pathways such as the MAPK pathway. Each TGFreceptor type has specific, 
Figure 1.2 TGFReceptors 
In the canonical TGFpathway there are three receptor types: TRIII (which consists of 
two different receptors- betaglycan and endoglin), TRII and TRI. TRII and TRI 
possess Ser/Thr kinase activity and are the signalling receptors in the pathway. The role 
of TRIII is primarily ligand presentation to the TRII and TRI complex. While all of the 
receptors are primarily found as homodimers at the cell surface, they have been drawn 
as single receptors for the sake of simplicity in this diagram.  Structural differences are 
indicated and described in the figure. 
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Figure 1.2 
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non-overlapping functions that are crucial to signal transduction.    
 In the TGFsuperfamily there are five type II TGFreceptors which can 
form homomeric complexes to bind ligand:  Act-RIIA, Act-RIIB, BMPR-II, AMHR-
II and TRII (31). In the classical TGFpathway, TRII is the primary type II 
receptor. TRII is a 62 kDa protein containing a short cysteine-rich, N-
glycosylated extracellular domain, a single transmembrane domain and a serine-
threonine kinase intracellular domain (reviewed in (18)).The cytoplasmic domain 
of TRII is also serine-threonine rich, which is lacking in TRI (32).   At the cell 
surface, TRII exists as a homodimer in the absence and presence of ligand 
(33). TRII binds TGF1 and TGF3 with relatively high affinity (34,35), but is 
unable to bind TGF2 without TRIII (18). In the absence of ligand, TRII is 
capable of autophosphorylation on serine residues Ser549, Ser551, Ser223, Ser226 
and Ser227 (34,36). Interestingly, TRII also has tyrosine kinase activity and its 
cytoplasmic tyrosine residues are subject to both autophosphorylation or Src 
phosphorylation leading to signalling cross-talk with the MAP kinase family (37).  
In response to TGF binding the receptor forms a heterotetrameric complex with 
and phosphorylates TRI. TRII function is tightly regulated by post-translational 
modification through ubiquitination, sumoylation, and/or phosphorylation, all of 
which result in specific signal transduction events (reviewed in (38)).    
In the TGFsuperfamily there are 7 type I receptors called activin linked 
kinases (or ALKS) 1 through 7. The type I receptor in the classic TGFsignalling 
pathway is TRI, also known as ALK5. TRI and TRII are structurally similar, 
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though TRI contains a shorter extracellular domain than TRII and cannot bind 
ligand in the absence of TRII (39). Akin to TRII, TRI also contains a 
serine/threonine kinase intracellular domain and exists as a homodimer at the 
cell surface (18). However, TRI contains a unique intracellular GS 
(glycine/serine rich) region that is highly conserved between type I receptor 
isoforms, and that is phosphorylated by TRII (17). Once phosphorylated, the GS 
domain of TRI acts as a docking platform for receptor-regulated Smad proteins 
(40). The receptor-regulated Smads are then phosphorylated by TRI, initiating a 
Smad signal cascade that culminates in transcription. Mutations of the GS 
domain have highlighted the importance of this region to TGFsignal 
transduction: Mutations of two or more glycine or serine residues in the GS 
domain impairs TGFsignalling activity (41). Mutation of threonine 204 to 
aspartic acid increases TGFsignal transduction in the absence of ligand, as it 
generates a constitutively active TRI (41). These mutational studies confirm that 
TRI is the key player in Smad signal transduction. Furthermore, SB-431542, a 
specific inhibitor of TRI, prevents TGF-induced Smad-mediated transcription, 
but does not affect the cross-talk of TGFwith the MAP kinase family, 
highlighting the role of TRI in Smad-dependent TGFsignalling (42).  
There are two type III TGF receptors: endoglin and betaglycan. These 
receptors are considered accessory receptors with roles in ligand presentation, 
as no enzymatic activity has been identified for either receptor.  Betaglycan and 
endoglin are structurally related, with large, heavily glycosylated extracellular 
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domains, and a short cytoplasmic region with high sequence similarity (43-45). 
Both receptors can be phosphorylated on serine/threonine residues in their 
cytoplasmic domain (46-48). At the cell surface, endoglin and betaglycan form 
homodimers (49) (50), as well as complexes with TGF receptors I and II 
(46,51). Though similar, these receptors differ in their ligand-binding ability and 
expression. Betaglycan can bind all three TGF ligand isoforms with high affinity 
(50); while it has been reported that endoglin requires complex formation with the 
TRII/TRI complex to bind ligand, and even in complex can only bind TGF1 
and TGF3 (46,47).  Betaglycan is the most widely-expressed TGF receptor, 
and is expressed in a number of adult and fetal tissues (18), whereas endoglin is 
primarily expressed on proliferating endothelial cells (52). Future studies to 
examine compensatory effects of the two type III TGF receptors would be 
interesting, as both Tgfbr3 -/- (betaglycan) and Eng -/- (endoglin) mice die mid-
gestation due to cardiovascular defects (52,53).   
1.2 TGFSignal Transduction 
To propagate TGF signalling, homodimeric TGF is presented by 
betaglycan (TRIII)  to TRII  (54) (Figure 1.3). The binding of ligand to TRII 
recruits TRI to the ligand-receptor complex, forming a receptor complex of two 
TRII and two TRI. TRII then phosphorylates TRI at serine-threonine 
residues in its GS domain (55). Phosphorylated TRI is essential in driving 
TGFsignal transduction, and works to activate a group of transcription factors 
known as Smads. There are three classes of Smads which are activated by the  
Figure 1.3 Smad Signal Transduction Pathway 
In the canonical TGFsignalling pathway, the ligand-bound, activated receptor complex 
propagates Smad signal transduction. Following ligand binding by TRII, TRI becomes 
active and phosphorylates Smad2/3 on its SSXS motif (where S=serine and X= any 
amino acid). This phosphorylation promotes its disengagement from TRI and promotes 
the association of Smad2/3 with the common Smad, Smad4. The Smad complex then 
translocates to the nucleus to activate transcription. 
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TGFsuperfamily of ligands: the receptor-regulated Smads (or R-Smads, Smads 
1, 2, 3, 5 and 8), which are able to interact with the type I receptor; the co- 
mediator Smad (Smad4), which can associate with R-Smads; and the inhibitory 
Smads (or I-Smads, Smads 6 and 7) which compete with R-Smads for receptor 
binding and target TGF receptors for degradation (17). In the classical 
TGFsignalling pathway, the R-Smads are Smads 2 and 3, whereas the 
inhibitory Smad is Smad7.  Smads typically consist of two domains separated by 
a variable linker region. The amino MH1 (Mad homology 1) domain has DNA 
binding capabilities in some Smad sub-types, while the carboxy MH2 (Mad 
homology 2) domain has been shown to mediate interactions with a variety of 
proteins (56). The activated GS domain of TRI serves as a docking site for 
Smad2 via its MH1 domain (55). The specificity of R-Smad binding is determined 
by the L45 loop, a nine amino acid sequence between the kinase subdomains IV 
and V of TRI (57). TRI phosphorylates R-Smads on the conserved SSXS motif 
located at the C-termini of Smads 2 and 3 (serine residues 465 and 467 in the 
MH2 domain of Smad2, for e.g.) (58-60). The phosphorylated serine residues of 
Smad2 serve as a docking site for Smad4, and promote the dissociation of 
Smad2 from TRI and the formation of a heteromeric complex with Smad4 
(31,59). Smad2 is generally located cytoplasmically in the absence of ligand, but 
upon ligand stimulation translocates to the nucleus with Smad4, which in the 
absence of ligand is found distributed equally between the nucleus and the 
cytoplasm (4). Smad4 is able to translocate to the nucleus due to its interactions 
with nucleoporins; the interaction of Smad4 with the nucleoporin importin-1is 
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thought to mediate the translocation of the Smad heteromeric complex to the 
nucleus (61). In the nucleus the heteromeric complex binds to promoters or 
enhancers of TGFtarget genes, such as the Smad binding element, via its MH1 
domain and interacts with transcriptional co-activators and co-repressors in order 
to induce cell-specific transcriptional programmes (4,17) (Figure 1.3).  
1.3 Membrane Trafficking of TGFReceptors 
Endocytosis refers to the process whereby cell-surface associated 
molecules enter the cell without passing through the plasma membrane. 
Essentially, the plasma membrane invaginates, budding off and forming a vesicle 
containing the internalized cargo. Internalization of cell-surface receptors is 
important in the control of signal transduction, functioning either to down-regulate 
signalling or trafficking receptors to specific endocytic compartments.  There are 
several methods of endocytosis of cell-surface receptors, including membrane-
raft dependent endocytosis, caveolin-dependent endocytosis, Arf6-dependent 
endocytosis, and clathrin-mediated endocytosis (reviewed in (62)). As clathrin-
mediated endocytosis and membrane-raft/caveolin-mediated endocytosis are 
implicated in the TGFpathway (63), these processes will be the focus of this 
introduction.  
1.3.1 Clathrin-mediated Endocytosis 
Clathrin-mediated endocytosis is a highly conserved mechanism 
implicated in the internalization of many receptor types. Clathrin-mediated 
endocytosis occurs when clathrin from the cytosol is recruited to the plasma 
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membrane and aggregates to form pits (62). Protein motifs of cargo play a role in 
the development of clathrin-coated pits, as di-leucine and tyrosine motifs in the 
cytoplasmic domains of receptors are detected by adaptor protein 2 (AP-2) and 
promote clathrin polymerization (64,65). The AP-2 complex is critical in the 
formation and function of clathrin-coated pits. AP-2 along with Eps15 (epidermal 
growth factor pathway substrate 15), aid in the polymerization of clathrin into 
lattices increasing plasma membrane curvature (62). Upon sufficient membrane 
curvature, dynamin forms a helix around the neck of the clathrin-coated pit and 
with GTP hydrolysis promotes scission of the clathrin-coated pit from the plasma 
membrane (66). These excised pits then form clathrin-coated vesicles, lose their 
clathrin-coat and become endosomes. Endosomes may be routed to the cell 
membrane for recycling, or may mature and go on to form other compartments.  
Ligand-binding is not a requirement for clathrin-mediated endocytosis: while 
some receptors are internalized following ligand stimulation, such as the 
epidermal growth factor receptor, other receptors such as the transferrin receptor 
and the T-cell receptor CTLA-4 internalize independently of ligand stimulation 
(67,68).  
1.3.2 The role of Rab GTPases following endocytosis 
Following receptor internalization, receptors are directed into distinct 
endocytic components by a large family of small GTPases called the Rab 
GTPases (Figure 1.4). There are over 60 members of the Rab GTPase family 
which function as molecular “on and off” switches- in their “on” state, they are  
Figure 1.4 Rab GTPases in vesicular trafficking following endocytosis 
The Rab small GTPase family is important in mediating trafficking of intracellular 
vesicles. Different endosomal compartment are enriched in distinct Rab GTPases. Rab4 
and Rab5 are found enriched in the early-endosome. From the early endosome, cargo 
may traffic to the recycling endosome, which is enriched in Rabs 4 and 11, or to the late 
endosome, which are enriched in Rabs 7 and 9.  
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bound to GTP, and in their “off” state, they are bound to GDP (69). Rab proteins 
are activated by Rab GEFs (GDP-GTP exchange factors), which promote the 
GTP bound form, and are inactivated by GAPs (GTPase activating proteins) (70). 
Rab GTPases can associate with membranes, vesicular coat components, and 
molecular motors to direct vesicular traffic by regulating the process of docking 
and tethering between compartments (Figure 1.4) (69,70).  
  One of the best-studied Rab proteins, Rab5, has been shown to play a 
crucial role in the formation of clathrin-coated pits and the internalization of  
transferrin receptors via clathrin-mediated endocytosis (71). GTP-bound Rab5 is 
also involved in early-endosome fusion (72) and has been used extensively as a 
marker for the early endosome.  Following trafficking into the early endosome, it 
has been proposed that cargo can either be recycled to the plasma membrane, 
or progress to the late endosome. A study by Rink et al. elegantly illustrated that 
progression from the early to late endosome is mediated by the loss of Rab5 
occurring simultaneously with the acquisition of Rab7 (73). Rab5 replacement 
with Rab7 depends on the GTP hydrolysis activity of Rab5, as a Rab5 mutant 
lacking hydrolytic activity recruited Rab7 but was not replaced by Rab7 (73). 
Following trafficking to the late endosome, cargo can be trafficked to the 
lysosome, which is mediated by Rab7, or to the trans-Golgi network, which is 
mediated by Rab9 (69). As mentioned, instead of progressing to the late 
endosome, cargo may traffic to a recycling endosome, which is enriched in Rab 4 
and 11 in distinct domains that do not intermix (69,74). These proteins are 
proposed to have different functions in the recycling pathway: Rab4 has been 
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implicated in “fast” recycling of cargo from to the cell-surface, whereas cargo in 
Rab11- positive vesicles has been proposed to take a “slow” recycling route, and 
can transition through the trans-Golgi network and secretory pathways (74).  
Overall, the regulation of cargo trafficking within the cell is essential for 
cellular function. Rab dysregulation can occur in a number of cancers, such as 
breast and ovarian cancer, which have been found to have over-expression of 
Rab25 (69).  
1.3.3 Membrane-raft mediated endocytosis 
Clathrin-independent endocytosis through membrane rafts is also a 
common mechanism for the uptake of signals and nutrients from the extracellular 
environment. First introduced in 1997, the membrane raft model proposes that 
cholesterol-sphingolipid-protein complexes form in the plasma membrane to 
make a tightly packed, liquid-ordered phase mediating endocytosis and signal 
transduction (75). Importantly, the lipid composition of membrane rafts is distinct 
from the rest of the plasma membrane as they are enriched in cholesterol and 
sphingolipids and are therefore more rigid and less fluid than the surrounding 
plasma membrane (76). Membrane rafts have been shown to be especially 
important in the endocytosis of proteins with glycophosphatidyl-inositol (GPI) 
binding domains (77).  It is thought that clustering of GPI-containing receptors 
may increase the affinity of the receptor complex for membrane rafts and 
increase membrane raft stability (78). Furthermore, it has been suggested that 
cytoskeletal proteins, such as actin, play an important role in forming membrane 
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rafts (79). Disrupting the actin cytoskeleton has major effects on the clustering of 
raft proteins (80). In a feed-forward mechanism, the clustering of proteins 
enriched in membrane rafts enhances the concentration of actin, which then 
further stabilizes membrane raft formation (81).  
The study of membrane rafts has been limited at times due to previous 
methodology used to isolate rafts.   Membrane rafts have been isolated by their 
detergent-insolubility. The tight packing of lipids in the liquid-ordered phase of 
membrane rafts prevents detergent incorporation and therefore disruption by 
detergents (82). Following detergent extraction of membrane rafts, cell lysates 
are frequently subjected to sucrose-density ultracentrifugation, as the enrichment 
of membrane rafts with cholesterol and sphingolipids increases their buoyancy 
relative to the rest of the plasma membrane.  Unfortunately, using detergent-
insolubility as the sole defining characteristic is laced with inconsistency. 
Different results can be obtained depending on the type of detergent and the 
duration of extraction (83). As it is possible to isolate membrane rafts using a 
detergent-free method with sodium carbonate (51,63,84,85), using this method 
may decrease extraction-based artifacts of membrane raft isolation. 
1.3.4 The role of Caveolae in endocytosis 
Another important mediator of TGFendocytosis are caveolae. Caveolae 
are a subset of membrane rafts which are composed of flask-shaped 
invaginations approximately 60-80 nm in diameter (77). Caveolae are enriched in 
a protein called caveolin-1. The caveolin family consists of three proteins: 
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caveolin-1, caveolin-2, and caveolin-3. Caveolin-1 and caveolin-2 are found in 
non-muscle cells, while caveolin-3 is primarily expressed in muscle (86,87). 
Caveolin-1 and caveolin-3 can form caveolae, whereas loss of caveolin-2 does 
not affect caveolae formation (88). As caveolin-3 is only expressed in muscle, 
caveolin-1 is the primary contributor to caveolae formation in most cells (89). 
Caveolin proteins have a unique hairpin structure. Their N and C termini are 
cytoplasmic, whereas the hairpin structure is embedded in the plasma 
membrane, associating with approximately 1-2 cholesterol molecules (90).  
Caveolae are formed by the oligomerization of caveolin-1 molecules and 
association with cholesterol-rich membrane rafts. This oligomerization results in a 
liquid-ordered, stable domain in the plasma membrane enriched in cholesterol, 
sphingolipids, and caveolin-1(89). Caveolin-1 has been shown to be important for 
clathrin-independent, membrane-raft dependent endocytosis through its 
interactions with the actin cytoskeleton (91). Caveolae-dependent endocytosis 
has been implicated in the uptake of viruses, nutrients, and cell-membrane 
receptors (92). 
Disruption of the caveolin-1 gene has provided insight into the many 
potential roles of this membrane protein. In the initial characterization of Cav1-/- 
mice it was shown that the loss of caveolin-1 disrupted caveolae formation in the 
lung, adipose tissue, kidney, and heart (93). Overall, these mice are viable but 
have significant vascular defects, and have increased deposition of extracellular 
fibrillar matrix in the lungs, suggesting that loss of caveolin-1 may initiate fibrosis 
in the lungs (93). However, loss of caveolin-1 expression also induced the hyper-
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proliferation of angioblastic cells (93). Further studies illustrated that loss of 
caveolin-1 induced many changes consistent with promoting tumourigenesis 
such as the spontaneous progression through the epithelial-to-mesenchymal 
transition in epithelial cells (94), increasing the susceptibility of mouse embryonic 
fibroblasts to transformation (95), and increasing beta-catenin transcriptional 
activation (96). Overall, these studies illustrate that caveolin-1 may have greater 
roles in signal transduction than simply in the internalization of cell-surface 
receptors. 
1.4 Endocytosis in TGFSignal Transduction 
Intriguingly, a role for membrane-raft/caveolar mediated signal 
transduction has been identified for TGF signalling by Di Guglielmo and 
colleagues. At the cell surface, TGF receptor complexes can access both 
clathrin-coated pits and membrane rafts (63) (Figure 1.5). Inhibition of clathrin-
coated pit internalization through the use of a dominant-negative Eps15 mutant 
shifted receptors into membrane raft fractions; similarly, inhibition of membrane 
raft formation through cholesterol depletion shifted receptors back into non-
membrane raft fractions (63).  TGF receptors internalized via clathrin-mediated 
endocytosis access the early endosome, a signalling endosome, which 
propagates TGF signal transduction through the recruitment of R-Smads 
(63,97). Membrane-raft mediated endocytosis, however, promotes ubiquitin-
dependent receptor degradation (63,98,99). The landmark paper by Di Guglielmo 
and colleagues illustrated an important principle regarding TGFsignal 
Figure 1.5 Regulation of TGFSignalling by Clathrin-dependent and -independent 
endocytosis 
TGFreceptors can be internalized by clathrin-dependent mechanisms and clathrin-
independent, membrane-raft dependent mechanisms. Receptors internalized via 
clathrin-coated pit mediated endocytosis traffic to the early endosome and propagate 
signal transduction. Receptors internalized by membrane-raft dependent endocytosis 
traffic to the caveolin-1 positive vesicle where they are targeted for degradation and 
prevented from signalling. 
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transduction: endocytic route plays a powerful role in dictating TGFreceptor 
intracellular trafficking and signal transduction (Figure 1.5).  
1.4.1 The role of the early endosome in TGFSignal Transduction 
 While the classic paradigm of signal transduction suggests that following 
receptor endocytosis signal transduction is terminated, it has been shown in 
many different systems that signalling continues following receptor internalization 
into endosomes. Following ligand-binding and internalization, receptors can 
undergo modifications that attract intracellular signalling molecules and can 
therefore continue to propagate signals (100). Early endosomes are considered 
to be a sorting station for internalized receptors, and are classified by their 
enrichment in Rab5 and EEA1 (early endosomal autoantigen 1) (100).   
As previously described, clathrin-mediated endocytosis of TGFreceptors 
targets their localization to the early endosome (63,97), which enhances 
TGFsignalling. An elegant study performed by Runyan and colleagues 
illustrated that internalization of the TGFreceptor complex is essential for 
maximal signal transduction (101). The authors illustrated that inhibition of 
clathrin-mediated endocytosis did not greatly prevent the ability of the receptor 
complex to phosphorylate Smad2; but inhibition of endocytosis did prevent 
nuclear translocation of Smad2 thus preventing TGF-dependent transcription  
(101). This paper suggested that there is a spatial component to TGFsignalling.  
One key player in the spatial control of TGFsignalling is SARA (Smad 
anchor for receptor activation). SARA was first identified by Tsukazaki and 
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colleagues by screening a X. laevis expression library using Smad2 as a bait 
(102). SARA contains a FYVE domain (Fab1, YOTB, Vac1, EEA1), a common 
motif in early endosomal proteins that has been shown to bind to phosphatidyl-
inositol-3-phosphate (PtdIns3P) (103). Since phosphatidyl-inositol-3 (PI3) kinase 
activity has been implicated in vesicular trafficking, and FYVE domains can 
directly bind PtdIns3P, proteins containing FYVE domains have been suggested 
to mediate endosomal trafficking (103). SARA has also been shown to bind to 
Smad2 and Smad3 via their MH2 domains, and preferentially binds the 
unphosphorylated forms of the Smads (102). Furthermore, TGFreceptors traffic 
into EEA1/SARA positive endosomes and disruption of SARA localization 
through the deletion of the FYVE domain perturbs Smad2/3 nuclear translocation 
(104). It has been proposed that SARA functions to link the TGFreceptors with 
Smad2. Once Smad2 has been phosphorylated by the receptor complex, Smad2 
dissociates from SARA and binds Smad4, translocating to the nucleus and 
initiating TGF-driven transcription (102). 
The length of time which TGFreceptors reside in the early endosome 
may also affect their signalling capacity. As previously mentioned, the early 
endosome is enriched in Rab5. Rab5 can control vesicular trafficking by 
promoting trafficking to the late endosome which is enriched in Rab7 (73). A 
Rab5 guanosine exchange factor (GEF), RIN1, has been shown to promote 
Smad signal transduction by activating Rab5 (105). Interestingly, SNAI1 a 
transcriptional target of TGF/Smad signalling, acts through a negative feedback 
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mechanism to decrease RIN1 expression and therefore decrease 
TGFsignalling (105).  
There is little information regarding the trafficking of TGFreceptors 
following their endocytosis to the early endosome. It has previously been shown 
that TGFreceptors can co-localize with Rab11, a recycling Rab protein (63). 
Furthermore, a dominant-negative version of Rab11 has been shown to impair 
the recycling of TGFreceptors to the cell surface (97); however, the authors of 
this paper used a hybrid GMCSF-TRII receptor composed of the extracellular 
domain of GMCSF and the cytoplasmic domain of TRII, therefore studies using 
wild-type TRII to assess TGFreceptor recycling would further improve our 
understanding of TGFreceptor recycling. 
1.4.2  The role of the caveolin-1 positive vesicle in TGFsignalling 
Membrane raft endocytosis of TGF receptors results in receptors being 
targeted to the caveolin-1 positive vesicle. Indeed, Razani et al., identified a 
caveolin-binding motif in the cytoplasmic tail of TRI which mediates its 
interaction with the scaffolding domain of caveolin-1 (106). Unlike the early 
endosome, the caveolin-1 positive vesicle promotes association of Smad7, not 
Smad2, with the receptor complex (63).  Smad7 belongs to the inhibitory Smads, 
or I-Smads, along with Smad6. Smad7 antagonizes the canonical TGFpathway 
and its expression is induced by TGFfamily ligands (107). The antagonistic role 
of Smad7 is mediated by two mechanisms. Firstly, Smad7 is able to interact with 
activated TRI and therefore sterically inhibits the association of TRI with 
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Smad2/3, preventing the subsequent activation of Smad2/3 and its association 
with Smad4 (108,109). Importantly, a mutant of Smad7 that is unable to bind to 
TRI (Smad7 408) loses its inhibitory activity of the TGFpathway, suggesting 
that the ability of Smad7 to bind to TRI is critical in its antagonistic function 
(109). Secondly, Smad7 acts as an adaptor between the TGFreceptor complex 
and a ubiquitin regulatory factor, Smurf2 (99). Smurf2 is an E3 ubiquitin ligase 
which is localized primarily in the nucleus (99). Upon TGFstimulation however, 
Smurf2 translocates to the cytoplasm and forms a stable interaction with Smad7 
and the receptor complex (99). Smurf2 then ubiquitinates the receptor complex, 
targeting it for degradation via proteasomal and lysosomal pathways (99,110). 
Further supporting the role of membrane rafts in receptor degradation, an 
interesting study by Chen and colleagues found that increasing cholesterol 
concentrations can inhibit cell TGFresponsiveness and promote receptor 
degradation. This suggests that cholesterol may shift TGFreceptors into 
membrane rafts and subsequently caveolin-1-positive vesicles (111).  
1.5 TGFReceptor Motifs Influencing Internalization 
At the cell surface, TRII and TRI are generally found in a heteromeric 
complex consisting of two TRII and two TRI. It has been well established that 
these receptors undergo internalization and degradation, but the mechanisms 
directing this internalization are not clear. The internalization rate of the 
TGFreceptors appears to vary depending on cell-type, with receptors being 
maximally internalized after 40 minutes of ligand-stimulation in Mv1Lu cells (112), 
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60 minutes after stimulation in HEK 293 cells (112), and less than 25% of 
receptors were internalized after 30 minutes in CR-26 mink lung cells  (113). 
While other receptor systems, such as the EGFR and numerous GPCRs, display 
agonist-induced internalization (114,115), this is not the case for the 
TGFreceptors. Mitchell and colleagues have shown that hybrid receptors 
consisting of the extracellular domain of GMCSFR and the intracellular domain of 
TRII undergo similar rates of internalization and recycling both in the presence 
and absence of ligand (97). Similarly, it has been shown that wild-type full-length 
TRII shows similar EEA1-endosomal enrichment (63) and partitioning into 
membrane rafts in the presence and absence of ligand (84).    
 While it does not appear that ligand binding plays a role in TGFreceptor 
internalization, several studies have identified motifs in the cytoplasmic domains 
of both TRII and TRI that permit their association with components of 
endocytic machinery. Yao and colleagues illustrated that the cytoplasmic 
domains of both TRII and TRI can bind directly to the 2 subunit of AP-2 and 
clathrin (116).  While TRI has a slightly lower affinity for binding to AP-2 than 
TRII, the presence of ligand does not affect the ability of either receptor to bind 
AP-2 or clathrin (116). The authors concluded that this interaction was essential 
for clathrin-mediated endocytosis of the receptors. TRII has another consensus 
sequence in its cytoplasmic tail that links it to the clathrin-mediated endocytic 
machinery. Ehrlich et al. identified a di-leucine motif in the cytoplasmic tail of 
TRII (I218I219L220) which is essential for its clathrin-mediated internalization (117). 
Indeed, mutation of each of the residues in the di-leucine motif to alanines 
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prevented internalization of the receptors (117). Importantly, the constitutive 
internalization of TRII via its di-leucine motif was also independent of ligand 
stimulation (117).         
While studies have identified motifs that link TRI and TRII to 
components of the clathrin-mediated endocytic machinery, others have shown 
that the receptors can also associate with components of the membrane-raft 
endocytic machinery. As previously mentioned, Razani et al. identified a 
caveolin-binding motif in the cytoplasmic tail of TRI which mediates its 
interaction with the scaffolding domain of caveolin-1 (106). Importantly, the 
interaction of TRI with caveolin-1 has functional consequences as well. 
Caveolin-1 is a marker for the caveolin-1 positive vesicle, where receptors are 
targeted for degradation and sterically prevented from interacting with the R-
Smads. In the study by Razani et al. it was shown that even when a constitutively 
active TRI construct was used, co-expression of caveolin-1 decreased TGF-
dependent transcription (106). Since the kinase activity of TRI is necessary for 
propagating Smad signal transduction, the interaction of TRI with caveolin-1 
may act as a powerful negative regulator of TGFsignalling.    
1.5.1 The role of receptor-interacting proteins on TGFendocytosis  
 TRII and TRI can bind a number of proteins at the cell surface and 
many of these proteins have been shown to direct receptor endocytosis.    
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ADAM12 (a disintegrin and metalloprotease protein 12) is an example of a 
cell-surface TGF receptor interacting protein that enhances TGF signal 
transduction.  ADAM12 is a proteoglycan with an extracellular metalloprotease 
domain and intracellular signalling domain (118). Using TRII as bait, ADAM12 
was identified as a novel binding partner for TRII, directing the receptor to 
undergo clathrin-mediated endocytosis. ADAM12 traffics receptors into the early 
endosome, and in agreement with other studies, accumulation of receptors into 
the early endosome enhances TGF signal transduction (119). The authors 
illustrated this increase in TGFsignal transduction by showing that ADAM12 
increases Smad2 phosphorylation, Smad2-Smad4 association, as well as 
increased modulation of gene transcription (119).  
There are also several cell-surface interacting proteins that direct TGF 
receptors into the degradative pathway. CD109 is a large glycophosphatidyl 
inositol (GPI)-linked protein which has been shown to bind TGF1 ligand and 
form a complex with TRI, TRII and TRIII (120). As previously mentioned, GPI-
linked proteins tend to accumulate in membrane rafts (77). Furthermore CD109 
can also interact with caveolin-1 (121).  An interesting paper by Bizet et al., 
demonstrated that the association of CD109 with the TGF receptor complex 
increased the internalization of the receptors via caveolae and enhanced 
receptor degradation (121). In a follow-up paper, Bizet et al., illustrated the 
importance of the subcellular localization of the receptors in terms of 
degradation, as CD109 enhanced the degradation of TRI by Smad7/Smurf2 by 
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enhancing the co-localization of TRI with Smurf2 (122).     
 The atypical protein kinase C (PKC) family represents another class of 
proteins that direct TGF internalization into the caveolin-1-positive vesicle. 
PKC and PKCare members of the atypical protein kinase C family. These 
proteins are serine-threonine kinases, which unlike members of the classic or 
novel groups of PKC family do not require diacylglycerol for their activation 
(reviewed in (123)). Previously, Ozdamar et al., observed that PKC interacts 
with TRII through an association with Par6 to control EMT in breast cancer cells 
(124). Our lab has shown that the atypical PKCs direct TRII into caveolin-1 
positive vesicles, and treatment with either inhibitors to the atypical PKCs (such 
as GF109203X), or siRNA directed against the atypical PKCs, extends Smad2 
phosphorylation and TRII half-life (125).  As the PKC family is primarily known 
for its role in GPCR endocytosis and trafficking (126), the identification of this 
family as controlling TGF receptor trafficking suggests that the PKCs may have 
a more general role in endocytosis than previously appreciated. 
Finally, cytoplasmic proteins have also been shown to control the 
endocytosis of TGFreceptors. arrestin2 is a multi-functional scaffolding protein 
best known for its role in GPCR signalling. Upon agonist stimulation, GPCRs are 
phosphorylated by G protein receptor kinases (GRKs). Following GPCR 
phosphorylation, arrestin2 binds to the phosphorylated receptor, promoting 
uncoupling of the receptor from the G protein and targeting the receptor for 
internalization (126). Interestingly, it has been shown that arrestin2 is also able 
31 
 
 
 
to interact with TRIII and mediate the endocytosis of TRIII and TRII (48). 
More specifically, the authors illustrated that TRII phosphorylates TRIII to 
recruit arrestin2. They also showed that when arrestin2 expression is 
decreased in HEK293 cells, TGF dependent apoptosis is increased (48), 
suggesting that arrestin2 has a negative regulatory effect on TGF signalling. 
Since arrestins have been shown to interact with components of the clathrin-
mediated endocytic machinery, such as clathrin and AP-2 (reviewed in (127)), it 
would be expected that the interaction of arrestin2 with TRII and TRIII would 
promote clathrin-mediated endocytosis, but the authors simply evaluated the 
internalization of the receptors, not their route. Furthermore, as clathrin-mediated 
endocytosis promotes TGF signalling (51,63), it would be of interest to assess 
the mechanism by which arrestin2 mediates signal down-regulation, in 
particular in regards to trafficking. 
1.6 TGFBiology 
1.6.1 TGFand Cell-cycle Arrest 
 While virtually every cell in the body is responsive to TGFits effects are 
context- and cell-dependent (Figure 1.6). TGFstimulates the growth of 
fibroblasts as well as their deposition of extracellular matrix proteins, such as 
fibronectin and collagen (128). However, in tissues such as the epithelium, 
mammary gland, endothelium and nervous system, TGF is growth inhibitory 
(129). Initial studies evaluating the growth-suppressive effects of TGFillustrated  
 
Figure 1.6 Cell-type Dependent TGFSignalling Outcomes 
While nearly all cells are responsive to TGFsignalling, the outcome of TGFsignalling 
is cell-type and context-dependent. In epithelial cells TGFis generally growth-
inhibitory, while in fibroblasts it stimulates ECM deposition and cell differentiation. In 
tumour cells TGFtransitions from being growth-inhibitory to stimulating migration and 
invasion. 
 
 
 
 
 
 
 
 
 
 
 
 
32 
 
 
 
Figure 1.6 
 
33 
 
 
 
that TGFprevented the phosphorylation of retinoblastoma protein (pRb) (130). 
Retinoblastoma protein has been proposed to function as a “gate-keeper” 
regulating the cell cycle. In its under-phosphorylated state, Rb protein arrests the 
cell in the G1 phase of the cell cycle, while in its phosphorylated state it allowsthe 
cell to undergo mitosis  (131). The phosphorylation of pRb in the G1 phase is 
mediated by the cyclin-dependent kinases CDK4 and 6 (131). Later work 
illustrated that TGFinhibits cell-cycle progression by up-regulating the cyclin-
dependent kinase inhibitors p15 and p21, therefore arresting cells by inhibiting 
the actions of CDK4 and CDK6 (129,132). TGFhas also been shown to inhibit 
the expression of the growth-stimulatory transcription factor c-Myc through 
stimulating the formation of a complex consisting of Smad3, p107 and E2F4/5 
(133). Therefore, TGFpotently inhibits growth through two mechanisms in 
epithelial cells. 
1.6.2 TGFand Apoptosis 
 Not only is TGFanti-tumourigenic through promoting cell-cycle arrest, but 
TGFhas also been shown to induce apoptosis in a number of cells via several 
mechanisms. There are two principal apoptotic pathways: the extrinsic/death 
receptor pathway and the mitochondrial pathway (134). Activation of either 
pathway results in the cleavage of caspase-3, inducing DNA fragmentation, 
protein degradation, and the expression of ligands to stimulate phagocytic cells 
to engulf the apoptotic cell (134). The extrinsic/death receptor pathway is initiated 
by transmembrane receptors responding to extracellular stimuli, such as the Fas 
ligand/Fas receptor complex (134). The binding of ligand to the Fas receptor 
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induces the accumulation of intracellular adaptor proteins which eventually 
results in the formation of the DISC, or death-inducing signalling complex, which 
stimulates caspase cleavage (135). The intrinsic pathway is mediated by 
mitochondria responding to either apoptotic signals or to the absence of certain 
growth factors or signals (135). TGFhas been shown to activate both apoptotic 
pathways.  For example, TRII is able to interact directly with Daxx, an 
intracellular component of the Fas-mediated apoptotic programme to activate 
JNK-mediated apoptosis (136). TGFcan also activate apoptosis via the intrinsic 
pathway. Jang and colleagues illustrated that Smad signal transduction initiated 
by TGFinduces the production of death-associated protein kinase, or DAP-
kinase (137). DAP-kinase functions upstream of mitochondrial-induced 
apoptosis. It has been shown that a dominant-negative form of DAP-kinase 
blocks the ability of TGF to induce cytochrome C release from mitochondria 
(137). 
1.6.3 TGFand EMT  
 Another important and well-studied outcome of TGFsignal transduction 
is EMT, a process whereby epithelial cells lose their apical-basal polarity and 
cell-cell junctions (such as tight junctions and adherens junctions) and gain a 
mesenchymal phenotype, increasing their ability to produce extracellular matrix 
proteins, migrate, and invade into other tissues (138) (Figure 1.7). The process of 
EMT is studied in vitro through the progressive loss of epithelial markers, such as 
E-cadherin, ZO-1, and cytokeratin; with the gain of mesenchymal markers such 
as N-cadherin, fibronectin, and vimentin (138).  
Figure 1.7 The Epithelial-to-Mesenchymal Transition (EMT) 
EMT can occur in both physiological conditions as well as pathologies such as cancer. 
During EMT epithelial cells lose their epithelial markers (such as E-cadherin and 
cytokeratins) as well as their apico-basal polarity and gain mesenchymal markers (such 
as N-cadherin and -SMA) and a mesenchymal phenotype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
35 
 
 
 
Figure 1.7 
 
 
36 
 
 
 
TGFwas first shown to induce EMT in 1994 in a study by Miettinen and 
colleagues. They found that TGFinduced mammary epithelial cells to gain a 
mesenchymal phenotype. This process is dependent on the type I 
TGFreceptor, as the over-expression of a dominant-negative form of TRI 
lacking the kinase domain prevented EMT (139). TGFmediates many of the 
phenotypic changes associated with EMT. One important event during EMT is 
the dissolution of tight junctions. A study by Ozdamar et al. showed that in 
epithelial cells, TGFtreatment induces TRII to phosphorylate Par6, thereby 
recruiting Smurf1, an ubiquitin ligase belonging to the same family as Smurf2, 
and targeting RhoA for degradation (124). The degradation of RhoA by Smurf1 
begins the dissolution of tight junctions in epithelial cells (124). Another important 
step in EMT is the down-regulation of E-cadherin. E-cadherin is an epithelial cell-
cell adhesion receptor and is important in regulating the epithelial phenotype 
(140). Loss of E-cadherin decreases epithelial cell junctions and also results in -
catenin being localized in the nucleus, activating the Wnt signalling pathway 
(140). TGFpotently decreases E-cadherin levels through the induction of the 
transcription factors SNAI1 and SNAI2 via Smad3 (141). SNAI1 and SNAI2 
repress E-cadherin transcription, therefore decreasing steady-state levels of E-
cadherin (142,143). Furthermore, not only do cells decrease E-cadherin during 
EMT, but they also undergo a “cadherin switch” increasing the production of N-
cadherin, or neuronal cadherin (144). N-cadherin up-regulation is also induced by 
TGF(145)and increased levels of N-cadherin are associated with an increase 
in cell motility, an important trait of mesenchymal cells (146). TGFalso induces 
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the production of fibronectin, which contributes to cell-adhesion and motility 
(128).  
EMT is essential in development for the generation of the three-layered 
body plan of the embryo consisting of endoderm, mesoderm, and ectoderm, 
which arises through gastrulation (140). Indeed, blocking EMT prevents 
development beyond the blastula stage (140). TGF is implicated in EMT during 
heart valve formation in the developing embryo. TGF3 expression is up-
regulated by atrioventricular endothelial cells and works in concert with BMP-2 to 
initiate EMT in these cells (147). 
 While EMT is essential for body patterning and organogenesis in 
development, it has also been implicated in a number of pathologies including 
cancer. In order for a tumour cell to disseminate to distant sites, it must first 
detach from adjacent tumour cells, invade into the tissue, intravasate into the 
blood or lymphatic system, extravasate and grow at a distant site (148). In 
cancer, the ability of an epithelial-derived cancer cell to obtain mesenchymal 
characteristics permits the migration and invasion of that cell to distant sites (2). 
Indeed, a number of histological sections of cancers show cells undergoing EMT 
at the leading edge of the invasive front of the tumour (2). Interestingly, EMT has 
recently been shown to endow cancer cells with stem-cell like features, such as 
the expression of stem-cell markers and self-renewal (149,150). Therefore, EMT 
gives two advantages to a cancer cell. By giving cells the ability to migrate and 
invade, EMT promotes metastasis, but by promoting stem-cell features, EMT 
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also imparts on these cells the potential for self-renewal (149). Therefore, 
identifying the mechanisms whereby TGFinduces and regulates EMT is an 
important area of research. 
1.7 Smad-independent Signalling  
 While the activation of the classical Smad-mediated TGFpathway has 
been well established, TGFhas also been shown to undergo cross-talk with 
several pathways including the PI3 kinase/Akt pathway, the Wnt pathway, the 
Notch pathway and the MAP kinase pathway (reviewed in (151)). For the 
purposes of this thesis I will focus on the cross-talk of TGFwith the Wnt and 
MAPK pathways. 
 The WNT and TGFpathways are both implicated in important processes 
such as development, fibrosis, and cancer. Research by Labbe and colleagues 
illustrated that TGFhas been shown to have a synergistic effect with Wnt 
signalling. For example, using a microarray approach, Labbe and colleagues 
found 78 novel genes up-regulated only by treatment with both TGFand Wnt3a 
and not each ligand independently, illustrating that the ligands are not simply 
having an additive effect (152). Importantly, a number of these TGF/Wnt3a 
target genes, such as CTGF, Inhba, and MMP14 are over-expressed in tumours 
from patients with familial adenomatous polyposis (152). Numerous cancers also 
have elevated Inhba, such as breast, lung, pancreatic and intestinal cancers 
(152). While the mechanism through which Wnt and TGFco-operatively signal 
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is not yet established, the co-operation of these two signalling pathways in 
tumourigenesis may have important implications in cancer progression. 
 The ability of TGFto activate components of the MAP kinase pathway 
has long been observed, however, the exact mechanisms whereby it accesses 
this pathway independently of Smads have only been recently elucidated.  The 
MAP kinase pathway consists of a series of phosphorylation events, ultimately 
resulting in the formation of a complex to activate transcription. There are three 
principle MAP kinase pathways: the ERK1/ERK2 pathway, the Jun N-terminal 
Kinase (JNK) pathway, and the p38 pathway. The MAP kinases are 
phosphorylated by the MAP kinase kinases (MAP2Ks), which in turn are 
activated by MAP kinase kinase kinases (MAP3Ks), which are activated in 
response to extracellular stimulation. ERK1/2 has been shown to be pro-
tumourigenic, with high expression levels in many tumours, whereas JNK and 
p38 kinases are stress-induced pathways with more complex roles in cancer 
(153).  
TGFcan activate all three MAP kinase pathways. It has been shown that 
TGFactivates Erk1/2 via TRI. Briefly, TGFstimulation induces TRI to 
directly phosphorylate ShcA on serine and tyrosine residues, though at a lower 
level than its phosphorylation of  Smads  (154). The phosphorylation of ShcA 
allows it to interact with Grb2, an adaptor protein which is constitutively 
associated with Sos (Son of sevenless) (155).  Sos is a guanine nucleotide  
 
Figure 1.8 Smad-independent activation of p38 and JNK by TGF
TGFstimulation can activate the p38 and JNK MAP kinase pathways. 
TGFstimulation facilitates Traf6 interaction with the receptor complex, where it is 
ubiquitinated. The ubiquitinated Traf6 then recruits TAK1 to activate p38 and JNK 
signalling.  
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exchange factor which promotes the exchange of GDP for GTP on Ras, thereby 
leading to the activation of Ras/ERK pathway  (154,155).   
TGFactivates both p38 and JNK MAP kinase pathways via TAK1 (TGF 
activated kinase 1) (Figure 1.8).   TAK1 is a MAP3K and was shown to be 
activated in response to TGFto induce MAPK-dependent transcription (156). A 
study by Yamashita and colleagues identified Traf6 as a functional link between 
the TGFreceptors and TAK1 (157). Traf6 can interact directly with the 
TGFreceptor complex and in response to TGFstimulation, is ubiquitinated 
which facilitates its interaction with TAK1 (157). The authors further illustrated 
that Traf6 is essential for TGF-mediated activation of the MAPK pathway, as 
siRNA mediated silencing of Traf6 abrogated the ability of TGFto increase p38 
and JNK phosphorylation (157) (Fig. 1.8). The importance of the p38 pathway to 
TGFsignalling has been highlighted by a study which illustrated that p38 is 
required for TGF-induced EMT as well as apoptosis (158). The p38 inhibitor, 
SB203580, blocked TGFinduction of cleaved caspase as well as the loss of E-
cadherin, but did not affect the ability of TGFto induce Smad2 phosphorylation; 
highlighting the fact that the p38 pathway is activated independently of Smad 
signalling (158). Therefore, when studying TGFsignal transduction, it is 
important to assess both Smad-dependent and Smad-independent signalling 
pathways.  
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1.8 Purpose of study, hypothesis, aims 
The TGFsignalling pathway is crucial to both normal development and 
tissue homeostasis. The regulation of this pathway must be tightly controlled- this 
is evident in pathologies which show hyper-activation of the TGFpathway such 
as cancer and fibrosis. Indeed, TGF signalling is commonly dysregulated in 
cancer, and the ability of TGFto induce EMT is a crucial step in cancer 
progression and the dissemination of tumour cells to distant sites. Interestingly, 
the endocytic route of the TGFreceptors directly influences their signalling 
outcome. Receptors internalized via clathrin-mediated endocytosis propagate 
TGFsignalling, while internalization of TGFreceptors via membrane rafts 
targets the receptors for degradation. Therefore, identifying proteins that direct 
TGF trafficking will directly impact TGFsignal transduction. Therefore, I 
hypothesize that protein interactions which alter TGFreceptor 
endocytosis will have a direct effect on TGFsignal transduction.  The 
specific aims of this study are: 
Aim 1: Identify TRII motifs that direct membrane raft partitioning. 
Aim 2: Evaluate the role of TRIII to TRII/TRI trafficking and signalling.  
Aim 3: Assess the impact of -arrestin2 on TGFreceptor trafficking and signal 
transduction. 
Aim 4: Study the role of TGFligand sub-types on TRII/TRI trafficking and 
signalling in non-small cell lung cancer cells. 
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CHAPTER 2 
             
THE EXTRACELLULAR DOMAIN OF THE TGF TYPE II RECEPTOR 
REGULATES MEMBRANE RAFT PARTITIONING 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter has been published in Biochem  J.  (2009) 421, 119-
131. 
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2 Chapter 2 
2.1 Chapter summary 
TGF-dependent Smad signal transduction has been shown to be mediated 
by the endocytosis and trafficking of the TRII/TRI complex. Receptors 
internalized by clathrin-mediated internalization traffic to the early endosome and 
propagate Smad signaling, while those internalized by membrane-rafts traffic to 
the caveolin-1 positive vesicle and are targeted for degradation. However, the 
signal(s) which direct membrane raft partitioning of the signal complex are 
unknown. In this chapter, I evaluate structural motifs of TRII which direct its 
partitioning and endocytosis. This chapter illustrates that the extracellular domain 
of TRII increases its entry into membrane-raft fractions and that the 
glycosylation state of the cell as a whole, but not of TRII itself, decreased entry 
of TRII into membrane rafts. Importantly, I showed that a chimeric construct 
consisting of the extracellular domain of GMCSF and the intracellular domain of 
TRII, does not greatly partition into membrane rafts, although the extracellular 
GMCSF is glycosylated similar to TRII. My data from this chapter therefore 
suggests that a glycosylated protein interacts with the extracellular domain of 
TRII to influence its partitioning. 
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2.2 Introduction 
Endocytosis of cell surface proteins occurs via multiple pathways, two of 
which are clathrin-dependent and membrane raft-dependent, with the latter 
leading in part to entrance into caveolin-positive endosomes (1).  Clathrin-coated 
vesicles, which form from the fission of plasma membrane clathrin-coated pits, 
carry receptors to the PtdIns3P-enriched early endosome, from which they can 
recycle back to the plasma membrane or continue into the late endosomal 
system for degradation (1).  Membrane rafts are heterogeneous microdomains in 
the plasma membrane that act to compartmentalize cellular processes (2). They 
are enriched in cholesterol, sphingolipids, and glycolipids, and fractionate based 
on light buoyant density on sucrose gradient (3).  Membrane raft/caveolar 
internalization of receptors occurs through small flask-shaped invaginations 
called caveolae (3).  They are rich in caveolins, hairpin-like palmitoylated integral 
membrane proteins that bind cholesterol (3).  Caveolae can act as signaling 
platforms from which receptors such as GPCRs, receptor tyrosine kinases, and 
steroid hormone receptors aggregate so as to facilitate downstream signaling 
events (4). Raft dependent internalization and caveolin-positive endosomes have 
also been described for the uptake of various viruses and toxins (4). 
 The transforming growth factor- (TGF) superfamily regulates many 
cellular functions, including proliferation, differentiation, apoptosis, migration and 
extracellular matrix production (5).  The signal transduction pathway initiated by 
cell surface TGFreceptor complexes is dependent on ligand binding as well as 
receptor internalization and trafficking (1).  Activation of the receptor is initiated 
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through ligand-induced heteromeric complex formation of type I (TRI) and type 
II (TRII) transmembrane Ser/Thr kinase receptors that target both Smad-
dependent and independent signaling pathways (6).  Smad activation by TGF 
involves the phosphorylation of the regulatory Smads, R-Smad2 and R-Smad3.  
TGF employs two internalization pathways one of which is clathrin-dependent 
and the other is clathrin-independent and membrane raft-dependent (rev. by (1)).  
Entrance into the early endosome is thought to promote Smad activation through 
Smad anchor for receptor activation (SARA) protein, which binds the receptors 
and recruits Smads to the membrane.  The early endosome also contains 
hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), which co-
operates with SARA to facilitate TGF signaling (7), and cytoplasmic 
promyelocytic leukemia protein (cPML), a scaffolding molecule that is necessary 
for TGF signaling (8). 
TGF signaling is antagonized by the inhibitory Smad7, which interacts 
with TRI and recruits the E3 ubiquitin ligase Smurf2, which directs ubiquitin-
dependent degradation of the TGF receptors (9,10).  Smad7 and Smurf2 
complexes are localized to the caveolin-positive compartment and perturbation of 
membrane rafts increases signaling and reduces the rate of receptor degradation 
(11-13). 
The partitioning of cellular transmembrane proteins into membrane rafts is 
complex and can be dependent on the extracellular domain, as in the case for 
the EGFR (14), the transmembrane domain as is the case for carboxypeptidase 
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E (15) or the intracellular domain as is the case for adenylyl cyclases (16). 
Recently, membrane rafts have been implicated in the endocytosis of other TGFβ 
superfamily members, namely bone morphogenetic receptor 1 and 2 (BMPRI, 
BRII) (17,18).  While cell surface TGF receptors reside in both membrane raft 
and non-raft membrane domains (11-13,19) the determinant that controls 
partitioning is unknown.  A short peptide sequence (I218I219L220) on the 
cytoplasmic region of TRII is the major signal for clathrin-mediated endocytosis 
(20) and the TGF receptors associate with both clathrin and AP-2 (21).  
However, the cytosolic TRII domain also contains consensus sequences that 
were previously identified as caveolin scaffolding domains (22) and the major 
binding partner of TRII, the type I TGF receptor, has also been shown to 
associate with caveolin-1 (13,23).  On the extracellular surface of the plasma 
membrane Galectin 3, a -galactose binding protein that contains a 
carbohydrate recognition domain (24), associates with receptors and is 
postulated to influence receptor internalization into EEA1 and caveolin-1 positive 
vesicles (25).  Due to the numerous interacting partners on both facets of the 
plasma membrane, the primary determinants that partition receptors into 
membrane rafts remain unclear.  
Using subcellular fractionation and mutants of TRII I demonstrate that the 
extracellular domain of TRII mediates receptor partitioning into membrane rafts.   
Consistent with these results, I illustrated that a GMCSF-TRII hybrid receptor 
that replaces the native TRII extracellular domain with that of the GMCSF 
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receptor, results in a chimeric receptor that is largely excluded from membrane 
rafts and caveolin-1-positive structures.  Also, studies using tunicamycin 
perturbed receptor membrane raft partitioning. Importantly, I showed that this 
was not due to a disturbance of membrane raft formation, as treatment of cells 
with tunicamycin did not disrupt membrane rafts. Furthermore, the glycosylation 
of TRII itself did not account for its differential membrane partitioning, 
suggesting that partitioning involves interactions with other cell surface 
glycoproteins.  Taken together, my results indicate that the extracellular region of 
TRII is necessary for receptor membrane raft partitioning. 
2.3 Materials and Methods 
2.3.1 Reagents 
Polyclonal anti-HA, anti-Flag and anti-TRII (Santa Cruz), monoclonal 
anti-HA (12CA5, Boehringer), monoclonal anti-EEA1 (Transduction 
Laboratories), monoclonal anti-Flag (Sigma), monoclonal anti-CD131 
(Bioscience) and polyclonal anti-caveolin-1 (Transduction Laboratories) 
antibodies were used as per the manufacturers’ instructions. Tunicamycin was 
purchased from Sigma-Aldrich. TGF1 ligand was purchased from Peprotech. 
2.3.2 Constructs 
Constructs encoding for the amino or carboxyl terminally hemagglutinin 
(HA) epitope-tagged wild-type TGF type II receptor (HA-TRII or TRII-HA; 
(26)), the intracellularly truncated receptor (HA-TRII-Cyt; (27)) and the 
GMCSF-TRII hybrid receptor (28), and the GMCSF2RB receptor (a.k.a. bC; 
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(29)) were previously described. The full length carboxyl HA-tagged TRII in 
pCMV5 was used as the template to construct a receptor that has the signal 
sequence and 13 amino acids of the extracellular domain (TRII-EX-HA) and 
the glycosylation mutant substituting asparagines 70, 94 and 154 of the TRII to 
aspartic acid residues (TRII-3ND-HA).  All constructs were generated using a 
PCR-based mutagenesis approach and were validated by sequencing analysis. 
       
2.3.3 Cell Culture 
HEK 293T human kidney epithelial cells (American Type Culture 
Collection) were cultured in DME medium (Gibco) supplemented with 10% fetal 
bovine serum.  Cells were maintained at 37C in a humidified atmosphere 
containing 5% CO2 . 
2.3.4 Transfection         
  
 HEK 293T cells were transiently transfected using the calcium phosphate 
precipitation method as previously described (12). Briefly, HEK293T cells were 
plated at approximately 50% confluency in 6 well dishes. The following day cells 
were transfected with 1.0 g of TRII-HA, 1.5 g of HA-TRII-Cyt, 0.5 g of 
TRII-EX-HA and/or 1.0 g TRI-flag as indicated in Figure 2.1.  
2.3.5 Preparation of Membrane Rafts/caveolin-enriched fractions 
 The caveolin/raft-rich membrane fractions were isolated as previously 
described (12).  Briefly, transfected cells grown to confluence in 100-mm dishes 
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were used to prepare the membrane fractions.  All steps were carried out at 4C.  
After two washes with cold 1 phosphate-buffer saline (PBS) cells were lysed 
with 0.5 M Na2CO3, pH 11.0, containing protease inhibitors.  After scraping, the 
cell lysate was collected and homogenized three times for 10s bursts using a 
Polytron tissue grinder (Brinkmann Instruments).  Homogenates were then 
sonicated three times for 20s with a Vibra Cell sonicator (Sonics Materials Inc.).  
The homogenates were adjusted to 40% sucrose and overlaid with 30% sucrose 
and 5% sucrose solutions. The samples were centrifuged at 200,000 x gav for 
16h at 4C, using a Beckman SW41 rotor. Twelve 1-mL fractions were collected, 
and an aliquot of each fraction was eluted with Laemmli sample buffer, boiled, 
and subjected to SDS-PAGE followed by Western blot analysis. 
2.3.6  Immunoblotting      
 Proteins were separated by SDS-PAGE and transferred to nitrocellulose 
membranes by electrophoretic transfer. Blots were then blocked in 5% skim 
milk/TBS-5 for one hour. Following overnight incubation with primary antibody at 
4˚C, blots were incubated with secondary antibody at room temperature for 45 
minutes. Bound antibodies were then detected using SuperSignal 
chemiluminescence reagent (Pierce) and blots were imaged on a VersaDoc (11). 
2.3.7  Immunoprecipitation  
 Transfected 293T cells were lysed (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 0.5 % Triton X-100, 1 mM PMSF, and cocktail protease 
inhibitors) and centrifuged at 15,000  gav at 4C for 5 min.  50 g aliquots of 
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supernatants were collected for analysis of total protein concentration.  The 
remaining cell lysates were incubated with anti-Flag mAb followed by protein G 
sepharose incubation.  The precipitates were washed 3 times, eluted with 
Laemmli sample buffer and subjected to SDS-PAGE and immunoblot analysis. 
2.3.8  Tunicamycin treatment  
 A dose response curve of tunicamycin treatment on HEK293T cells was 
completed and a concentration of 2g/mL was found to be optimal and did not 
induce cell death. HEK 293T cells were treated with 2 µg/mL tunicamycin in 
DMEM supplemented with 0.2% fetal bovine serum, 24h after transfection.  After 
20h of incubation with the antibiotic, cells were homogenized and fractionated by 
sucrose density ultracentrifugation as described above. 
2.4 Results 
2.4.1  An extracellular truncation mutant of TRII interacts with TRI 
To understand if the partitioning of TGF receptors between raft and non-
raft membrane domains is dependent on a molecular address in the receptor, we 
first explored the extracellular and intracellular domains of the TGF type II 
receptor (TRII).  A mutant containing only 13 amino acids of the extracellular 
domain (TRII-EX-HA) was generated and examined along with a truncated 
TRII which contains only 10 amino acids of the intracellular domain (HA-TRII-
Cyt; (27); Figure 2.1A).  The full length TRII-HA and HA-TRII-Cyt have been 
previously described and are both present at the cell surface.  They also bind 
ligand and the TGF type I receptor (27).  However, TRII-EX-HA had not been  
Figure 2.1 Characterization of TRII lacking the extracellular domain. 
(A) TRII mutants lacking the extracellular or the intracellular domain.  Full length TRII-
HA and intracellularly truncated TRII (HA-TRII-Cyt) have been previously 
characterized (26,27).  The extracellularly truncated receptor tagged at the carboxyl 
terminus (TRII-EX-HA) was generated for this study. The different domains of the 
receptors, the hemagglutinin tag (HA) as well as the plasma membrane (PM) and 
cytoplasm are indicated. 
 (B) TRII-EX-HA interacts with wild type TRI.  HEK 293T cells were transiently 
transfected with cDNA encoding the indicated receptors.  Cell lysates were subjected to 
immunoprecipitation (IP) with mouse anti-Flag antibody followed by immunoblotting with 
rabbit anti-HA antibody (-HA) to detect TRI-associated type II receptor or rabbit anti-
Flag (-Flag) antibody to detect total TRI expression as indicated (top panel).  The 
relative expression of each construct was assessed by immunoblotting 50 g of total 
cell lysates.  The relative mobilities of the receptors are indicated (N=3). 
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Figure 2.1 
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characterized.  Therefore, I sought to assess whether TRII-EX-HA is able to 
associate with the type I TGF receptor (TRI).  This occurs independently of 
ligand binding and is mediated by the cytoplasmic domains of the receptors (30).  
Indeed, immunoprecipitation of TRI and immunoblotting for type II receptors 
revealed that TRII-EX-HA associated with TRI (Figure 2.1B). It is noteworthy 
that both forms of the membrane-bound TRII-EX receptor, the 50 and 52 kDa 
forms, associate with the TRI, whereas the 47 kDa cytosolic fragment of TRII-
EX does not associate with membrane-localized TRI. As positive controls, I 
assessed the interaction of TRI with the wild type TRII-HA as well as HA-
TRII-Cyt and I observed that they both associate with immunoprecipitated 
TRI.  
2.4.2  TRII-EX-HA is largely excluded from membrane raft fractions 
Having found that the TRII-EX-HA associates with TRI, the membrane 
raft partitioning of the three versions of TRII was next compared (Figure 2.2).  
To assess membrane partitioning, cell homogenates were fractionated via 
sucrose density centrifugation as previously described (11-13,19).  Briefly, cell 
homogenates were adjusted to 40% sucrose, overlaid with 30% and 5% sucrose 
cushions and centrifuged (Figure 2.2A; left panel). One mL fractions were then 
collected and immunoblotted with markers of either membrane rafts or early 
endosomes.  Confirmation of the partitioning of raft from non-raft membranes is 
shown in Figure 2.2A (right panel) where fractions 4-6 on the sucrose gradient 
contained the majority of caveolin-1, a membrane raft resident protein (31) and  
Figure 2.2 The TRII extracellular domain is important for membrane raft 
partitioning. 
(A) Subcellular fractionation of HEK 293T cells.  Schematic representation of membrane 
raft isolation protocol (left panel).  Cell homogenates were sonicated and adjusted to 
40% sucrose, overlaid with 30% and then 5% sucrose cushions prior to 
ultracentrifugation (C).  Twelve 1 mL fractions were then collected with membrane rafts 
(white region) usually present in fractions 4-6.  Aliquots were immunoblotted for 
endogenous EEA1 (-EEA1), or endogenous cav-1 (-Cav-1), (right panel) (N=3). 
(B) Membrane raft partitioning of full length TRII and the truncation mutants.  HEK 
293T cells transiently transfected with cDNA containing the indicated receptor 
constructs were subjected to subcellular fractionation as described in panel A.  All 
fractions were then immunoblotted with anti-HA antibody (-HA). HEK 293T cells 
transiently transfected with wild-type TRII cDNA were treated with 500 pMol TGF for 
1 hour and subjected to subcellular fractionation (bottom panel).  The fractions were 
then subjected to SDS-PAGE and immunoblotted with anti-TRII antibody (N=3).  
(C) Quantitation of wild-type and mutant forms of TRII in membrane raft and non-raft 
fractions.  Membrane raft (fractions 4-6) or non-raft (fractions 8-12) fractions from 
experiments described in (B) were pooled, adjusted to the same volume and 
immunoblotted with anti-HA (-HA) antibody. The relative amount of TRII receptors in 
membrane-raft and non-raft fractions were quantitated using QuantityOne software and 
graphed as a percentage of total receptors expressed.  Each data point represents the 
mean of three experiments ± standard deviation (N=3). 
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Figure 2.2 
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fractions 8-12 contained the early endosomal auto-antigen 1 (EEA1), an early 
endosomal resident protein (32,33) .  To analyze receptor partitioning TRII-HA, 
HA-TRII-Cyt or TRII-EX-HA was transiently expressed in HEK 293T cells 
and fractionated cell homogenates on sucrose gradients (Figure 2.2B).  TRII-HA 
was found to be present in both the raft and non-raft fractions and HA-TRII-Cyt 
was also observed in raft and non-raft fractions (Figure 2.2B).  In contrast, the 
TRII-EX-HA receptor was predominantly observed in the non-raft fractions. To 
assess whether ligand treatment affects TRII membrane partitioning, I treated 
HEK 293T cells with 500 pM TGFone hour prior to membrane raft isolation. 
Following SDS-PAGE and immunoblotting, I observed that TGFtreatment does 
not affect partitioning, as TRII was still found primarily in raft fractions.  To 
measure the relative amounts of receptors in the raft and non-raft fractions, raft 
fractions (fractions 4-6) or non-raft fractions (8-12) were pooled from experiments 
carried out as shown in Figure 2.2B, adjusted to the same volume and were 
subjected to quantitative immunoblotting (Figure 2.2C). It was observed that 
approximately 65% of TRII was in rafts whereas 85% of TRII-Cyt fractionated 
in rafts (Figure 2.2C; right panel).  In marked contrast, only 20% of TRII-EX-
HA was in the membrane raft fractions.  These results indicate that the 
extracellular domain of TRII mediates partitioning into membrane rafts, but the 
extracellular domain is not affecting partitioning via its ligand-binding capabilities. 
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2.4.3  Perturbation of glycosylation alters membrane raft partitioning of TRII  
Cells lacking proper glycosylation have defects in cytokine, and in 
particular TGF signaling (25).  Therefore the pharmacological perturbation of 
cellular glycosylation was assessed to determine if this would alter TGF 
receptor partitioning in membrane raft domains (Figure 2.3). HEK293T cells 
transiently expressing wild-type TRII were incubated with tunicamycin, an 
antibiotic that blocks the reaction of UDP-GlcNAc and  Dol-P in the first step of 
glycoprotein synthesis and  thus inhibits the synthesis of all N-linked 
glycoproteins (34).  A reproducible decrease of receptors in the raft fractions and 
a concomitant increase in non-raft fractions in tunicamycin-treated cells was 
observed (Figure 2.3A).  Importantly I illustrated that this shift was not due to 
perturbation of lipid rafts with tunicamycin treatment as shown in Figure 2.3B. 
2.4.4 The glycosylation status of TRII does not alter its membrane raft 
partitioning 
These results suggest that the glycosylation state of TGF receptors 
and/or the proper glycosylation of other cell surface proteins regulate the 
membrane raft partitioning of receptors.  To distinguish between these two 
possibilities, a construct of TRII that contains mutations in all three putative N-
linked glycosylation sites was generated (TRII-3ND-HA; Figure 2.4A). Based on 
the molecular weight of the mutant compared to the wild-type receptor, it appears 
that the three putative sites are indeed glycosylation sites (Figure 2.4).The 
partitioning of TRII-3ND-HA in membrane raft and non-raft fractions was next 
assessed.  It was shown that this receptor co-fractionated with both membrane  
Figure 2.3 Perturbation of glycosylation alters membrane raft partitioning of TRII   
 (A) Quantitation of pharmacological inhibition of glycosylation on receptor partitioning. 
Membrane raft (fractions 4-6) or non-raft (fractions 8-12) fractions from experiments 
described in were pooled, adjusted to the same volume and immunoblotted with anti-HA 
(-HA) antibody.  The relative amount of TRII receptors in membrane-raft and non-raft 
fractions were quantitated using QuantityOne software and graphed as a percentage of 
total receptors expressed.  Each data point represents the mean of three experiments ± 
standard deviation. 
(B)  Evaluation of tunicamycin treatment on membrane raft formation. HEK 293T cells 
were grown in the presence or absence of 2 ug/mL tunicamycin for 20 hours. Cells were 
then subjected to sucrose-density ultracentrifugation and immunoblotted for early 
endosome autoantigen 1 (-EEA1) or caveolin-1 (-Cav-1) (N=3). 
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Figure 2.3 
  
 
Figure 2.4.  The TRII glycosylation mutant partitions in membrane rafts. 
(A) Schematic representation of wild type TRII and the mutant in which the three N-
linked glycosylation sites were mutated from asparagine (N) to aspartic acid (D) (TRII-
3ND-HA). 
(B) Membrane raft partitioning of TRII-HA and TRII-3ND-HA.  HEK 293T cells 
transiently transfected with control vector (pCMV5) or cDNA containing the indicated 
receptors were subjected to subcellular fractionation in order to separate cellular 
membrane raft and non-raft components.  The fractions were immunoblotted with anti-
HA antibody (-HA; top panel).  The membrane-raft and non-raft fractions were pooled, 
immunoprecipitated (IP) with anti-TRII antibody and immunoblotted with anti-TRII 
antibody (-TRII; bottom panel).  The percentage of receptors in membrane rafts was 
quantitated using QuantityOne software and is indicated as % in the raft compartment 
(N=3). 
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raft and non-raft fractions in a similar fashion to the wild type TRII (Figure 2.4B).  
Quantitation of pooled raft and non-raft fractions revealed that in both cases 
approximately 60% of the receptors were found in the raft fractions and 40% in 
the non-raft fractions (Figure 2.4B, bottom panel).  Together, these results 
demonstrate that the glycosylation state of TRII per se is not a determinant for 
membrane-raft partitioning, and suggest that partitioning may rely on the proper 
glycosylation of other cell surface proteins. 
2.4.5  GMCSF-TRII does not partition with membrane rafts  
Having observed that the glycosylation state of the TRII was not a factor 
in raft vs. non-raft partitioning, I therefore assessed whether a substitution of the  
extracellular domain of TRII with another receptor that also contained 3 N-linked 
glycosylation sites would affect membrane raft partitioning. To do this I studied a 
hybrid GMCSF-TRII receptor construct (28).  This hybrid receptor contains the 
extracellular domain of the granulocyte/macrophage colony stimulating factor 
(GMCSF) 2B receptor, fused to the transmembrane and intracellular domains of 
the TRII.  Similar to the wild-type TRII, it has three N-linked glycosylation sites 
but was reported to be excluded from caveolin-positive membrane domains 
structures ((35); Figure 2.5A). In contrast to the wild type TRII, I found that the 
wild type GMCSF2BR was predominantly found to partition in non-raft fractions 
(Figure 2.5B and C).  Interestingly, the GMCSF-TRII chimeric receptor was also 
found to mostly partition with the non-raft fractions (Figure 2.5B and C).  This 
supports the previous findings that the glycosylation state of the receptor does  
Figure 2.5 GMCSF-TRII hybrid receptors partition predominantly in non-raft 
fractions. 
(A) Schematic comparison of TRII, the GMCSF-TRII receptor hybrid, and GMCSF-
2RB. 
(B) HEK 293T cells transiently expressing the receptor constructs as indicated were 
subjected to subcellular fractionation to separate membrane raft and non-raft 
components. Fractions were then immunoblotted with anti-HA or anti-CD131 antibody 
as indicated. All fractions were also subjected to immunoblotting with caveolin-1 
antibodies (-Cav1) in order to indicate membrane rafts (N=3).  
(C) Fractions from the experiments carried out as described in (B) were pooled into raft 
and non-raft fractions and adjusted to the same volume. Pooled membrane raft and 
non-raft fractions were then immunoblotted with anti-TRII (-TRII) antibody or anti-
CD131 (-CD131) antibody (top panel), quantitated and graphed as a percentage of 
total receptor expressed (bottom panel).  Each data point represents three experiments 
± standard deviation. 
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  Figure 2.5 
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not play a direct role in membrane raft partitioning and that the native 
extracellular domain of TRII is essential for raft partitioning. 
 
2.5 Discussion 
Different transmembrane proteins have been shown to partition into 
membrane raft domains via their extracellular, intracellular or transmembrane 
regions (14-16). For TRII it was unclear which domain is responsible because 
this receptor associates with proteins on both the extracellular and intracellular 
facet of the plasma membrane.  On the outer aspect of the plasma membrane, 
Galectin 3 interacts with TRII and maintains receptors at the cell surface (25) .  
The intracellular domain of the receptor associates with clathrin and AP2 (21), 
and the TRII/TRI complex associates with caveolin-1, a resident membrane 
raft protein (13,23).         
To address this problem, the partitioning of TRII lacking the majority of 
the extracellular or intracellular domains was assessed.  It was found that a 
mutant TRII that lacked the intracellular domain almost entirely partitioned with 
membrane rafts similarly to wild type TRII, whereas the extracellularly truncated 
receptor was mostly excluded from rafts. These results indicate that while the 
extracellular domain of TRII directs receptors into rafts, the intracellular domain 
directs them to non-raft domains.  This was surprising because it was assumed 
that the intracellular domain, which contains a caveolin-1 binding motif, would 
play a larger role in membrane partitioning.  If receptor partitioning is not 
73 
 
 
 
mediated by caveolin-1 binding, then the association may be important for other 
functions within the membrane raft compartment after receptor partitioning.  
Indeed, it was previously found in HEK 293T cells that the association of 
receptors with Smad7 and Smurf2 occurred in membrane rafts and the 
degradation of the receptor complex was enhanced when caveolin-1 protein was 
expressed (11).  Furthermore, the chemical perturbation of membrane rafts 
induced an increase in TGF signal transduction.  Therefore, the partitioning of 
receptor complexes may be important for receptor degradation and/or inhibition 
of signal transduction and this may be dependent on caveolin-1 association with 
receptors post membrane raft targeting. 
The partitioning of receptors into membrane rafts also has important 
implications in receptor trafficking.  The intracellular domain that has the AP2 and 
clathrin binding sites was shown to be important for clathrin-dependent 
internalization (20).  Internalization from membrane rafts/caveolae leads to the 
formation of caveolin-1-positive vesicles.  The balance between the two 
internalization pathways would therefore be an important mediator in receptor 
signaling and degradation. 
Previous work showed that TGF receptors bound the cell surface N-
glycan binding protein Galectin 3 (25).  In that study, Mgat5-/- cells were found to 
contain more receptors in the EEA1-early endosomal compartment compared to 
wild type cells and the receptor half-life was prolonged (25). In this study, it was 
shown that mutation of all of the N-linked glycosylation sites of the full-length 
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receptor did not affect entrance into membrane rafts.  Therefore, it was 
concluded that glycosylation of TRII per se does not control trafficking but that 
the interaction of TRII with other cell surface glycoproteins or glycoprotein 
binding proteins, are critical.  This mode of raft/caveolae association is similar to 
that of the EGF receptor where the extracellular domain was found to be critical 
in the targeting of receptors to membrane rafts (14).  In fact, there are several 
parallels between EGF receptor and TRII raft partitioning: 1) they both bind cell 
surface Galectin-3, and  2) their partitioning is dependent on proper cellular 
glycosylation but not their own glycosylation.  Moreover, studies have shown that 
the ubiquitination and trafficking of EGF receptors are membrane raft-dependent 
processes (36,37).  It would therefore be of interest to assess if both of these 
receptors associate with common glycoproteins at the cell surface, which could 
direct them into membrane rafts. 
 Since the glycosylation state of the receptor was not responsible for the 
partitioning of receptors into membrane rafts and the scanning deletion mutants 
did not provide insight into the extracellular domain that regulate partitioning of 
receptors, I assessed if replacing the extracellular domain would influence raft 
partitioning.  I therefore turned my attention to a chimeric receptor, GMCSF-
TRII, which has three N-linked glycosylation sites, as does wild-type TRII, and 
upon endocytosis was shown to co-localize exclusively with clathrin-positive, but 
not caveolin-positive, structures (35).  Based on previous data, I therefore 
considered that absence of the native extracellular domain of TRII would 
interfere with normal raft partitioning and entrance into the caveolin-1 
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compartment.  Indeed, I found that partitioning of the GMCSF-TRII hybrid into 
rafts was substantially reduced compared to the wild type TRII. Since the 
partitioning was not completely abolished, a question remains as to why there 
are still a proportion of the hybrid receptors observed in the raft fractions?  
Previously, it was shown that TRI directly interacts with caveolin-1 via a 
consensus motif in the cytoplasmic tail of the receptor (23).  Interestingly, TRII 
contains putative caveolin-1 binding motifs, which may play a partial role in the 
partitioning of receptors into membrane rafts.  It was estimated that this 
partitioning is approximately 20% based on the observations using the TRII-
EX-HA construct (Figure 2.2).  The wild type GMCSF receptors also partially 
partition into membrane rafts (Figure 2.5).  Therefore the combination of a 
caveolin-1-binding motif and the small propensity of GMCSF receptors to 
partition into membrane rafts may account for the 40% of GMCSF-TRII hybrid 
receptor membrane raft partitioning.  
 Receptors that are endocytosed via clathrin-mediated endocytosis enter 
the early endosome, access Smad 2/3, and propagate TGF signal transduction; 
however, receptors that are localized in membrane rafts are targeted for 
degradation by ubiquitination (1). While the downstream signal transduction of 
the TGF signalling pathway has been well characterized, the signal(s) directing 
receptors to either method of endocytosis is still unclear. Here, it is shown that 
the extracellular domain of the type II receptor is necessary for entrance into 
caveolin-1 positive vesicles. It is also shown that the glycosylation status of the 
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cell, but not of TRII itself, affects the membrane partitioning of TRII. This 
suggests that there may be interacting glycosylated protein(s) acting at the cell 
surface that direct the partitioning of the type II receptor. 
 Several articles have attempted to identify signals affecting TRII 
partitioning at the cell surface. A study by Chen and colleagues illustrated that 
cells lacking heparin sulphate synthesis have significantly less TRII found in 
membrane rafts (38). The authors postulated that since TRIII has many 
proteoglycan attachments, it may be the signal that dictates TRII internalization. 
TRIII is the least well characterized of the TGF receptors, and its role in TGF 
signaling is only beginning to be understood. Several reports show that loss of 
TRIII can potentiate TGF-dependent epithelial-to-mesenchymal transition. 
Gordon and colleagues have shown that TGF-dependent EMT in pancreatic 
cancer cells results in a loss of TRIII expression (39). TRIII loss also occurs in 
prostate cancer cells and non-small cell lung adenocarcinoma cells, with 
increased loss of TRIII correlating with a more aggressive cancer phenotype 
(40, (40). However, a study by Criswell and colleagues showed that loss of 
TRIII in breast cancer cells decreased TGF dependent invasion, migration, 
and signal transduction (41). Recently, an article evaluated the endocytosis of 
TRIII and its membrane localization. The authors showed that while the receptor 
can internalize via both clathrin-dependent and independent mechanisms, 
inhibiting membrane raft internalization decreased TGF signal transduction (42). 
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All of these studies illustrate the fact that the role of TRIII in TRII endocytosis 
and signaling will be a fascinating area of study.   
Another interesting line of investigation will be to assess the contribution of 
TGF type I receptors in the partitioning of receptor complexes.  Huang and 
colleagues have observed that membrane raft and non-raft fractions contain 
altered ratios of the type I receptor to the type II receptor (38, 44, 45) .  They 
further found that this ratio plays a role in clathrin vs. caveolar endocytosis of 
receptors and influences their signaling potential. Therefore, future studies 
identifying how the different TGF receptors, as well as other cell surface 
receptor-interacting proteins, regulate TGF signaling and trafficking will be of 
great interest. 
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CHAPTER 3 
             
TGF RECEPTOR TYPE III DIRECTS CLATHRIN-MEDIATED ENDOCYTOSIS 
OF TGF BETA RECEPTOR TYPES I AND II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A version of this chapter has been published in Biochem J. (2010) 429, 137-145 
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3 Chapter 3 
3.1 Chapter Summary 
Chapter 2 of my thesis illustrated that the extracellular domain of TRII and 
the glycosylation status of the cell as a whole was important in directing 
membrane-raft partitioning of TRII. This suggested that a glycosylated protein 
which could interact with TRII at the cell surface may direct TRII partitioning. In 
this chapter, I assessed a candidate protein, TRIII, for its ability to direct 
internalization and trafficking of TRII/TRI complexes. Overall, I found that 
TRIII increased non-membrane raft partitioning of TRII/TRI complexes and 
increased their trafficking to early endosomal compartments. Furthermore, the 
interaction of TRIII with the receptor complex could occur both in the presence 
and absence of ligand. Finally, the interaction of TRIII with TRII/TRI 
complexes increased the complex half-life as well as basal TGFsignalling.  
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3.2 Introduction 
The Transforming Growth Factor Beta (TGF) signalling pathway is 
necessary for the normal functioning of a variety of cells; its cell-type specific 
responses often mediate growth inhibition, extracellular matrix synthesis and cell 
migration. While this signalling pathway is crucial for normal development, it also 
plays a much more sinister role in a number of pathologies, including cancer (1). 
Somatic mutations of the TGFβ receptors, along with activation of potent growth-
promoting oncogenes can override the tumour-suppressive effects of TGFβ 
(reviewed in (2)). 
There are three principle receptor subtypes in the classical TGFβ 
pathway. TGFβ receptor I (TβRI) and TGFβ receptor II (TβRII) are structurally 
related glycoproteins with cytoplasmic serine/threonine kinase domains 
(reviewed in (3)). A third receptor, TGFβ receptor III (TβRIII) or betaglycan, is a 
large proteoglycan that is able to regulate TGFβ signal transduction by binding 
and presenting active TGFβ ligand to TRII (1).   
In the canonical TGFβ signalling pathway, the binding of ligand to TβRII 
causes TβRII to phosphorylate the TβRI receptor at serine-threonine residues in 
its GS domain (1). Activated TβRI then phosphorylates and activates Smad 
transcription factors.  With the aid of specific nuclear localization signals, the 
Smad complex translocates to induce TGF-dependent transcriptional 
programmes (4).  The signal transduction pathway of activated TGFβ receptors 
has been well characterized. However, the role of receptor interactions at the 
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plasma membrane and their effect on endocytosis and trafficking has yet to be 
fully evaluated.  
Endocytosis of nutrients, growth factors and receptors is necessary for the 
normal functioning of a cell. When cell-surface receptors are activated, they are 
able to interact with cytosolic adaptor proteins that can promote polymerization of 
clathrin (reviewed in (5)). Clathrin from the cytosol is recruited to the plasma 
membrane and aggregates to form pits (6). These pits can then form vesicles for 
the transportation of nutrients and signals from the extracellular environment to 
the cell interior (7).  
Clathrin-independent endocytosis through membrane rafts is also a 
common mechanism for the uptake of signals and nutrients from the extracellular 
environment. Membrane rafts are microdomains in the plasma membrane that 
are enriched in cholesterol and sphingolipids (8). Membrane rafts have been 
implicated in the endocytosis of a variety of receptors, including the group I 
metabotropic glutamate receptors (9), insulin-like growth factor receptor (10), and 
epidermal growth factor (reviewed in (11)). Similarly, membrane raft mediated 
endocytosis plays a crucial role in TGFβ signalling, specifically in regards to 
receptor turnover and degradation. TGF receptors endocytosed by clathrin-
dependent endocytosis increase TGFβ signal transduction, while membrane raft 
endocytosis of receptors promotes receptor degradation (12). It has been shown 
that the extracellular domain of TRII is necessary for entrance into membrane-
raft domains (13). Furthermore the glycosylation state of the cell, though not of 
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TRII itself, mediates TRII endocytosis (13). This suggests that TRII may 
interact with glycosylated protein(s) at the cell surface to direct receptor 
partitioning.   
While many studies have evaluated the contribution of the type II and type 
I TGF receptors to Smad signalling, few have investigated the role of TRIII. 
The type III TGF receptor is a highly glycosylated proteoglycan with a large 
extracellular domain (14, 15).  Previously, TRIII was thought to simply function 
in presentation of ligand to the type II receptor (16); however, several recent 
studies illustrate that TRIII may play a crucial role in TGF-dependent cancer 
metastasis. Expression levels of TRIII have been correlated with a number of 
cancers, including prostate cancer (17), ovarian cancer (18), granulosa tumours 
(19), and non-small cell lung adenocarcinomas (20). In some instances, TRIII 
overexpression appears to contribute to cancer cell motility and invasion (21), 
while in other cases knockdown of TRIII increases tumour cell metastasis (22).  
Furthermore, TRIII endocytosis has been implicated in the activation of 
TGFsignalling (23). These studies highlight the fact that TRIII may play a 
crucial role in TGF signalling, particularly in cancer.  
The objective of the present study is to evaluate the role of the type III 
TGF receptor in TGF receptor endocytosis and degradation.  Using 
immunofluorescence microscopy and sucrose-density ultracentrifugation, I show 
that TRIII directs TRII and TRI to undergo clathrin-mediated endocytosis. 
TRIII also increases trafficking of TRII into early endosomal compartments. 
86 
 
 
 
Furthermore, this re-directed trafficking increases TRII/TRI complex half-life 
and basal TGF signalling.    
3.3  Materials and Methods 
3.3.1 Cell culture  
HEK (human embryonic kidney)-293T cells were maintained in DMEM 
(Dulbecco’s modified Eagle’s medium) (Gibco) supplemented with 10% fetal 
bovine serum.  Mink Lung cells stably transfected with HA-tagged TRII (Mink 
Lung HAT cells) were cultured in MEM supplemented with non-essential amino 
acids, 10% fetal bovine serum and 0.3% hygromycin. HepG2 cells were 
maintained in MEM supplemented with non-essential amino acids and 10% fetal 
bovine serum. All cells were maintained at 37°C in 5% CO2. 
3.3.2 Constructs 
Constructs encoding the carboxy terminus hemagluttinin (HA) epitope 
tagged  type II  TGF receptor (TβRII-HA), the intracellularly truncated receptor 
(TβRII-Δcyt) and an extracellularly truncated receptor (TβRII-ΔEX) were 
previously described (13, 24).  The GFP-tagged Rab5 wild-type (WT), 
constitutively active (Q79L) and dominant negative (S34N) constructs were used 
as previously described (25). 
3.3.3 Transfection 
HEK293T cells were transiently transfected using the calcium phosphate 
precipitation method as previously. Cells were plated at 50% confluency in 
100mm dishes. The following day cells were transfected with 5 g TRII-HA, 5 
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g of TRI-flag, and 5 g of myc-TRIII. Mink lung HAT cells were transiently 
transfected using the polyethyleneimine (PEI) method.  
3.3.4 Isolation of caveolae/membrane-raft-enriched membrane fractions 
  
Membrane rafts were isolated as previously described  (12, 13) . Briefly, 
transfected HEK293T cells were grown to confluence in 100-mm-diameter 
dishes. Cells were washed twice with cold 1X PBS and lysed in 0.5M Na2CO3, 
pH 11.0 containing protease inhibitors. After the cells were scraped, the cell 
lysate was homogenized in three 10 second bursts using a Polytron tissue 
homogenizer (Brinkmann Instruments). Cells were then sonicated three times for 
20 seconds each with a Vibra Cell sonicator (Sonics and Materials). The 
homogenates were then adjusted to 40% sucrose, and overlaid with 30% 
sucrose and 5% sucrose solutions. The samples were centrifuged for 16h at 
200,000 gav at 4°C using a Beckman SW41 rotor. Following centrifugation, 
12x1mL samples were collected and an aliquot of each sample was denatured 
with Laemmli sample prep buffer, boiled and subjected to SDS-PAGE followed 
by immunoblotting. 
3.3.5 Immunoblotting  
Proteins were separated by SDS-PAGE (10% gels) and transferred to 
nitrocellulose by electrophoretic transfer. Blots were incubated for 1 hr in 5% 
skim milk/TBST. After incubation with primary and secondary antibodies, bound 
antibodies were detected using SuperSignal chemiluminescence reagent 
(Pierce) and a VersaDoc imager (Biorad).  
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3.3.6 Immunoprecipitation 
 HEK293T cells transiently transfected with cDNA were lysed in TNTE 
(50mM Tris/HCl, pH 7.4, 150 mM NaCl, 1mM EDTA, 0.5% Triton X-100, 1mM 
PMSF and protease inhibitors) and centrifuged at 14000 gav for 10 min. at 4°C. A 
protein assay was conducted on total cell lysates for analysis of protein 
concentration. The remaining cell lysates were then incubated with 1g -HA 
primary antibody for 16 hrs at 4°C followed by incubation with Protein G 
sepharose beads for 2 hrs at 4°C. The precipitates were washed three times, 
eluted with Laemmli sample prep buffer and subjected to SDS-PAGE (10% gels) 
and immunoblotting. 
3.3.7 Immunofluorescence/Receptor Internalization 
HAT Mv1Lu cells were plated on coverslips in 12 well dishes. Twenty-four 
hours post-transfection of myc-TRIII (0.3 g/well), Rab5-GFP (0.5 g/well), 
Rab5-S34N-GFP (0.5 g/well), Rab5-Q79L-GFP (0.5 g/well) or Cav-1 GFP (0.5 
g/well) cDNA with polyethylenimine, cells were serum-starved and treated with 
50 μM ZnCl2 to induce HA-TRII expression.  The following day, cells were 
cooled to 4°C, and treated with -HA antibody for 2 hours at 4°C to label 
receptors at the cell surface. Coverslips were then incubated with donkey anti-
rabbit Cy3 antibodies. After labelling, cells were either permitted to internalize, by 
incubating at 37°C for 30 minutes or 1 hour, or were immediately fixed and 
permeabilized. Cells were incubated with -EEA1 antibody, followed with donkey 
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-mouse Cy5.  All coverslips were then immunomounted and visualized using an 
IX81 inverted immunofluorescence microscope (Olympus, Canada).  
3.3.8 Affinity Labelling 
 Transiently transfected HEK293T cells were labelled for 2 hrs with 250 pM 
[125I] TGF1 ligand in 0.5% bovine serum albumin (BSA) in Krebs Ringers Hepes 
(KRH) at 4°C. Cells were cross-linked to ligand using disuccinimidyl suberate 
(DSS)  as described previously (12). Cells were then either immediately lysed in 
1XTNTE or incubated in media/10% FBS at 37°C for 2, 4 or 8 hrs prior to lysis. 
Samples were eluted with Laemmli sample prep buffer, and separated using 
SDS-PAGE (7.5% gels). Receptors were visualized using phosphorimaging 
(Molecular Dynamics). 
3.3.9 Luciferase Reporter Assay 
 HepG2 cells were transiently transfected using the calcium phosphate 
precipitation method with an Activin Response element upstream of a luciferase 
construct (ARE-Lux), -galactosidase, and FoxH1 alone (control) or with TRI, 
TRII and/or increasing concentrations of TRIII. FoxH1 is a transcriptional co-
activator necessary to induce maximal Smad-dependent transcription.  Cells 
were serum-starved in 0.2% FBS/MEM for 4 hrs prior to treatment. Cells were 
incubated in the presence or absence of 100 pMol TGF1 for 16 hrs. Luciferase 
activity was normalized to -galactosidase activity prior to analysis.  
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3.4  Results 
3.4.1 TRIII is concentrated in non- raft membrane fractions 
 Previous work has shown that the extracellular domain of the type II 
TGFreceptor is necessary for membrane raft partitioning (13). Deletion of the 
extracellular domain decreases the endocytosis of TRII receptors via membrane 
raft-dependent mechanisms (13). As both the type I and type III TGF receptors 
interact with the type II receptor, I first sought to identify the membrane 
localization of the three TGF receptor subtypes.   
 To evaluate the membrane localization of the TGF receptor subtypes, 
membrane raft fractions were isolated using sucrose-density ultracentrifugation 
as previously described  (12,13). Briefly, HEK293T cells were transiently 
transfected with myc-TRIII, TβRII-HA or TRI-flag cDNA. Cells were lysed in 1 
M Na2CO3 with protease inhibitors, homogenized and sonicated, then overlaid 
with a sucrose gradient.  Following overnight high-speed ultracentrifugation, 
fractions were collected and subjected to SDS-PAGE. Immunoblotting for 
endogenous caveolin-1, a marker of membrane rafts, was performed to ensure 
membrane raft isolation. As shown in Figure 3.1A, membrane rafts were 
concentrated in fractions 4-6. Membrane raft and non-raft fractions were pooled, 
adjusted for the same volume, and subjected to SDS-PAGE as shown in Figure 
3.1B. Interestingly, I observed that TRII and TRI largely partition in membrane 
raft fractions, with approximately 70% of type II receptors and 75% of type 
 
Figure 3.1 Membrane partitioning of TGF receptors.  
(A)  HEK293T cells transiently expressing myc-TRIII, HA-TβRII or TRI-flag were 
subjected to sucrose-density ultracentrifugation as described in experimental 
procedures. Fractions 1-12 were then collected and immunoblotted using -myc, -HA, 
and -flag antibodies as indicated. Fractions were also immunoblotted for endogenous 
caveolin-1, a marker for membrane rafts (N=3).  
(B)  Quantification of TGF receptor membrane partitioning. Fractions 4-6 (membrane 
raft) and 8-12 (non-raft) from each condition were pooled, adjusted to the same volume, 
and subjected to SDS-PAGE. Following immunoblotting with -myc, -HA or -flag 
antibodies (left panel), receptors levels were quantified using QuantityOne software and 
graphed (right panel; N=3 ± SD).  
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receptors found in membrane raft fractions (Figure 3.1B). However, TRIII is 
found more heavily concentrated in non-raft fractions with only 30% of receptors 
found in membrane raft fractions, and approximately 70% of receptors found in 
non-raft fractions (Figure 3.1B).   
I also evaluated the partitioning of endogenous TRII and TRI in HepG2 
cells by sucrose-density ultracentrifugation (Figure 3.2). I first assessed the 
membrane raft content of HepG2 cells by immunoblotting collected fractions for 
caveolin-1 (Figure 3.2A). To visualize endogenous receptors, I used [125I] TGF1 
ligand to label cell-surface receptors, subjected lysates to sucrose-density 
ultracentrifugation and performed autoradiography. Importantly, the radioactive 
ligand is cross-linked to the receptors, and and it has been shown that 
TGFligand does not dissociate from the receptor complex at low pH (pH 2) 
(12). Similar to what has been previously shown for Mv1Lu cells (12), 
endogenous TRII is found primarily concentrated in membrane raft fractions in 
HepG2 cells (Figure 3.2B), similar to my over-expression studies. TRI is found 
in both raft and non-raft fractions, with slightly more receptors found in non-raft 
fractions (Figure 3.2B).  While I show more TRI in membrane raft fractions in 
our over-expression studies, (Figure 3.2B), this difference may be due to the 
relative levels of TRI and TRII in HepG2 cells. 
 
 
 
Figure 3.2 Partitioning of endogenous TRI and TRII. 
(A) HepG2 cells were subjected to sucrose density subcellular fractionation as 
previously described. Fractions were immunoblotted with a marker for the early 
endosome (-EEA1) or a marker for membrane rafts (-cav1) to ensure isolation of 
membrane raft fractions.  A non-specific band is seen underneath the caveolin-1 protein 
band and is indicated (*) (N=3).  
(B) HepG2 cells were affinity-labelled with [125]I-TGF prior to sucrose density 
subcellular fractionation, as previously described. Following subcellular fractionation, 
lysates were subjected to SDS-PAGE. Receptor partitioning was visualized and 
quantified by phosphorimaging (Molecular dynamics). TRI and TRII partitioning into 
raft and non-raft fractions was quantified using QuantityOne software (N=3 ± SD).  
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3.4.2 TRIII forms a stable interaction with TRII in the presence and 
absence of ligand and affects its membrane partitioning 
Having found that TRIII was more concentrated in non-raft fractions, I 
sought to evaluate whether TRIII could alter the partitioning of TRII. I initially 
wanted to assess the ability of TRIII to form a stable interaction with TRII, as 
previous studies had simply suggested that the role of TRIII was to present 
TGF ligand to the receptor. To address this question, I used a co- 
immunoprecipitation approach in HEK 293T cells transiently transfected with 
TβRII-HA, myc-TRIII and TRI-flag cDNA (Figure 3.3A). Following transfection, 
cells were serum-starved and then either treated with 500 pMol TGF for 1 hr or 
left untreated.  Immunoprecipitation of cell lysates with -HA pAb and 
subsequent immunoblotting with -myc mAb revealed that TRIII is able to form 
a stable interaction with TRII in both the presence and absence of TGF (Figure 
3.3A). The interaction of TRIII with TRII in the absence of ligand suggests that 
TRIII may play a greater role in TGF signal transduction than simply ligand 
presentation.  
Since TRIII is found robustly in non-membrane raft fractions and can 
stably associate with TRII, I speculated that the interaction of TRIII with TRII 
might increase the partitioning of TRII in non-membrane raft fractions.  
 To evaluate the ability of TRIII to differentially partition TRII, HEK 293T 
cells transiently transfected with TβRII-HA and myc-TRIII cDNA were subjected 
to sucrose-density ultracentrifugation as previously described. Figures 3.3B and  
Figure 3.3. TRIII stably interacts with TRII and affects its membrane partitioning. 
(A)  HEK293T cells were transiently transfected with myc-TRIII, TβRII-HA and/or TRI-
flag as indicated in the panel. Cells were then serum-starved and incubated in low-
serum media in the presence or absence of 500 pMol TGF1 for 1 hr. Cell lysates were 
immunoprecipitated with -HA antibody and subjected to SDS-PAGE and 
immunoblotting as indicated.  The non-specific heavy chain of the immunoprecipitating 
antibody is indicated as IgG. (N=3) 
(B)  Fractions 4-6 (membrane raft; R) and 8-12 (non-raft; NR) were pooled, adjusted to 
the same volume, and subjected to SDS-PAGE and immunoblotting. (N=3) 
(C)  Membrane partitioning of TRII in the presence and absence of TRIII. HEK293T 
cells were transiently transfected with TβRII-HA or TβRII-HA + myc-TRIII. Cells were 
then subjected to sucrose-density ultracentrifugation. Twelve 1mL fractions were 
collected and subjected to SDS-PAGE and immunoblotted as indicated. (N=3) 
(D) Quantitation of membrane raft partitioning was then performed on the pooled 
fractions using QuantityOne software and graphed (N=3 ± SD). 
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3.3C illustrate that the interaction of TRII with TRIII increases the proportion of 
TRII found in non-membrane raft fractions. Quantitation of membrane raft 
partitioning was performed by pooling raft (R) and non-raft (NR) fractions and 
performing SDS-PAGE (Figure 3.3B).  Quantitative analysis of this differential 
partitioning was performed using Quantity One software. As shown in the graph 
in Figure 3.3D, upon co-expression with TRIII, 72% of TGF type II receptors 
are found in non-membrane raft fractions, as opposed to the amount of TRII 
found in non-membrane raft fractions in the absence of TRIII (33%). This 
suggests that the association of TRIII with TRII increases the endocytosis of 
TRII by clathrin-mediated mechanisms. As clathrin-dependent endocytosis 
promotes TGF signalling, TRIII expression may increase downstream 
signalling events.  
3.4.3 TRIII alters the endocytosis of the cytosolic truncation mutant of TRII  
  It has been previously shown that the cytosolic truncation mutant of 
TRII, TRIIΔcyt, is found nearly exclusively in membrane raft fractions (13). To 
assess whether TRIII can also re-direct the partitioning of TRIIΔcyt, I first 
performed a co-immunoprecipitation experiment to assess the interaction of 
TRIII with TRIIΔcyt and TRIIΔEX, which lacks the extracellular domain 
(Figure 3.4). As TRIII has a large, heavily glycosylated extracellular domain, I 
predicted that it primarily interacts with the extracellular domain of TRII. I used 
-HA primary antibodies to immunoprecipitate full-length TRII and the truncation  
Figure 3.4 TRIII interacts with the extracellular domain of TRII  
HEK293T cells were transiently transfected with myc-TRIII and full length TβRII-HA 
(WT), HA-TβRII lacking the intracellular domain (TRII-cyt) or TβRII-HA lacking the 
extracellular domain (TRII-EX-HA).  Cell lysates were immunoprecipitated with -HA 
antibody and immunoblotted with -myc or -HA antibodies (top panel).  Total cell 
lysates were also immunoblotted with -myc or -HA antibodies to indicate relative 
protein expression (bottom panel) (N=3). 
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mutants and to evaluate their association with the myc-TRIII. I observed that 
while TRIII can interact with both truncation mutants, it forms a more robust 
interaction with TRIIΔcyt (Figure 3.4).  
To address whether TRIII can re-direct the partitioning of TRIIΔcyt, I 
used sucrose-density ultracentrifugation to concentrate membrane rafts from 
HEK293T cells over-expressing TRIIΔcyt, and TβRIIΔcyt in the presence of 
TβRIII (Figure 3.5). Interestingly, I found that similar to full-length TRII, TRIII 
also shifts TRIIΔcyt from membrane rafts into non-membrane raft fractions 
(Figure 3.5). As an internal control, I also confirmed that TRIII was able to alter 
the membrane partitioning of full-length TRII (Figure 3.5). As TRIII can re-
direct the partitioning of TRIIΔcyt, this illustrates that the ability of TRIII to re-
direct the partitioning of TRII is not dependent on the intracellular domain of 
TRII, which has binding sites for clathrin (26).  
3.4.4  TRIII associates with TRI in the absence of ligand and affects its 
partitioning          
    
As TRI plays a crucial role in the propagation of TGF signalling by 
phosphorylating downstream R-Smads, I also wanted to assess whether TRIII 
may affect the partitioning of TRI.  
 I first assessed whether TRIII could interact with TRI using a co-
immunoprecipitation approach (Figure 3.6). I used -flag antibodies to 
immunoprecipitate TRIII, and similar to my results with TRII, I found that TRI  
Figure 3.5 TRIII moderately re-directs the membrane partitioning of a cytosolic 
truncation mutant of TRII 
HEK293T cells were transiently transfected with full length TβRII-HA, TβRII-HA lacking 
the intracellular domain (HA-TβRII-cyt) and/or myc-TβRIII and subjected to sucrose 
density subcellular fractionation and immunoblotted with -HA or  -myc antibodies 
(N=3). 
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Figure 3.5 
 
Figure 3.6. TRIII interacts with TRI in the absence of ligand and directs its 
membrane partitioning. 
(A) HEK293T cells were transiently transfected with TRI-flag, myc-TRIII or p3xflag 
(control) as indicated. Cell lysates were immunoprecipitated with -flag antibodies, 
processed for SDS-PAGE and immunoblotted with -myc or -flag antibodies (left 
panel). 50 g of total cell lysates were also immunoblotted with -myc or -flag 
antibodies to indicate relative protein levels (right panel) (N=3). 
(B) HEK293T cells were transiently transfected with TRI-flag, and/or myc-TRIII and 
subjected to sucrose density subcellular fractionation as previously described. Fractions 
were then processed for SDS-PAGE and were immunoblotted with -myc or -flag 
antibodies (N=3).  
 
 
 
 
 
 
 
 
 
 
 
100 
 
 
 
Figure 3.6 
 
101 
 
 
 
can form a robust interaction with TRIII in the absence of ligand (Figure 3.6A). 
Importantly, this interaction occurs in the absence of TRII, as HEK293T cells 
express very little endogenous TGF receptors.  To assess the membrane 
partitioning of TRI, I again used sucrose-density ultracentrifugation to isolate 
membrane rafts. Similar to Figure 3.1A, TRI is found predominantly in 
membrane raft fractions. To assess whether TRIII can re-direct concentrated in 
membrane raft fractions (Figure 3.6B). Interestingly, and complementary to my 
findings with TRII, TRIII also shifts TRI into non-raft fractions (Figure 3.6B). 
My results evaluating the partitioning of both TRI and TRII in the presence of 
TRIII suggest that TRIII is able to direct the partitioning of the TRII/TRI 
complex, but importantly, can interact with either receptor independently. 
3.4.5  TRIII decreases entry of TRII into caveolin-1-positive vesicles 
The intracellular trafficking of TGF receptors is also directly influenced by 
their endocytosis.  When TGF receptors are endocytosed via membrane 
rafts/caveolae, the receptors enter into caveolin-1-positive vesicles, and the 
receptors are targeted for ubiquitination and degradation (12). Furthermore, no 
signal transduction occurs in caveolin-1-positive vesicles, as TRI is blocked 
from interacting with Smad 2/3 by the inhibitory Smad, Smad7 (12). Thus, I 
predicted that since TRIII shifted TRII out of membrane raft fractions, less 
TRII would also be found in caveolin-1 positive vesicles.  To address this 
question, I used an immunofluorescence microscopy approach to visualize co-
localization of TRII and TRIII with GFP-tagged caveolin-1.  Mv1Lu HAT cells 
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stably over-express HA-TRII under the control of a zinc-inducible promoter. 
Cells were transiently transfected with myc-TRIII and GFP-tagged caveolin-1. 
The following day cells were cooled to 4˚C to prevent receptor internalization, 
and then were labeled with -HA antibodies and Cy3 donkey anti-rabbit 
secondary antibodies. Receptors were then permitted to internalize by warming 
the cells to 37ºC. I then performed immunofluorescence microscopy to visualize 
TRIII and caveolin-1. at 4˚C to label HA-tagged TRII at the cell surface.  
 The top panel of Figure 3.7 shows that in the absence of TRIII, a large 
fraction of TRII co-localizes with caveolin-1. However, upon addition of TRIII,  
less TRII is found co-localized with caveolin-1 (Figure 3.7). Furthermore, very 
little co-localization between TRIII and caveolin-1 was found. Not only do these 
results confirm my ultracentrifugation data, they also illustrate that TRIII can 
direct TRII out of the caveolin-1-positive vesicles, and therefore may also have 
a direct effect on TRII half-life. 
3.4.6  TRIII increases early-endosomal trafficking of TRII 
 Having shown that TRIII directs TRII out of caveolar vesicles, I sought 
to evaluate whether TRIII also increases TRII entrance into the early 
endosome. It has been previously shown that receptors internalized via clathrin-
coated pit mediated endocytosis traffic into early endosomes, where they can 
interact with Smad transcription factors to propagate TGF signalling (12).  
Figure 3.7. TRIII decreases TRII localization into caveolin-1 positive vesicles  
Top panel- Mv1Lu HAT cells stably expressing extracellularly HA-tagged TRII were 
transiently transfected with caveolin-1 GFP. Tagged TRII receptors were incubated 
with -HA antibodies at 4ºC. Following incubation with Cy3-labelled secondary 
antibodies (red), the cells were incubated at 37ºC to allow receptor endocytosis. TRII 
co-localizing with caveolin-1-GFP results in yellow staining (N=3). 
Bottom panel- Mv1Lu HAT cells stably expressing extracellularly HA-tagged TRII were 
transiently transfected with myc-TRIII cDNA and caveolin-1 GFP.  Tagged TRII 
receptors were incubated with -HA antibodies as described above. After receptor 
internalization, TRIII was labelled with Cy5 secondary antibodies (blue) to assess 
receptor co-localization. TRII co-localizing with caveolin-1 results in yellow staining, 
TRII co-localizing with TRIII results in magenta staining, and all three co-localizing 
results in white staining (N=3). 
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Therefore, if TRIII can re-direct the intracellular trafficking of TRII, then it may 
also have a direct effect on TGF signal transduction. To evaluate the ability of 
TRIII to affect TRII receptor trafficking I used an immunofluorescence 
microscopy approach to evaluate the co-localization of the receptors. As before, 
Mv1Lu HAT cells were transiently transfected with myc-TRIII cDNA. 
Approximately 36 hrs post-transfection, receptors were labelled at the cell 
surface by cooling cells to 4°C and incubating with -HA pAb. After labelling with 
 -rabbit Cy3, receptors were permitted to internalize by warming to 37°C. Cells 
were also labelled with -myc primary antibody, followed by donkey -mouse 
secondary antibody to visualize TRIII. To evaluate early endosomal trafficking of 
receptors two markers for the early endosome, early endosomal antigen 1 
(EEA1-FITC) (Figure 3.8A) and Rab5-GFP a GTPase involved in early 
endosomal sorting, (Figure 3.8B) were evaluated in terms of co-localization with 
receptors. 
Using immunofluorescence microscopy, I found that in the absence of 
TRIII, TRII co-localized with EEA1; however, a substantial proportion of 
receptors did not localize with EEA1 (Figure 3.8A). One possibility is that 
receptors are internalized by both clathrin and non-clathrin mediated 
mechanisms. However, upon co-expression with TRIII, more TRII was found 
co-localized with EEA1, suggesting an increase in clathrin-mediated endocytosis 
or endosomal retention (Figure 3.8A). Co-localization experiments with Rab5 
also showed that in the presence of TRIII, it appears that more TRII are found  
Figure 3.8 TRIII increases early-endosomal trafficking of TRII 
(A) Top panel- Mv1Lu HAT cells stably expressing extracellularly HA-tagged TRII were 
incubated with -HA antibodies at 4ºC. Following incubation with Cy3-labelled 
secondary antibodies (red), the cells were incubated at 37ºC for 1 hr to allow receptor 
endocytosis. After receptor internalization, the cells were immunostained with FITC-
labelled -EEA1 antibodies (green). TRII co-localizing with early endosomes results in 
yellow staining and non-EEA1 localized TRII is also found in the cytoplasm (red) 
(N=3). 
Bottom panel- Mv1Lu HAT cells stably expressing extracellularly HA-tagged TRII and 
transiently expressing myc-TRIII were incubated with -HA and -Myc antibodies at 
4ºC and processed for immunofluorescence microscopy as described in Figure 3.7 
(N=3).  
(B) Top panel- Mv1Lu HAT cells stably expressing extracellularly HA-tagged TRII were 
transiently transfected with Rab5-GFP. Following incubation with Cy3-labelled 
secondary antibodies (red), the cells were incubated at 37ºC to allow endocytosis. TRII 
co-localizing with Rab5-GFP results in yellow staining (N=3). 
Bottom panel- Mv1Lu HAT cells expressing HA-tagged TRII and myc-TRIII were also 
assessed for their co-localization with Rab5-GFP. Cells were processed as before. 
TRII co-localizing with Rab5-GFP results in yellow staining, TRIII co-localizing with 
TRII results in magenta staining, and all three co-localizing results in white staining 
(N=3).  Bar= 10m. 
 
 
 
 
105 
 
 
 
Figure 3.8 
 
106 
 
 
 
in early endosomes (Figure 3.8B). As Rab5 has been shown to cause endosomal 
enlargement, I also performed co-localization studies with GFP-labelled S34N 
(dominant-negative) or Q79L (constitutively-active) Rab5 mutants to assess 
whether the co-localization of the receptors with the Rab5-positive vesicle was 
simply due to endosomal enlargement (Figure 3.9). My results indicate that while 
Rab5 Q79L can cause endosomal enlargement, this does not appear to increase 
the localization of TRII with the early-endosomal compartment (Figure 3.9). 
Overall, my study strongly suggests that the type III TGF receptor is able to 
direct the trafficking of TRII.   
3.4.7 TRIII extends the half-life of TRII 
Efficient turnover of TGF receptors is essential for optimal TGF signal 
transduction, as TGF receptors and ligand are ubiquitously expressed. It has 
been previously shown that the intracellular compartmentalization of TGF 
receptors directs receptor degradation and recycling. Receptors in early 
endosomal compartments are recycled to the cell surface, whereas receptors 
localized in caveolin-1 positive compartments are targeted for ubiquitination and 
degradation (12). Therefore, having found that TRIII re-directs trafficking of 
TRII into early endosomal compartments, I predicted that TRIII expression 
would also increase the half-life of TRII. To assess this further, I used [125I]-
labelled TGF1 ligand to track cell-surface TGF receptor half-life in both the 
presence and absence of TRIII. Briefly, HEK293T cells were transfected with 
TRI, TRII, TRIII, Smurf2 and Smad7, as shown in Figure 3.10. 
Figure 3.9 TRII trafficking in the presence of S34N or Q79L Rab5. 
(A) Top panel- Mv1Lu HAT cells stably expressing extracellularly HA-tagged TRII and 
transiently expressing Rab5 S34N-GFP (Rab5-GDP) were incubated with -HA 
antibodies at 4ºC. Following incubation with Cy3-labelled secondary antibodies (red), 
the cells were incubated at 37ºC for 1 hour to allow receptor endocytosis. TRII co-
localizing with Rab5-GDP results in yellow staining and non-Rab5-GDP localized TRII 
is also found in the cytoplasm (red) (N=3). 
Bottom panel- Mv1Lu HAT cells stably expressing extracellularly HA-tagged TRII and 
transiently expressing myc-TRIII and Rab5 S34N-GFP (Rab5-GDP) were incubated 
with -HA and -myc antibodies at 4ºC and processed for immunofluorescence 
microscopy as described above (N=3).  
(B) Top panel- Mv1Lu HAT cells expressing HA-tagged TRII were also assessed for 
their co-localization with transiently expressed Rab5 Q79L-GFP (Rab5-GTP), shown in 
yellow (N=3). 
Bottom panel- Mv1Lu HAT cells expressing HA-tagged TRII and myc-TRIII were also 
assessed for their co-localization with Rab5 Q79L-GFP (Rab5-GTP). As before, 
receptors were labelled at the cell surface, internalized, then assessed for their co-
localization.  TRII co-localizing with Rab5-GTP results in yellow staining, TRIII co-
localizing with TRII results in magenta staining, and all three co-localizing results in 
white staining (N=3).  Bar= 10m. 
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Figure 3.10 TRIII expression reduces TRII and TRI complex degradation. 
HEK293T cells were transiently transfected with TβRII-HA (II), TβRI-flag (I) and myc-
TβRIII  (III) in the presence or absence of Smurf2/Smad7 (Smf2/S7).  Cells were then 
incubated with [125]I-TGFβ , cross-linked and incubated at 37˚C for 2, 4 or 8 hrs.  
Following cell lysis and SDS-PAGE, receptors levels were visualized and quantified by 
phosphorimaging (Molecular dynamics). Relative receptor levels of TRII (left) and TRI 
(right) were compared to the amount of receptor measured at time zero and graphed 
(bottom panel; N=3). Shown is a representative graph of receptor levels. 
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Smurf2 and Smad7 were transiently transfected to promote receptor degradation, 
as in the absence of Smurf2 and Smad7 TGF receptors over-expressed in 
HEK293T cells have a prolonged half-life (Figure 3.10, top panel). Post-
transfection, cells were labelled with [125I] TGF1 at 37˚C. The ligand was then 
cross-linked to receptors and the cells were warmed to 37ºC to promote receptor 
internalization. Cells were lysed at 0, 2, 4 and 8 hrs of internalization, subjected 
to SDS-PAGE and visualized using autoradiography.  
 The top panels of Figure 3.10 illustrate that in the absence of Smurf2 and 
Smad7, TRII has a prolonged half-life both in the presence and absence of 
TRIII. However, upon addition of Smurf2 and Smad7, which promote receptor 
ubiquitination and degradation, TRIII greatly extends the half-life of both TRI 
and TRII. These results confirm my receptor trafficking studies and imply that 
TRIII can have direct effects on TGF signal transduction by altering the 
TRII/TRI complex half-life.  
3.4.8  TRIII enhances basal TGFsignalling 
 As it has been previously shown that clathrin-mediated endocytosis 
enhances TGF signal transduction (12), I sought to identify whether TRIII 
expression could affect TGF signalling (Figure 3.11). To address this question, I 
used a TGF-responsive promoter upstream of a luciferase construct to 
quantitatively assess the role of TRIII expression on signalling. HepG2 cells 
have previously been shown to be TGF-responsive and are amenable to 
calcium chloride transfection and were therefore used as my model system to  
Figure 3.11 TRIII expression increases basal TGF signalling 
HepG2 cells were transfected with ARE-lux, -gal and FoxH1 alone (control) or together 
with TRII/I (RII+RI) and/or increasing concentrations of TRIII (RIII). Transfected cells 
were incubated in the absence (gray bars) or presence (black bars) of 100 pM TGF. 
Luciferase activity was normalized to -galactosidase activity and is plotted as the mean 
± SD of triplicates from a representative experiment (N=3). 
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assess TGF-depdendent transcription (12). HepG2 cells were transiently 
transfected with ARE-Lux, -galactosidase,FoxH1 (a transcriptional co-activator) 
and/or TRII and TRI, or increasing concentrations of TRIII (Figure 3.11). 
Interestingly, it seems that TRIII expression may increase Smad-dependent 
signalling in the absence of TGF  (Figure 3.11). This result was surprising, as 
TRIII is best known for its role in ligand presentation. I hypothesize that the 
ability of TRIII to enhance basal TGF signalling is due to its enhanced clathrin-
mediated endocytosis of the TRII/TRI complex. Indeed, it has been shown that 
TGF receptors can signal at a basal level in the absence of ligand (27). In 
contrast to this result, it appears that increasing levels of TRIII cDNA 
transfection decreases TGF signalling in the presence of ligand (Figure 3.11). I 
hypothesize that this may be accounted for the ability of over-expressed TRIII to 
pre-load the early endosomes with receptors. This would result in a loss of 
TRII/TRI from the cell surface, and therefore may explain why luciferase 
activity is decreased in the presence of increasing concentrations of TRIII. 
Future studies to evaluate the role of TRIII to mediate expression of validated 
TGF-responsive genes, such as PAI-1 and Smad7 should be performed to 
confirm these results. 
 In conclusion, analysis of both membrane fractionation and receptor 
trafficking illustrate that TRIII promotes clathrin-mediated endocytosis of both 
TRII and TRI and directs TRII into the early endosome. TRIII expression 
therefore has functional consequences on TGF signal transduction, as it 
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extends receptor half-life by re-directing the TRII/TRI complex out of the 
degradative membrane raft pathway and enhances basal TGFsignalling. 
3.5 Discussion  
The mechanism of endocytosis at the cell membrane can have immediate 
downstream effects in signal transduction. In the canonical TGF signalling 
pathway, clathrin-mediated endocytosis increases TGF signalling through 
enabling the association of the receptors with SARA (Smad anchor for receptor 
activation) in the early endosome. SARA is able to mediate the interaction of the 
TGF receptors with Smad proteins, which are the downstream effectors of 
TGF signal transduction (12). Membrane raft/caveolar endocytosis however, 
decreases TGF signalling through promoting the degradation of the receptors 
(12). In membrane rafts, Smurf2 (Smad ubiquitination regulatory factor 2) 
associates with the receptors, promotes the ubiquitination and degradation of the 
TGF receptors, and prevents the association of Smad proteins (reviewed in (7)).  
 Therefore, since the endocytic mechanism of TGF receptors can have 
such profound effects on TGF signalling, and a number of pathologies including 
metastatic cancers and fibrotic diseases show aberrant TGF signalling, an in-
depth study evaluating the mechanism through which TGF receptors are 
directed to endocytose is warranted.  
 To address the issue of endocytic partitioning in TGF signalling, I first 
attempted to evaluate the contribution of TGF receptor subtypes to the raft and 
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non-raft partitioning of TRII. Interestingly, using co-immunoprecipitation studies, 
I showed that TRIII, the least characterized TGF receptor, is able to associate 
with both TRII and TRI even in the absence of ligand.  I confirmed these 
results with sucrose-density ultracentrifugation, which quantitatively illustrated 
that the association of TRIII with TRII and TRI can greatly shift the partitioning 
of TRII and TRI into non-membrane raft/clathrin fractions. In support of my 
subcellular fractionation studies, I also show that TRIII directs TRII into the 
early endosome and out of the degradative pathway using immunofluorescence 
microscopy.  Using [125I] labelled TGF1 to track TRII and TRI half-life, I show 
that TRIII can have a direct effect on the signalling capacity of the TRII/TRI 
complex, as its association can extend the half-life of TRII/TRI. Finally, I 
illustrate that TRIII increases basal TGF signalling, but decreases signalling in 
the presence of ligand. 
While my study evaluates the contribution of TRIII to TGF receptor 
trafficking, other studies have also attempted to evaluate factors that affect TGF 
receptor half-life. Koli and Arteaga illustrated that binding of TGFto TRII can 
shorten its half-life (28). Interestingly, it has also been recently shown that 
inhibiting clathrin-mediated endocytosis of TRII extends receptor half-life and 
promotes TGF signalling (29). In this study, the authors illustrated that inhibitors 
of clathrin-mediated endocytosis prevent internalization of TGF receptors, but 
allow the association of SARA and TRI at the cell surface; this then promotes 
and extends TGF signalling (29).  
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Another study has attempted to evaluate the contribution of TRIII to 
TRII membrane partitioning. The authors concluded that TRIII was 
endocytosed via membrane rafts in Cos7 and HepG2 cell lines (23). 
Furthermore, they reported that membrane-raft associated TRIII regulates 
phosphorylation of Smad2 and p38 (23). While I show differing results in this 
report, in that TRIII is primarily found in non-membrane raft fractions, and is 
able to differentially partition the TRII/TRI complex, this result may be due to 
the cell types used in both studies. Differences in membrane raft content 
between HepG2 and HEK 293T cells may account for some of the discrepancies 
observed. This study nonetheless illustrates that while TRIII endocytosis can 
affect TGF signalling, there may be other interacting protein partners that 
influence the effect of TRIII. Indeed, a recent review highlights several 
RhoGTPases which can have a modulating effect on TGF endocytosis and 
signal transduction (30).  
The importance of the effect of TRIII on TGF signal transduction is only 
beginning to be explored. This TGF receptor has recently drawn attention due 
to its aberrant expression in several cancers. Indeed, TRIII overexpression is 
found in seminomas (31) and knockdown of TRIII decreases invasiveness and 
motility of breast cancer cells  (21). However, it has also been shown that loss of 
TRIII can promote metastasis and invasiveness in a number of cancers, 
including non-small cell lung cancer (20), pancreatic cancer (22) and prostate 
cancer (17,32). Our finding that TRIII promotes basal TGF signalling but 
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decreases ligand-dependent signalling may help explain some of the duality of its 
function in cancer. Perhaps the levels of TRIII may play a role- a total loss of 
TRIII may increase TGF signalling by preventing ligand sequestration from the 
TRII/TRI complex and thus may promote the metastatic effects of TGF 
signalling. While the opposing effects of TRIII warrant further investigation of 
this pathway, my studies suggest that TRIII expression may play a critical role in 
control of TGFsignal transduction. 
Overall, in this study I have shown that TRIII directs TRII and TRI to 
undergo clathrin-mediated endocytosis. This altered endocytosis directs TRII 
into early endosomal pathways, extends TRII and TRI half-life and enhances 
basal TGF signalling. As TRIII is aberrantly expressed in a number of 
pathologies, my study suggests that TRIII may mediate TGF signal 
transduction by altering TGF receptor endocytosis.  
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CHAPTER 4 
             
ARRESTIN2 INTERACTS WITH TRII TO REGULATE SMAD-DEPENDENT 
AND SMAD-INDEPENDENT SIGNAL TRANSDUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
A  version of this chapter has been submitted to Cellular Signalling, manuscript # 
CLS-D-12-00204. 
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4 Chapter 4 
4.1 Chapter Summary 
In chapter 3 I assessed the ability of TRIII, a heavily-glycosylated cell-
surface protein, to mediate receptor partitioning of TRII/TRI complexes. 
Reports have shown that TRIII interacts with arrestin2 to mediate its 
internalization with TRII. Therefore, in this chapter I assessed the ability of 
arrestin2 to influence TGF receptor trafficking and signal transduction. 
Interestingly, I found that arrestin2 can interact with TRII in the absence of 
TRIII. Furthermore, arrestin2 traffics to the early endosome with TRII where it 
increases the association of TRII with SARA. Depletion of endogenous 
arrestin2 increased levels of TRII at the cell-surface and also induced hyper-
phosphorylation of p38. Increased phosphorylation of p38 correlated with an 
increased sensitivity of cells to cell death both in the presence and absence of 
TGF. 
 
 
 
 
 
120 
 
 
 
4.2  Introduction 
The Transforming Growth Factor Beta (TGF) signalling pathway is a cell 
and context-dependent pathway that is under intense study due to its complex 
roles in cancer and fibrotic diseases. In the classical TGF pathway, TGF 
ligands stimulate the formation of a heteromeric serine/threonine kinase complex 
of TGF receptor I (TRI) and TGF receptor II (TRII). Ligand-binding to TRII 
activates its kinase domain, promoting phosphorylation of TRI on its GS domain 
(reviewed in (1)). Activated TRI then induces a Smad signalling cascade by 
phosphorylating Smad2/3, which allow them to interact with the Co-Smad, 
Smad4, and translocate to the nucleus to activate cell-type specific 
transcriptional programmes (1).  
While endocytosis of plasma membrane receptors is classically thought to 
function to downregulate signalling, it has been shown in the TGF pathway that 
the endocytic route of the receptors can play a direct role in signalling outcome. 
TRII/TRI complexes internalized via clathrin-coated pits enter the early 
endosome, where SARA (Smad Anchor for Receptor Activation) enhances 
Smad-dependent signal transduction by recruiting Smad 2/3 and facilitating their 
phosphorylation by TRI (2,3). Receptor complexes internalized by clathrin-
independent, caveolin-positive vesicles however, are sterically prevented from 
signalling by the inhibitory Smad7 and targeted for degradation by Smurf2, an E3 
ubiquitin ligase (2). Indeed, several studies have shown that trafficking of the 
TGF receptors inside the cell has important signalling consequences. For 
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example, it has been shown that Dab2 is necessary for sorting of TBRII from the 
early endosome into the late endosome (5). Furthermore, the regulation of 
trafficking to late endosomes plays a role in Smad signal transduction, as a 
dominant-negative Rab5 causes constitutive, ligand-independent Smad 
signalling and nuclear translocation (5).  
While the importance of trafficking in regards to signal transduction is well-
appreciated in the TGF pathway, the specific signal(s) directing receptors to be 
internalized and trafficked via either pathway is not well-understood. Previously I 
have shown that the type III TGF receptor (TRIII, or betaglycan) which was 
thought to simply present ligand to TRII, can direct TRII/TRI complexes into 
the early endosome (3). As others have shown that TRIII can interact with 
arrestin2 (7), and arrestin2 is known to have an important role in GPCR 
internalization (4), I sought to evaluate the contribution of arrestin2 to TRII 
internalization, trafficking and signal transduction.  
 The relatively simplified view of arrestin2 solely acting to internalize 
GPCRs has been challenged by a myriad of experiments that implicate it as a 
pleiotropic scaffolding protein. While it is true that arrestin2 can interact with 
components of the endocytic machinery, including clathrin (5) and AP-2 (6), it 
can also act as a scaffolding protein and binds to a variety of proteins in the 
cytoplasm including Src, cofilin, Akt and MAP kinases (reviewed in (7)).  Indeed, 
arrestin2 has been implicated in diverse processes such as Ras-independent 
cytoskeletal re-arrangement (12), ERK signal transduction (8), activation of beta-
122 
 
 
 
catenin via endothelin receptors (14) and activation of epidermal growth factor 
receptors (9). Based on this plurality of arrestin2 function, and the fact that 
TRIII can bind to arrestin2 (7), I sought to further evaluate the role of arrestin2 
in TGF signal transduction. In this chapter I show that arrestin2 interacts with 
TRII and that decreased arrestin2 levels cause an increase in TRII cell-
surface levels, and the phosphorylation of Smad2. Interestingly, decreased 
arrestin2 levels do not increase Smad-dependent transcription, as decreased 
arrestin2 decreases the production of luciferase under the control of a Smad-
responsive promoter. I also assessed a Smad-independent pathway, the p38 
pathway, and found that the increased phosphorylation of p38 through decreased 
arrestin2 levels functionally results in an increase in TGF-dependent and -
independent apoptosis.  
4.3   Materials and Methods 
4.3.1  Antibodies and reagents 
Commercially available antibodies were used as per manufacturers’ 
instructions from the following sources: -HA (Santa Cruz-Y11-SC-805),  -myc 
(Santa Cruz sc-40), -flag (Sigma F3165), -EEA1 (BD Trans Labs-610457), -
GFP (Clontech- 632381),  -PSmad2 (Millipore- AB3849), -arrestin2 (Abcam-
AB54790), -actin (Sigma-A2668), -Smad2/3 (BD- 610843), -PSmad3 (Cell 
Signaling- 3101), -pp38 (Cell Signaling-92115), -p38 (Cell Signaling-92125), 
-PARPc (Cell Signaling- 9541). HRP-conjugated goat -mouse (Thermo 
Scientific- 31430), and goat -rabbit (Thermo Scientific-31460) were used for 
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western blotting. Fluorescently labelled donkey -rabbit Cy3 (Jackson- 711-165-
152) and donkey -mouse AlexaFluor 647 (Invitrogen- A21236) were used for 
visualization of immunofluorescence experiments. The constructs encoding 
TRII-HA, myc-TRIII, arr2-flag, arr2-GFP and SARA-flag were used as 
previously described (3,10,11). Stealth siRNA (negative control, 634978; 
arrestin2 siRNA1, ARRB2VHS40600; or arrestin2 siRNA2, ARRB2VHS40604) 
and Lipofectamine RNAiMax were purchased from Invitrogen. TGF1 was 
purchased from Peprotech. Hoechst 33342 was a generous gift from Dr. S. 
Cregan (Robarts Research Institute, Western University).  
4.3.2 Cell Culture 
HEK 293T human embryonic kidney cells (American Type Culture 
Collection) were maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS). Mink lung cells stably 
expressing a carboxy terminus HA tagged TRII construct (HAT Mv1Lu) were 
maintained in Modified Eagle’s medium (MEM) supplemented with 10% FBS, 
non-essential amino acids and 0.3% hygromycin. A549 non-small cell lung 
adenocarcinoma cells (American Type Culture Collection) were maintained in 
F12K media supplemented with 10% FBS. H1299 non-small cell lung 
adenocarcinoma cells (ATCC) were maintained in RPMI media supplemented 
with 10% FBS. HepG2 hepatocellular carcinoma cells were maintained in 
Modified Eagle’s medium (MEM) supplemented with 10% FBS and non-essential 
amino acids. All cells were kept in a humidified atmosphere at 37°C and 5% CO2. 
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4.3.3 Transfection 
HEK 293T and HepG2 cells were transiently transfected using the calcium 
phosphate method. HAT Mv1Lu cells were transfected using polyethylenimine.  
4.3.4 Immunoprecipitation        
  
Transfected HEK 293T cells were lysed (50 mM Tris-HCl, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 0.5% Triton X-100, 1 mM PMSF, and cocktail protease 
inhibitors) and centrifuged at 14,000 × gav at 4°C for 10 min. Aliquots of 
supernatants were collected for analysis of total protein concentration. The 
remaining cell lysates were incubated with antibody followed with protein G 
sepharose incubation. The precipitates were washed 3 times, eluted with 
Laemmli sample buffer and subjected to SDS-PAGE and immunoblot analysis. 
4.3.5 Immunoblotting 
Proteins were separated by SDS-PAGE and transferred to nitrocellulose 
membranes by electrophoretic transfer. Following blotting with primary and 
secondary antibodies, bound antibodies were detected using SuperSignal 
chemiluminescence reagent (Pierce). 
4.3.6 Isolation of Caveolae/membrane-raft enriched membrane fractions 
The caveolin/raft-rich membrane fractions were isolated as previously 
described (12). Briefly, transfected HEK 293T cells grown to confluence in 100-
mm dishes were used to prepare the membrane fractions. All steps were carried 
out on ice. After two washes with cold phosphate-buffer saline (PBS), cells were 
lysed with 0.5 M Na2CO3, pH 11.0, containing protease inhibitors. After scraping, 
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the cell lysate was collected and homogenized three times for 10 s by using a 
Polytron tissue grinder (Brinkmann Instruments). Homogenates were then 
sonicated three times for 20 s with a Vibra Cell sonicator (Sonics Materials Inc.). 
The homogenates were adjusted to 40% sucrose and overlaid with 30% sucrose 
and 5% sucrose solutions. The samples were centrifuged at 200,000 x gav for 16 
h at 4°C, using a Beckman SW41 rotor. Twelve 1-mL fractions were collected, 
and an aliquot of each fraction was eluted with Laemmli sample buffer, boiled, 
and subjected to SDS-PAGE followed by Western blot analysis. 
4.3.7  Immunofluorescence/Receptor Internalization 
HAT Mv1Lu cells were plated on coverslips in 12 well dishes. Twenty-four 
hours post-transfection of arrestin2-GFP cDNA with polyethylenimine, cells 
were serum-starved and treated with 50 μM ZnCl2 to induce HA-TRII expression 
as previously described (3,10).  The following day, cells were cooled to 4°C, and 
treated with -HA antibody for 2 hours at 4°C to label receptors at the cell 
surface. Coverslips were then incubated with donkey anti-rabbit Cy3 antibodies. 
After labelling, cells were either permitted to internalize, by incubating at 37°C for 
30 minutes or 1 hour, or were immediately fixed and permeabilized. Cells were 
incubated with -EEA1 antibody, followed with donkey -mouse Cy5.  All 
coverslips were then immunomounted and visualized using an IX81 inverted 
immunofluorescence microscope (Olympus, Canada).  
126 
 
 
 
4.3.8 siRNA-mediated Knockdown of arrestin2 in A549 and H1299 cells 
Endogenous levels of arrestin2 protein were decreased by Stealth siRNA 
(Invitrogen). At approximately 50% confluency, cells were transfected with siRNA 
(negative control,  arrestin2 siRNA1, or arrestin2 siRNA2) using Lipofectamine 
siRNA Max as per manufacturers’ instructions. Forty-eight hours following 
transfection, cells were assayed for silencing by SDS-PAGE and immunoblotting 
with -arrestin2 antibodies and - actin antibodies. 
4.3.9 TGF Receptor Binding Assay 
A549 cells were transiently transfected with arrestin2 siRNA as 
previously described. Approximately 48 hours following transfection, cells were 
placed on ice and then labelled with 250 pM [125-I] labelled TGF  ligand. Cells 
were incubated with ligand for 2 hours at 4C and then receptors were cross-
linked using 10 mg/mL DSS in DMSO for 15 minutes.  Cells were then either 
lysed in 1X TNTE (time 0) or were placed in 10% FBS in DMEM and incubated at 
37C for 2, 4, or 8 hours prior to lysis. Lysates were then subjected to SDS-
PAGE and visualized using phosphorimaging. 
4.3.10 Phospho-Smad and phospho-p38 Time Course 
A549 and H1299 cells were transiently transfected with control or 
arrestin2 siRNA as described above.  Prior to TGF treatment, cells were 
serum-starved overnight in 0.2% FBS in F12K or 0.2% FBS in RPMI media. The 
following day cells were treated with 250 pM TGF ligand for 30 minutes. Cells 
were then washed with PBS, and were either lysed or incubated at 37C for an 
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additional 1 or 4 hours. Lysates were subjected to SDS-PAGE and were 
immunoblotted with -phospho-Smad2, -phospho-Smad3, -phospho-p38, -
p38 or -Smad2/3 antibodies.  
4.3.11 siRNA-mediated Knockdown of arrestin2 in HepG2 cells 
Endogenous levels of arrestin2 were decreased by Stealth siRNA 
(Invitrogen) using a reverse-transfection method as per manufacturers’ 
instructions. Approximately 72 hours following transfection, cells were assayed 
for knockdown by SDS-PAGE and immunoblotting. 
4.3.12 Luciferase reporter assay 
HepG2 cells were transiently transfected using the calcium phosphate 
precipitation method with ARE (activin-response element)-Lux (luciferase), β-
galactosidase, arrestin2 cDNA and FoxH1 reporter plasmids. Cells were serum-
starved in 0.2% FBS/MEM/NEAA for 4 hours prior to treatment. Cells were then 
incubated in the presence or absence of 250 pM of TGFβ for 16 hours. 
Luciferase activity was normalized to β-galactosidase activity. 
4.3.13 cleaved-PARP assay 
A549 cells were transiently transfected with control or arrestin2 siRNA as 
previously described. Sixteen hours following transfection, cells were serum-
starved in 0.2% FBS/F12K media for 4 hours. Cells were then incubated in the 
presence or absence of 250 pM TGF for 48 hours. Cells were then lysed, and 
subjected to SDS-PAGE and immunobloted with -cleaved-PARP antibodies.  
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4.3.14 Hoechst Cell Death assay 
A549 cells were transiently transfected with control or arrestin2 siRNA as 
previously described. Sixteen hours following transfection, cells were serum-
starved in 0.2% FBS/F12K media for 4 hours. Cells were then incubated in the 
presence or absence of 250 pM TGF for 48 hours. Following the 48 hour 
incubation, cells were treated with cell-permeant Hoechst (Hoechst 33342) for 30 
minutes at 37˚C. Apoptotic and non-apoptotic cells were then visualized using an 
IX71 inverted immunofluorescence microscope (Olympus, Canada). The number 
of apoptotic vs. non-apoptotic cells were then counted and plotted as percentage 
of apoptotic cells per condition. Statistical analysis was performed using 
GraphPad Prism® 5.0 software. 
4.3.15 Statistical analysis 
One-way ANOVA analyses followed by post-hoc Bonferroni test were 
used to evaluate the significance of the results. Statistical analyses were 
performed using GraphPad Prism ® 5.0 software and p values of <0.05 were 
considered statistically significant. 
4.4 Results 
4.4.1 TRII binds arrestin2 in the absence of TRIII 
TRII functions primarily as a serine/threonine kinase capable of both 
autophosphorylation and TGF signal propagation through the trans-
phosphorylation of TRI (reviewed in (13)). As arrestin2 has been shown to bind 
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TRIII following its phosphorylation by TRII (14), I sought to assess whether 
TRII may also be able to bind arrestin2. 
To address this question I used an immunoprecipitation approach using 
HEK293T cells, as they express very few endogenous TGF receptors (10). 
HEK293T cells were transiently transfected with combinations of arr2-Flag, 
TRII-HA, and myc-TRIII cDNA.   Cells were then lysed and immunoprecipitated 
with -Flag antibodies and subjected to SDS-PAGE and immunoblotting (Figure 
4.1).  I observed that TRII interacts with arrestin2 both in the presence and 
absence of TRIII (Figure 4.1, lanes 4 and 8).  As a positive control, I evaluated 
the ability of arrestin2 to interact with TRIII. Indeed, I was able to 
immunoprecipitate TRIII with arrestin2 (Figure 4.1, lane 6). Since TRII is 
essential for TGF signal transduction, my finding that  TRII can interact with 
arrestin2 when they are over-expressed in HEK 293T cells suggests that 
arrestin2 may have an important role in TRII signal transduction and receptor 
internalization. 
4.4.2 arrestin2 localizes to early endosomal compartments with TRII 
The intracellular trafficking of the TGF receptor complex can have 
significant implications in TGF signal transduction, as TGF receptors that traffic 
to the early endosome have enhanced TGF signalling capacity (2). Having 
shown that arrestin2 can interact with TRII, I next assessed the intracellular 
 
Figure 4.1 TRII interacts with arrestin2 in the absence of TRIII 
HEK 293T cells were transiently transfected using the calcium phosphate precipitation 
method to express Flag-tagged arrestin2, HA-tagged TRII and/or myc-tagged TRIII, 
as indicated. Cells were lysed, immunoprecipitated with 1 g -Flag antibodies and 
subjected to SDS-PAGE and immunoblotting as indicated. Fifty g of lysates was used 
to assess total expression. The top panel shows immunoprecipitated proteins, while the 
bottom panel illustrates total protein expression in cell lysates. (N=3). 
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trafficking of TRII/arrestin2 complexes.  In order to address this question, I 
used a receptor-chase approach. Briefly, Mv1Lu cells stably expressing TRII 
were cooled to 4˚C to halt receptor internalization, and receptors were labelled at 
the cell surface. Cells were then warmed to 37˚C to permit receptor 
internalization for 30 minutes or 1 hour, and then the cells were fixed, 
permeabilized, and processed for immunofluorescence microscopy. Early 
endosomal compartments were visualized by using antibody against early 
endosomal autoantigen 1 (EEA1). As I have previously shown, at time 0 all TRII 
is found at the cell surface and does not co-localize with EEA1 (3) (Figure 4.2, 
top panel). Following 30 minutes of internalization, TRII began to cluster and 
partially co-localize with EEA1, and it appears that further co-localization with 
EEA1 occurring at 60 minutes (Figure 4.2, middle panel). Interestingly, it appears 
that arrestin2 co-localizes with TRII at the early endosome at 30 minutes 
(Figure 4.2, middle panel). Strikingly, following 60 minutes of internalization, 
TRII was observed to co-localize with EEA1 and arrestin2 in large vesicles 
(Figure 4.2, bottom panel).  
4.4.3 arrestin2 does not alter the membrane raft partitioning of TRII 
 The intracellular trafficking of TGF receptors is dependent upon their 
internalization route; TGF receptors gain access to the early endosome 
following clathrin-mediated internalization.  Having found that TRII can directly 
interact with arrestin2, and since arrestin2 has been shown to directly interact 
 
Figure 4.2. arrestin2 localizes to the early endosome with TRII 
Mv1Lu cells stably transfected with HA-tagged TRII were transiently transfected with 
arr2-GFP cDNA. To assess receptor internalization and trafficking, cells were 
incubated at 4˚C to prevent receptor internalization, and cell-surface receptors were 
labeled with -HA antibody. Following incubation with fluorescently labeled secondary 
antibodies, cells were either immediately fixed and permeabilized (time 0, top panel), or 
were warmed to 37˚C and permitted to internalize for 30 minutes (middle panel) or 60 
minutes (bottom panel). Cells were incubated with -EEA1 antibodies followed by Cy5 
secondary antibody to visualize early endosomes (N=5). To analyze receptor co-
localization, 5-10 cells per condition per experiment were evaluated. Shown are 
representative cells from each condition. Bar= 10 m 
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with components of the clathrin-coated pit machinery (6,15) I sought to establish 
whether arrestin2 could enhance clathrin-mediated internalization of TRII. To 
evaluate this question, I performed sucrose-density ultracentrifugation of HEK 
293T cells as previously described (3,12). I found TRII to be primarily in 
membrane raft fractions, TRIII in both membrane raft and non-raft fractions, and 
arrestin2 solely enriched in non-membrane raft fractions (Figure 4.3). The co-
expression of arrestin2 with TRII did not shift its partitioning into non-
membrane raft fractions (Figure 4.3). Since I have previously shown that TRIII is 
able to increase clathrin-mediated endocytosis of TRII (3), I next sought to 
establish whether the interaction of TRIII and arrestin2 with TRII could further 
drive its non-membrane raft partitioning. Co-expression of TRII and TRIII shifts 
the partitioning of TRII into non-membrane raft fractions, as I have previously 
shown (3). However, the addition of arrestin2 did not further increase the 
partitioning of TRII into non-membrane raft fractions (Figure 4.3).  
4.4.4 Loss of arrestin2 increases steady-state levels of cell-surface TRII 
 The path of TRII trafficking directly influences TRII recycling and/or 
turnover. Receptors trafficked to the early endosome promote signal propagation; 
while receptors trafficked to the caveolin-1 positive vesicles are targeted for 
degradation. As I have shown that arrestin2 traffics to the early endosome with 
 
Figure 4.3. arrestin2 does not alter the membrane raft partitioning of TRII  
(A) Lipid raft partitioning of TRII upon co-expression with TRIII, arrestin2 both 
individually and together. HEK 293T cells transiently expressing the indicated constructs 
were subjected to sucrose-density ultracentrifugation as described in methods. Samples 
were then pooled into raft (R) and non-raft (NR) fractions and subjected to SDS-PAGE 
and immunoblotting with the antibodies indicated. (N=3) 
(B) Using Quantity One software, partitioning of TRII into either raft or non-raft 
fractions was measured and calculated as a % of total TRII levels for all conditions. 
The graph shown is the mean ± SD. (N=3) 
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TRII, I wanted to assess the role of arrestin2 in a second way, and evaluate its 
role in the internalization of cell-surface TGFreceptor complexes. To assess the 
role of arrestin2 in internalization, I again used siRNA to decrease arrestin2 
protein levels.  
Following siRNA transfection, cells were treated at 4˚C with 250 pM [125I-
TGF to label cell-surface receptors. Following cross-linking, cells were either 
immediately lysed, or warmed to 37˚C and incubated for 2, 4, or 8 hours. Lysates 
were subjected to SDS-PAGE and then developed by phosphorimaging. I 
observed that decreasing arrestin2 levels had little effect on TGFreceptor half-
life (Figure 4.4A). Surprisingly, decreasing protein levels of arrestin2 induced 
increased TRII cell-surface levels at time zero, which were sustained at 2 hours. 
To quantify my results, phosphorimaging analysis was performed. Figure 4B 
illustrates TRII levels as a percentage of TRII levels in the negative control 
condition at time 0. Quantification revealed that the levels of TRII were 
approximately 1.5 fold higher at time 0 in the arrestin2 siRNA conditions 
compared to the siRNA control (Figure 4.4A and 4.4B). 
4.4.5 Effects of arrestin2 siRNA on Smad2 phosphorylation levels 
 Having discovered that decreased arrestin2 expression increased TRII 
cell-surface levels, I was interested to assess the effect of decreased arrestin2 
levels on Smad signal transduction. TRII initially propagates the Smad 
signalling cascade by phosphorylating TRI, which can then propagate signal 
Figure 4.4. Decreased arrestin2 protein expression increases TRII levels at the 
cell surface. 
(A) A549 cells transiently transfected with control siRNA (Ctrl siRNA) or two different 
siRNA to arrestin2 (arr2 siRNA1 or arr2 siRNA2) were assessed for TRII half-life. 
Following labelling with 125I-TGF1 at 4˚C for 2 hours, cells were cross-linked and 
immediately lysed, or were warmed to 37˚C and were permitted to internalize for 2, 4 or 
8 hours. Lysates were subjected to SDS-PAGE and visualized using phosphorimaging 
(left panel) (N=4). Total lysates not labelled with 125I-TGF1 were also subjected to 
SDS-PAGE and immunoblotted to ensure efficient arrestin2 silencing (right panel). 
(B) Receptor levels were quantitated from experiments carried out as described in 
Panel A and graphed as receptor levels (% of control siRNA at time zero) vs. time for 
each condition (mean ± SD, N=4)  
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transduction by phosphorylating Smad2 (reviewed in (1)). As it is necessary for 
TRII to bind TGF ligand in order to activate TRI, I predicted that increased 
cell-surface levels of TRII should increase Smad 2 phosphorylation, as a 
greater number of receptors would be exposed to ligand.    
To assess the role of arrestin2 in Smad signalling, I performed a 
phospho-Smad signalling assay. Non-small cell lung adenocarcinoma A549 cells 
were chosen for the signal transduction studies, as these cells have negligible 
TRIII levels (16), and any results I observed would therefore be TRIII-
independent. In A549 cells transfected with control siRNA I observed that 250 pM 
TGFinduced robust Smad2 phosphorylation within 30 min of ligand treatment 
which then gradually decreased after 1.5 hours and 4.5 hours. In cells 
transfected with siRNA constructs towards arrestin2, the phospho-Smad2 levels 
appeared similar to those transfected with negative siRNA control (Figure 4.5A). I 
confirmed these results in another non-small cell lung cancer cell line, H1299 
cells, which also showed little difference  in phospho-Smad2 levels between 
arrestin2 siRNA treated cells and control (Figure 4.6). To ensure that I was 
accurately assessing the levels of phospho-Smad2 in each instance, I quantified 
the levels of phospho-Smad2 using Quantity One software and densitometric 
analysis (Figure 4.5B). Indeed, quantitative analysis supported my observation 
that the silencing of arrestin2 increased TGF-dependent Smad2 
phosphorylation. 
Figure 4.5 Effects of decreased arrestin2 protein expression on Smad2 
phosphorylation 
(A) A549 cells transiently transfected with control siRNA (Ctrl siRNA) or two different 
siRNA to arrestin2 (arr2 siRNA1 or arr2 siRNA2) were assessed for TGF-
dependent Smad2 phosphorylation. Serum-deprived cells were either immediately lysed 
or treated with 250 pM TGF1 for 30 minutes. Cells were then washed in PBS and 
further incubated for 1 or 4 hours or were lysed. All lysates were subjected to SDS-
PAGE and immunoblotted for phospho-Smad 2, Smad 2, arrestin2 and actin levels 
(N=3).   
(B) Using Quantity One software analysis, phospho-Smad2 levels as a ratio of total 
Smad2 levels were plotted for all conditions. The graph shown represents the mean 
±SD vs. time (N=3). 
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Figure 4.6 Effects of decreased arrestin2 protein expression on PSmad2 levels 
in H1299 cells 
H1299 cells transiently transfected with non-specific control siRNA (Ctrl siRNA) or two 
different siRNA to arrestin2 (arr2 siRNA1 or arr2 siRNA2) were assessed for TGF-
dependent Smad2 phosphorylation. Serum-deprived cells were either immediately lysed 
or treated with 250 pM TGF1 for 30 minutes. Cells were then washed in PBS and 
further incubated for 1 or 4 hours or were lysed. All lysates were subjected to SDS-
PAGE and immunoblotted for phospho-Smad 2, Smad 2, arrestin2 and actin levels 
(N=3).  
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4.4.6 Transcription of a Smad-dependent luciferase construct in response to 
decreased arrestin2 protein expression 
 In the canonical TGF signalling pathway, following phosphorylation of 
Smad2 by TRI, phospho-Smad2 translocates to the nucleus with Smad4 to 
activate TGF-dependent signal transduction. My results thus far illustrated that 
decreasing arrestin2 protein levels increased Smad2 phosphorylation.  I was 
therefore interested to assess the effects of arrestin2 expression on TGF-
dependent transcription. To address this question I performed ARE-Lux 
luciferase analysis (Figure 4.7).  I was surprised to find that loss of arrestin2 
decreased TGF-dependent transcription (Figure 4.7A). While siRNA1 had a 
modest dampening effect on luciferase production, siRNA2 showed greater than 
two-fold decreases in luciferase production relative to negative control (Figure 
4.7A).   
As a complementary approach, I sought to evaluate the effect of 
increasing levels of arrestin2 on TGF-dependent transcription. As in Figure 
4.7A, HepG2 cells were transiently transfected with ARE-lux construct, as well as 
FoxH1 and -galactosidase. Furthermore, cells were transfected with increasing 
amounts of arrestin2 as indicated (Figure 4.7C). The specificity of my 
experiment was assessed using the inhibitory Smad, Smad7, which decreases 
transcriptional responses and causes decreased luciferase production in this 
assay. I observed that increasing concentrations of arrestin2 enhanced TGF-
dependent luciferase transcription (Figure 4.7C). As a control, we also 
transfected increasing amounts of arrestin1 cDNA and found that arrestin1 
Figure 4.7 Decreased arrestin2 protein levels decreases TGF-dependent 
transcription 
(A) HepG2 cells were transiently transfected with control siRNA (Ctrl) or two different 
siRNA to arrestin2 (siRNA1 or siRNA2). The following day, cells were transfected with 
cDNA encoding ARE-lux, FoxH1, and -galactosidase. To induce ARE-lux activation, 
transfected cells were incubated in the absence or presence of 250 pM TGF overnight. 
The graph is representative of the mean of triplicates (± SD) from one representative 
experiment. (N=4) 
(B) HepG2 cells were transiently transfected with control siRNA (Ctrl) or two different 
siRNA to arrestin2 (siRNA1 or siRNA2) as described in Panel A. Forty eight hours 
post-transfection, cells were lysed, subjected to SDS-PAGE and immunoblotted to 
assess arrestin2 protein expression. 
(C) HepG2 cells were transiently transfected with cDNA encoding ARE-lux, FoxH1, and 
-galactosidase and increasing amounts of arrestin2 cDNA or arrestin1 cDNA (as 
indicated). Smad7 was also transfected in condition 2 to assess the robustness of the 
system. Transfected cells were incubated in the absence or presence of 250 pM TGF. 
Luciferase activity was normalized to -galactosidase activity and is represented as the 
mean ± SD of triplicates from one representative experiment (N=3). 
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did not greatly increase TGF-dependent transcription (Figure 4.7C). This result 
supported my finding in Figure 4.7A that arrestin2 mediates TGF 
transcriptional responses.  
4.4.7 arrestin2 expression increases SARA-TRII association 
 My results from figures 4.5 and 4.7 showed paradoxical effects. Although 
loss of arrestin2 had minimal effects on Smad2-phosphorylation, loss of 
arrestin2 decreased Smad-dependent transcription. To confirm this result, we 
showed that increasing the amount of arrestin2 increased TGF-dependent 
luciferase production. Runyan et al. illustrated that Smad2 phosphorylation can 
occur independently of receptor internalization, but receptor internalization is 
necessary for TGF-dependent transcription. Since SARA is enriched in the early 
endosome, and it has been shown that TGF receptor localization to the early 
endosome propagates TGF signal transduction (10), I decided to assess 
whether arrestin2 modulated the interaction of TRII with SARA. Using a co-
immunoprecipitation approach in HEK293T cells, I observed that over-expression 
of arrestin2 increased the association of TRII with SARA (Figure 4.8). Since 
access to the early endosome facilitates TGFsignalling, the ability of TRII to 
associate with components of the early endosome may therefore be a regulatory 
mechanism in TGF signal transduction. Thus, my finding that arrestin2 
increases SARA-TRII association and Smad-dependent transcription suggests 
 
Figure 4.8 arrestin2 increases the interaction of SARA with TRII 
HEK293T cells were transiently transfected with Flag-tagged SARA, GFP-tagged 
arrestin2 and/or HA-tagged TRII, as indicated. Approximately 36 hours post-
transfection, cells were lysed and immunoprecipitated with -Flag antibodies. 
Immunoprecipitates were subjected to SDS-PAGE and immunoblotting. The top panel 
shows immunoprecipitated proteins, while the bottom panel shows total protein 
expression levels (N=3). 
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that arrestin2 may enhance Smad-dependent TGF signal transduction. 
4.4.8 siRNA directed to arrestin2 enhances p38 phosphorylation  
 TGF can also activate signal cascades that are independent of the 
canonical Smad pathway. As I had discovered that loss of arrestin2 protein 
expression caused increased phosphorylation of Smad2 but decreased Smad-
dependent transcription, I wanted to assess the effect of decreasing arrestin2 
levels on TGF-dependent, Smad-independent signalling pathways. 
 Several groups have shown that TGF can activate the MAPK pathway 
through MKK3/6 (22,23). Importantly, the induction of p38 and JNK 
phosphorylation by TGF is independent of the Smad pathway and is mediated 
by TRAF6 and TAK1 (17,18).   
To evaluate the role of arrestin2 on Smad-independent pathways, I 
silenced endogenous arrestin2 levels in A549 cells using siRNA, then treated 
the cells with 250 pM TGF1 for 30 minutes (Figure 4.9). I observed that 
phosphorylated p38 increased robustly at 1.5 hours, and is sustained at 4.5 
hours (Figure 4.9A). Similar to my observations with phosphorylated Smad2, I 
found that loss of arrestin2 increases levels of phosphorylated p38, with a 
statistically significant difference between negative control and arrestin2 
knockdown occurring at 4.5 hours (Figure 4.9B). I also assessed levels of 
phosphorylated p38 in H1299 cells (Figure 4.10), and found that loss of 
arrestin2 levels also increased phosphorylated p38 levels, similar to my results 
with A549 cells. 
Figure 4.9 Decreased arrestin2 expression increases p38 phosphorylation 
(A) A549 cells transiently transfected with non-specific control siRNA (Ctrl siRNA) or 
two different siRNA to arrestin2 (arr2 siRNA1 or arr2 siRNA2) were assessed for 
TGF-dependent p38 phosphorylation. Serum-deprived cells were either immediately 
lysed or treated with 250 pM TGF1 for 30 minutes. Cells were then washed in PBS 
and further incubated for 1 or 4 hours or were lysed. All lysates were subjected to SDS-
PAGE and immunoblotted for phospho-p38, total p38, arrestin2 and actin levels (N=3).  
(B) Using Quantity One software, phospho-p38 levels as a ratio of total p38 levels were 
plotted for all conditions. The graph shown represents the mean ±SD vs. time (N=3). 
*p<0.05 
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Figure 4.10 Decreased arrestin2 expression increases p38 phosphorylation in 
H1299 cells 
H1299 cells transiently transfected with non-specific control siRNA (Ctrl siRNA) or two 
different siRNA to arrestin2 (arr2 siRNA1 or arr2 siRNA2) were assessed for TGF-
dependent p38 phosphorylation. Serum-deprived cells were either immediately lysed or 
treated with 250 pM TGF1 for 30 minutes. Cells were then washed in PBS and further 
incubated for 1 or 4 hours or were lysed. All lysates were subjected to SDS-PAGE and 
immunoblotted for phospho-p38, total p38, arrestin2 and actin levels (N=3).  
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4.4.9 siRNA directed to arrestin2 predisposes cells to apoptosis and 
increases TGF-dependent apoptosis 
Having found that decreasing arrestin2 expression increased levels of 
phosphorylated p38, I wanted to assess whether this increase in phosphorylation 
would have functional outcomes for the cell; or, similar to my results with 
phosphorylated Smad2, would not result in increased signal transduction. The 
p38 MAPK pathway is well-known as a stress-activated pathway, and its 
activation has been shown to induce apoptosis (19). Furthermore, Yu and 
colleagues have shown that p38 is necessary for TGF-induced apoptosis (20).  
Therefore, I decided to assess TGF-induced apoptosis in A549 cells as a 
functional read-out for phosphorylated p38. A549 cells were plated in 12-well 
dishes and transfected with siRNA against arrestin2, as previously described. 
The day following transfection, cells were serum-starved in 0.2% FBS/F12K for 4 
hours, then were either left in low-serum media or were treated with 250 pM 
TGFfor 48 hours. Following treatment, cells were incubated with Hoechst 
33342 prior to imaging on an inverted IX-71 immunofluorescence microscope. 
Figure 4.11 illustrates the outcome of the apoptosis assays. In the negative 
control siRNA treated cells, cells that were not stimulated with TGF 
demonstrated little apoptosis (approximately 7% of cells) (Figure 4.11A, 4.11B), 
while those treated with TGF had a moderate increase in apoptosis 
(approximately 12% of cells) which did not reach statistical significance (Figure 
4.11). 
Figure 4.11 Decreased arrestin2 protein levels increase cell death 
(A) A549 cells were transiently transfected with ctrl siRNA or two different siRNA to 
arrestin2 (arr2 siRNA1 or arr2 siRNA2). Following transfection cells were serum-
starved and either treated with 250 pM of TGF1 for 48 hours or left untreated. Cells 
were then incubated with Hoechst 33342 and imaged on an inverted IX-71 
immunofluorescence microscope. Panel A illustrates representative fields of view for the 
different conditions. (N=4). Bar= 10 µm. 
(B) Quantification of apoptosis assay. Nine fields of view over four separate 
experiments (>100 cells/condition/experiment) were quantified by dividing apoptotic 
cells by total number of cells per field of view. The graph illustrates the percentage of 
apoptotic cells. One-way ANOVA followed by Bonferroni correction statistical analysis 
was performed.  (*) indicate a statistically significant difference between the indicated 
conditions (p<0.05). 
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Interestingly, in the absence of TGF stimulation, both arrestin2 siRNA 
conditions had a statistically significant increase in apoptotic cells compared to 
control (Figure 4.11B). Furthermore, both arrestin2 siRNA conditions showed a 
statistically significant increase of apoptosis with TGF treatment, with 
approximately a 10% increase in total apoptosis (Figure 4.11B). This figure 
illustrates that decreasing arrestin2 expression sensitizes cells to cell death. 
 As the Hoechst apoptosis assay only allowed me to qualitatively assess 
dead cells, I wanted to ensure the cell death that I had found was indeed 
apoptosis and not necrosis. In order to answer this question, I performed a 
western blot to evaluate levels of the protein cleaved PARP. Poly(ADP- 
ribosylation) is a post-translational modification that is commonly implicated in 
DNA repair (21). The process of poly(ADP-ribosylation) is regulated in part by 
PARP, poly(ADP-ribosylation) polymerase (21). During the intermediate phase of 
apoptosis, PARP is activated but is later cleaved by a number of proteases, with 
the best-known being caspase-3 (22). The cleavage of PARP inactivates its 
activity, and apoptosis continues to progress.     
 To assess levels of cleaved-PARP in my cells, I performed western blot 
analysis and immunoblotting (Figure 4.12). Cells were transfected with arrestin2 
siRNA, then 16 hours post-transfection, cells were serum-starved for 4 hours and 
then either treated with 500 pM TGF for 48 hours or left untreated. Similar to my 
results using the Hoechst assay, I found that decreasing arrestin2 levels 
increased the amount of cleaved-PARP, in the absence of TGFparticularly in 
the case of siRNA2 (see Figure 4.12, arr2 siRNA2).  However, similar to the 
Figure 4.12 Decreased arrestin2 levels increase cleaved-PARP 
A549 cells were transiently transfected with ctrl siRNA or two different siRNA to 
arrestin2 (arr2 siRNA1 or arr2 siRNA2). Following transfection, cells were serum-
starved and either treated with 500 pM of TGF1 for 48 hours or left untreated. Cells 
were then lysed and subjected to SDS-PAGE and immunoblotting for cleaved-PARP as 
well as arrestin2 and actin (N=3). 
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Hoechst experiments I saw an inductive effect of TGF in enhancing levels of 
cleaved-PARP (Figure 4.12).         
 Taken together, my results indicate a role for arrestin2 in modulating 
TGF signalling pathways. 
4.5 Discussion 
  While receptor complexes were previously thought to signal solely at the 
cell surface, a number of studies have shown that the localization of receptor 
complexes in different subcellular compartments can directly affect signal 
transduction. For example, it has recently been shown that the trafficking of the 
VEGF receptor, VEGFR-2, is dependent on its interaction with NRP-1, which 
enhances VEGFR-2 signalling and entrance into a recycling pathway (23). 
Similarly, Purvanov and colleagues found that the early endosomal GTPase 
Rab5 can directly interact with G to activate the planar-cell-polarity pathway of 
Frizzled signalling (24).  In the TGFsignalling pathway, SARA, an early 
endosomal protein, enhances the ability of TRI to phosphorylate Smads by 
bringing them into close proximity with one another (3, 27). 
 In this chapter, I have attempted to elucidate the role of arrestin2 in 
TGF signal transduction. arrestin2 has greater than twenty known binding 
partners (7), and is an important scaffolding protein in GPCR signalling. Chen et 
al., originally reported that arrestin2 functions to promote the internalization of 
TRIII/TRII complexes following the phosphorylation of TRIII by TRII (7). 
However, I have shown that the role of arrestin2 in TGF signal transduction is 
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not merely limited to its interactions with TRIII. Rather, I have shown that 
arrestin2 can interact with TRII in the absence of TRIII. This interaction has 
significant implications in TGFsignal transduction, as A549 cells, which have 
been shown to have very little endogenous TRIII (16), show significant 
differences in TGF signal transduction through both canonical and non-
canonical pathways. My results indicate that the loss of arrestin2 promotes 
increased phosphorylation of both Smad2 and p38. However, the 
phosphorylation of Smad2 does not translate into functional signalling, as loss of 
arrestin2 decreases TGF-dependent luciferase production. In their manuscript, 
Chen et al suggested that arrestin2 increased TGF receptor endocytosis and 
loss of arrestin2 increased TGF signalling (14). In this chapter, I have shown 
that loss of arrestin2 increases the phosphorylation and activity of the p38 
pathway.  
While it may seem contradictory that loss of arrestin2 increases 
phosphorylated Smad2 levels but decreases TGF-dependent transcription, an 
elegant study by Runyan et al. supports my findings. In their report, Runyan and 
colleagues evaluated the role of internalization in TGF-dependent Smad signal 
transduction. Using human kidney mesangial cells, the authors illustrated that 
inhibition of internalization only slightly affected levels of phosphorylated Smad2, 
and Smad2-SARA complexes (25). However, the authors also showed that 
inhibition of endocytosis greatly decreased Smad2 nuclear localization as well as 
Smad2-dependent transcriptional activation (25). Indeed in my study, I found 
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increased cell-surface levels of TRII in the absence of arrestin2. Since the 
inhibition of internalization does not affect the ability of Smad2 to be 
phosphorylated (25), it follows then that loss of arrestin2 should not decrease 
Smad2 phosphorylation. However, given our finding that arrestin2 increases the 
association of TRII with SARA, it is plausible that while loss of arrestin2 does 
not affect Smad2 phosphorylation, it may traffic with the receptor complex to the 
early endosome and enhance SARA-TRII association.  
In my study I also assessed a Smad-independent pathway, the p38 
pathway, and my results showed that loss of arrestin2 greatly increases p38 
phosphorylation in the presence of TGF. Since one possibility is that greater 
numbers of TGF receptors are found at the cell surface in the absence of 
arrestin2, this would mean that more receptors would be exposed to ligand and 
therefore activated for signalling. Since the activation of the p38 pathway by 
TGF is Smad-independent (17, 18); the internalization of the receptor complex 
does not appear to be necessary for p38 signal transduction. Indeed, I showed 
that increased levels of phosphorylated p38 had a functional outcome in the cell, 
as loss of arrestin2 increased apoptosis, a well-established signalling event 
downstream of p38 signal transduction.   
The trafficking of TGF receptors plays a crucial role in signal 
transduction, not only biochemically but in disease states as well. Recently, Park 
and colleagues showed that a TRII mutant found in oral squamous cell 
carcinoma exhibits delayed internalization and promotes cancer cell migration 
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and invasion (26). Similarly, in scleroderma, a fibrotic disease which exhibits 
elevated TGF signalling, patients exhibit decreased levels of caveolin-1, a key 
component of membrane raft dependent internalization (32). These studies 
suggest that internalization and trafficking of TGF receptors can have significant 
implications in disease states. Therefore proteins like arrestin2, which alter 
TGF trafficking can have significant affects on signal transduction and should be 
studied in detail to evaluate their effects in disease states such as cancer and 
fibrosis. 
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CHAPTER 5 
             
TGF3 IS A LESS POTENT INDUCER OF TGF SIGNALING THAN TGF1 IN 
NON-SMALL CELL LUNG CANCER CELLS 
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5 Chapter 5 
5.1 Chapter summary 
 
In Chapters 3 and 4 of my thesis, I assessed the ability of proteins which 
interact with TRII, namely TRIII and arrestin2, to influence trafficking and 
signaling of the receptor complex. In this chapter I have evaluated the role of 
TGFligand types 1 and 3, which can bind all three TGF receptors, in their 
ability to affect TGFtrafficking and signaling.  I show that overall TGF3 is much 
less potent than TGF1 at propagating TGFsignalling. While I initially 
hypothesized that this would be due to alterations in endocytosis and trafficking 
similar to my other chapters, I found that both TGFligands induced similar 
membrane raft partitioning and trafficking of the TGFreceptor complex. 
However, I found that TGF3 induced a different binding ratio of TRII/TRI cell-
surface complexes than TGF1. Therefore the level of receptor engagement at 
the cell surface may differ between the two ligands and may be able to account 
for the observed differences in signal transduction. 
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5.2 Introduction 
 The TGFsuperfamily consists of structurally and functionally related 
cytokines that are released into the extracellular matrix as inactive precursors (1). 
The TGFβ superfamily has two distinct subfamilies: the TGFβ/Activin/Nodal 
subfamily and the bone morphogenetic protein (BMP)/growth and differentiation 
factor (GDF)/ Muellerian inhibiting substance (MIS) subfamily (2). The 
TGF/Activin/Nodal subfamily binds to serine-threonine kinase receptors at the 
cell surface which results in signal propagation utilizing Smads 2 and 3 (3). 
Similarly, signal transduction by the  BMP/GDF/MIS subfamily  is also 
propagated by serine-threonine kinase receptors, but their activation results in 
signal transduction utilizing Smads 1, 3, 5 and 8 (2).   While signal transduction 
by the TGFsuperfamily has been implicated in normal development, such as 
dorsal/ventral patterning and angiogenesis, the TGFsuperfamily, in particular 
the canonical TGFpathway has been implicated in pathologies such as cancer 
and fibrosis (3).    
 There are three TGFβ ligands which share significant sequence 
homology and have relatively specific, non-overlapping functions in vivo: TGF1, 
TGF2 and TGF3 (4). For example, while Tgfb1-/- mice and Tgfb2-/- mice both 
generally die during development, Tgfb1-/- mice have significant vasculogenic 
defects (5), whereas Tgfb2-/- mice have cardiovascular, skeletal and pulmonary 
issues (6). Interestingly, Tgfb3-/- mice survive gestation but die shortly after birth 
due to an inability to suckle caused by cleft palate (7). Although TGFβ ligands 
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have different functional roles, they are all secreted as inactive, homodimeric 
proproteins that must be cleaved by TGFβ activating molecules, such as matrix 
metalloproteinase 2, thrombospondin-1 and plasmin (8-10) . Active TGFβ is a 
homodimer stabilized by disulfide bridges and hydrophobic interactions (11). 
Once TGFβ has been activated, it is able to elicit downstream transcriptional 
events through binding and activating TGFβ receptors.  
To propagate TGFβ signaling, ligand is presented to the TβRII with the aid 
of ΤβRIII. The binding of ligand to ΤβRII causes ΤβRII to transphosphorylate the 
ΤβRI at serine-threonine residues in its GS domain (12). Phosphorylated ΤβRI 
recruits the receptor-regulated Smads, or R-Smads, and phosphorylates, and 
thereby activates them. Once the R-Smads have been phosphorylated, they are 
able to recruit the Co-Smad, Smad4, to form a heteromeric complex. With the aid 
of specific nuclear localization signals, the heteromeric Smad complex is able to 
translocate to the nucleus and interact with transcriptional co-activators and co-
repressors in order to induce cell-specific transcriptional programs (11). 
Despite activating the same signal transduction pathway, the 
TGFligands have vastly different effects in the wound microenvironment. For 
example,  TGF1 signalling in fibroblasts promotes ECM production and 
myofibroblast differentiation, resulting in a scar following wound-resolution (13). 
Similarly, inhibition of either TGF1 or TGF2 with neutralizing antibodies 
improves wound resolution and scar appearance in adult rodent wounds (14,15).  
However, application of exogenous TGF3 results in scar-free wound-resolution 
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in the same model system (16). This suggests that the different TGFligandsdo 
not have the same signalling effect in the wound microenvironment.  
 The vast majority of studies on TGFin cancer have focussed on 
TGF1 (4). TGF1 has a dual role in cancer: in early stages of tumourigenesis, 
TGF1 is growth-inhibitory and induces cell cycle arrest (17). However, in 
advanced cancers, TGF1 promotes epithelial-to-mesenchymal transition of 
tumour cells and promotes migration and invasion (17). While all three 
TGFligands are elevated in various tumours, the role of TGF3 has simply 
been assumed to be the same as TGF1 without subsequent in-depth 
biochemical studies to support this notion (4). Given the opposite roles of TGF1 
and TGF3 in the wound microenvironment and in development, it is unlikely that 
these two ligands have the same signalling outcome in the tumour 
microenvironment and cancer cells. Therefore in this chapter I have attempted to 
evaluate the mechanism of how structurally related TGF ligands activate 
receptor signaling cascades and downstream cellular events. 
 
5.3  Materials and Methods 
5.3.1  Cell culture 
 HEK293T cells were maintained in DMEM (Dulbecco’s modified Eagle’s 
medium) (Gibco) supplemented with 10% fetal bovine serum. A549 cells were 
maintained in F12K media (ATCC) supplemented with 10% fetal bovine serum.  
Mink Lung cells stably transfected with HA-tagged TRII (Mink Lung HAT cells) 
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were cultured in MEM supplemented with non-essential amino acids, 10% fetal 
bovine serum and 0.3% hygromycin. All cells were maintained at 37°C in 5% 
CO2. 
5.3.2  Constructs 
The pCMV5 cDNA construct encoding the carboxy terminus hemagluttinin 
(HA) epitope tagged type II TGF receptor (TβRII-HA) was used as previously 
described (18). 
5.3.3 Transfection 
HEK293T cells were transiently transfected using the calcium phosphate 
precipitation method; 5g of TRII-HA was transfected per 100mm dish (19,20).   
5.3.4 Isolation of caveolae/membrane-raft-enriched membrane fractions-  
Membrane rafts were isolated as previously described (18-20). Briefly, 
transfected HEK293T cells were grown to confluence in 100-mm-diameter 
dishes. Cells were washed twice with cold 1X PBS and lysed in 0.5 M Na2CO3, 
pH 11.0 containing protease inhibitors. After the cells were scraped, the cell 
lysate was homogenized in three 10 second bursts using a Polytron tissue 
homogenizer (Brinkmann Instruments). Cells were then sonicated three times for 
20 seconds each with a Vibra Cell sonicator (Sonics and Materials). The 
homogenates were then adjusted to 40% sucrose, and overlaid with 30% 
sucrose and 5% sucrose solutions. The samples were centrifuged for 16h at 
200,000 gav at 4°C using a Beckman SW41 rotor. Following centrifugation, 
12x1mL samples were collected and an aliquot of each sample was denatured 
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with Laemmli sample prep buffer, boiled and subjected to SDS-PAGE followed 
by immunoblotting. 
5.3.5  Immunofluorescence Microscopy  
Mv1Lu HAT cells were plated on coverslips in a 12 well plate and 
transfected with the indicated constructs. Cells were then incubated with 
biotinylated-TGF1 or biotinylated-TGF3 (Peprotech) in 0.5% BSA in KRH for 
2hrs at 4°C. Cells were washed three times with buffer, and then incubated with 
Cy3-labelled streptavidin for 1 hr at 4°C. Cells were fixed, permeabilized and 
incubated with anti-EEA1 primary and secondary antibodies as described 
previously (18,19). Images were obtained using an Olympus Ix81 inverted 
microscope using InVivo® software.  
5.3.6  Immunoblotting  
Proteins were separated by SDS-PAGE (10% gels) and transferred to 
nitrocellulose by electrophoretic transfer. Blots were incubated for 1 hr in 5% 
skim milk/TBST. After incubation with primary and secondary antibodies, bound 
antibodies were detected using SuperSignal chemiluminescence reagent 
(Pierce) and a VersaDoc imager (Biorad).  
5.3.7 Epithelial to mesenchymal cell marker analysis  
A549 cells were incubated with low-serum containing control medium or 
low-serum media containing increasing concentrations of TGF1 or TGF3 for 48 
hours. Cells were then lysed and immunoblotted with -E-cadherin (epithelial cell 
marker) or -N-cadherin (mesenchymal cell marker) as described above. 
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5.3.8 Affinity labelling  
A549 cells were labelled for 2 hrs with 250 pM [125I] TGF1 or 250 pM 
[125I] TGF3 ligand (Peprotech) in 0.5% BSA in KRH at 4°C. Cells were cross-
linked to ligand using DSS as described previously (19). Cells were then either 
immediately lysed in 1XTNTE or incubated in media with 10% FBS at 37°C for 2, 
4 or 8 hrs prior to lysis. Samples were eluted with Laemmli sample prep buffer, 
and separated using SDS-PAGE (7.5% gels). Receptors were visualized using 
phosphorimaging (Molecular Dynamics). 
5.4 Results 
5.4.1  TGF3 is less potent at inducing Smad2 phosphorylation than TGF1 
 As it has previously been shown that TGFβ1 and TGFβ3 exert vastly 
different outcomes in the wound microenvironment (21), I wanted to assess the 
ability of these ligands to transmit signals in cancer cells, as many of the same 
growth factors elevated in the wound microenvironment are also elevated in the 
tumor microenvironment. A549 non-small cell lung adenocarcinoma cells were 
used as a model to begin to characterize the role of these ligands in cancer cell 
signaling.  A549 cells were serum-starved overnight prior to a one hour treatment 
with TGFβ1 or TGF3 ligand, ranging in concentration from 50 pM to 1 nM prior 
to lysis and immunoblotting with anti-phosphoSmad2 antibodies (Figure 5.1A).  I 
observed that TGF1 induced the phosphorylation of Smad2 maximally at 50 pM.  
This is consistent with our previous results using Mv1Lu cells (20).   TGFβ3 was 
also observed to stimulate a similar amount of Smad2 phosphorylation, however 
Figure 5.1. TGF3 is less potent than TGF1 in inducing Smad2 phosphorylation. 
(A) A549 cells were serum-starved and treated with increasing concentrations of TGF1 
or TGF3 for 1 hour. Following lysis, cells were subjected to SDS-PAGE and 
immunoblotting for phosphorylated Smad2 (PSmad2) or Smad 2 (N=3). 
(B) Three separate experiments as described in Panel A were carried out and the 
amounts of PSmad2 and Smad2 were quantified using QuantityOne software and 
plotted as the ratio of PSmad2/Smad2.  The mean (Arbitrary Units) ± SD is shown. One-
way ANOVA followed by a Tukey’s Multiple Comparison test was conducted to evaluate 
statistical significance. * indicates a statistical significance of p<0.05.  
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Figure 5.1 
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at a concentration of 250 pM (Figure 5.1B).  This five-fold difference in the 
stimulation of Smad2 phosphorylation was next functionally tested in the ability of 
TGF1 and TGF3 to induce differences in protein expression of the EMT 
markers E-cadherin and N-cadherin.  
5.4.2 TGFβ1 is more potent at altering steady-state cellular EMT markers 
than TGFβ3 
 In order for epithelial-based cancers to metastasize, they first must 
release their cell-cell contacts, change their cytoskeletal arrangement, and 
acquire a motile phenotype (22). Loss of E-cadherin, an adhesion molecule, is 
one of the first indications of epithelial-to-mesenchymal transition. As TGFβ1 has 
been shown to induce loss of E-cadherin (reviewed in (22)), I wanted to assess 
whether TGFβ3 also shared this capability. A549 cells were serum-starved 
overnight and then treated with increasing concentrations of TGFβ1 or TGFβ3 for 
48 hours (Figure 5.2). I observed that TGF1 stimulated a loss of steady state E-
cadherin levels in A549 cells that was maximal at 250 pM (Figure 5.2B).  
Interestingly, TGFβ3 did not induce a pronounced decrease in the steady-state 
levels of E-cadherin, compared to TGFβ1 (Figure 5.2A). Indeed, I observed a 10-
fold difference in the abilities of TGFβ3 or TGFβ1 to decrease the steady-state 
levels of E-cadherin by 50% (Figure 5.2B; 100 pM for TGFβ1 vs. 1 nM for 
TGFβ3). 
 While loss of E-cadherin occurs frequently with the progression of cancer, 
upregulation of N-cadherin, a neuronal cadherin, has also been shown to occur 
during EMT (23). Increased levels of N-cadherin are correlated with tumor  
Figure 5.2. TGF1 is more potent than TGF3 at reducing E-cadherin levels  
(A) A549 cells were serum-starved and treated with increasing concentrations of TGF1 
or TGF3 for 48 hours. Following lysis, cells were subjected to SDS-PAGE and 
immunoblotting for E-cadherin (Ecad) or Actin (N=3). 
(B) Three separate experiments as described in Panel A were carried out and the level 
of E-cadherin was quantitated using QuantityOne software.  The means (Arbitrary Units) 
± SD are shown. Statistical significance was evaluated using a One-Way ANOVA test 
followed by a Bonferroni correction (* p<0.05). 
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Figure 5.2 
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metastasis (23). Therefore I wanted to assess the effect of TGFβ3 on steady-
state levels of N-cadherin. Again, A549 cells were serum-starved then treated 
with increasing concentrations of either TGF1 or TGF3 for 48 hours (Figure 
5.3). I observed that TGFβ3 is less potent than TGFβ1 in increasing N-cadherin 
steady-state levels (Figure 5.3A). While TGFβ1 induces more N-cadherin protein 
at concentrations as low as 100 pM, TGFβ3 required higher concentrations to 
induce only very minor increases in N-cadherin levels (Figure 5.3B).  These 
differences in steady state EMT markers may be a global effect that these two 
TGF sub-types have on cells.   
5.4.3  TGFβ1 and TGFβ3 ligand treatment do not alter TGFβ receptor 
membrane partitioning 
 As I have shown that TGFβ1 and TGFβ3 have strikingly different signal 
transduction capabilities I hypothesized that these differences in signaling could 
be accounted for by receptor membrane partitioning, similar to my other data 
chapters. To address this question, HEK293T cells were transiently transfected 
with HA-TβRII cDNA.  Cells were serum-starved 16 hours prior to membrane raft 
preparation, and were then treated with either 250 pM TGFβ1, 250 pM TGFβ3, 
0.2% FBS or 10% FBS (as indicated) for 30 minutes. Cells were subjected to 
sucrose-density ultracentrifugation and immunoblotting with anti-HA antibodies to 
identify tagged TGF receptors. Figure 5.4 illustrates that in the presence and 
absence of ligand, the ΤGFβ receptors were observed primarily in membrane raft 
fractions.  Therefore, it appeared that ligand treatment of specific TGF isoforms 
did not directly affect membrane partitioning of receptors. 
Figure 5.3. TGFβ1 induces greater N-cadherin steady-state levels than TGFβ3 
(A) A549 cells were serum-starved and treated with increasing concentrations of TGF1 
or TGF3 for 48 hours. Following lysis, cells were subjected to SDS-PAGE and 
immunoblotting for N-cadherin (Ncad) or Actin (N=3). 
(B) Three separate experiments as described in Panel A were carried out and the level 
of N-cadherin was quantitated using QuantityOne software.  The means (Arbitrary 
Units) ± SD are shown. One-way ANOVA followed by a Tukey’s Multiple Comparison 
test was conducted to evaluate statistical significance. * indicates a statistical 
significance of p<0.05, whereas ** indicates a statistical significance of p<0.001. 
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Figure 5.3 
 
Figure 5.4. Ligand treatment does not influence TGFβ receptor partitioning 
HEK 293T cells were transiently transfected with TβRII-HA cDNA. Cells were serum-
starved for 16 hours prior to a 30 minute treatment with 250 pM ligand or FBS (as 
indicated). The cells were then lysed and processed for ultracentrifugation as previously 
described (18). The collected fractions containing membrane rafts (R) and non-raft (NR) 
were immunoblotted with anti-HA antibodies to visualize the partitioning of expressed 
TRII (N=3). 
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Figure 5.4 
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5.4.4 TGF1 or TGF3 treatment do not differ in their trafficking of TRII to 
the early endosome 
 Although TGFβ1 and TGFβ3 do not alter TGFβ receptor complex 
membrane partitioning, I wanted to assess the trafficking of receptors following 
ligand treatment. It has been shown that the greater the amount of time spent in 
the early endosome, the greater the Smad signalling potential (20,24,25). 
Therefore, I hypothesized that perhaps the differences in signaling could be 
accounted for by receptor trafficking to the early endosome. Using biotinylated-
TGFβ1 or TGFβ3, HAT Mv1Lu cells stably expressing TβRII were labelled at the 
cell surface at 4˚C. Receptors were then incubated with streptavidin-Cy3, and 
permitted to internalize for 10, 20, or 60 minutes (Figure 5.5). Using EEA1 (early 
endosomal autoantigen-1) as a marker for the early endosome, I found that both 
ligands co-localized in EEA1-positive compartments at 20 minutes, and 
significant co-localization occurred at 60 minutes.  
5.4.5 TGFβ3 promotes a different binding ratio of TβRII/TβRI complexes 
than TGFβ1 
 While it has been previously found that TGFβ3 binds to TβRII dimers with a 
greater affinity than TGFβ1 (26), I wanted to ensure that our ligands bound 
similarly in our experiments. To address this question, TGFβ1 and TGFβ3 were 
labelled with 125I and performed receptor binding studies. Briefly, Mv1Lu cells 
were labelled with saturating doses of 125I-TGFβ isoforms, for 2 hours at 4˚C. The 
ligands were cross-linked, and lysates were subjected to SDS-PAGE.  
Figure 5.5 Cells treated with TGFβ1 or TGFβ3 exhibit similar trafficking of TRII 
Mv1Lu cells stably over-expressing HA-TβRII were labelled at 4˚C for 2 hours with 
biotinylated TGFβ1 (A) or TGFβ3 (B). Following incubation of Cy3-labelled streptavidin 
at 4˚C, cells were incubated for 10, 20 or 60 minutes (as indicated) at 37˚C to permit 
receptor internalization. Standard immunofluorescence staining was used to visualize 
EEA1, a marker for the early endosome, and nuclei (DAPI staining). Cells were 
assessed for receptor complex co-localization with the early endosome, which results in 
a yellow overlay (N=4). Bar= 10 m 
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Figure 5.5 
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I observed that both TGFβ1 and TGFβ3 associated with TβRII (Figure 5.6A).  
However, it appears that the amount of TβRI recruited to the TGFβ/TβRII 
complex was lower for TGFβ3 than TGFβ1 (Figure 5.6B). As the kinase activity 
of TβRI is responsible for initiating the Smad signaling cascade, and TβRI must 
be activated by TβRII following ligand binding to initiate the cascade, TβRII/TβRI 
ratios may play a crucial role in determining signaling potential.  Therefore, if 
TGFβ3 induces less TβRI to be bound to TβRII, this may result in fewer activated 
TβRI to propagate Smad signal transduction.  
5.5  Discussion 
 In the canonical TGF signaling pathway, the association of TGF to the 
type II receptor (TRII) is the first step in activation of the signaling cascade 
(27,28).  This is followed by the recruitment of the type I receptor (TRI) to the 
TRII/TGF complex and the transphosphorylation of TRI in its GS domain by 
TRII.  The now active TRI initiates downstream R-Smad (Smad2/3) 
phosphorylation leading to the formation of a complex between R-Smads with the 
common Smad, Smad4, and their nuclear import to affect transcription (2). 
 In this chapter, I have demonstrated that the degree of recruitment of TRI 
to the TRII/TGF complex is dependent on isoform-specific TGF ligands.  I 
observed that TGF1 is more effective in recruiting TRI to the complex than 
TGF3.  This has greater implications to signal transduction and I observed a 
muted response to ligand-dependent activation of the Smad signaling pathway 
Figure 5.6. TGF isoform specific receptor complex formation 
(A) Mv1Lu cells were labelled at 4˚C for 2 hours with 125I-TGFβ1 or 125I-TGFβ3, cross-
linked, subjected to SDS-PAGE and visualized by phosphorimaging (N=3). 
(B) Ratios of TβRI and TβRII were determined using QuantityOne software. The graph 
illustrates the amount of TβRI associated with TβRII. (mean ± SD). (N=3) 
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Figure 5.6 
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and muted changes of EMT markers when  cells were incubated with TGF3 
compared to TGF1. As previously mentioned, during adult wound healing, 
TGFβ1 is found at very high levels, and promotes myofibroblast differentiation, 
extracellular matrix production, and fibroblast chemotaxis (29). In contrast, 
TGFβ3 promotes scar-free healing (29). Therefore, my results may account for 
some of the differences seen in wound healing because even though TGFβ 
ligands can activate the same receptors to propagate signal transduction, the 
level of isoform specific receptor engagement will influence transcriptional 
outcome in TGFβ signaling. To confirm these results, it may be of interest to 
assess the ability of TGF3 to induce differentiation of fibroblasts to 
myofibroblasts.        
 Though studies have shown that TGF3 promotes scar-free healing (29), 
few studies have assessed the ability of TGF3 to induce myofibroblast 
differentiation. Interestingly, a study by Waddington and colleagues showed that 
increasing the bioavailability of TGF3 may increase its efficacy in promoting 
scar-free wound-healing. In this study, the authors created a mutant TGF3 
which did not bind latent TGFbinding protein (LTBP), thereby increasing its 
bioavailability, as LTBP has been shown to sequester TGFligand in the ECM 
(30). The authors used a lentiviral-based delivery system to deliver this construct 
in vivo and illustrated that it decreased scar tissue markers in a mouse wounding 
model (30). Therefore, modulating the bioavailability of TGF3 in the ECM may 
provide an interesting therapeutic target for scar tissue formation. Since my 
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results also show differences between TGF1 and TGF3 signalling ability in 
cancer cells, it may be interesting to assess whether modulating the 
bioavailability of TGF3 in the tumour microenvironment through a similar system 
could mediate tumourigenicity in an in vivo model.  
 An intriguing avenue of study to complement my work on isoform-specific 
TGFsignal transduction would be to assess the binding capacity of TGF1 and 
TGF3 to the TGFreceptor complex. It has been reported that TGF3 has the 
greatest ability to bind TRII  (4). Therefore it would be interesting to assess 
whether TGF1 and TGF3 could compete for binding of TRII. If TGF3 is able 
to displace TGF1 from TRII, and since my results show that TGF3 induces 
less signal transduction in cancer cells, increasing the amount of TGF3 may be 
able to competitively displace TGF1 and therefore decrease the detrimental 
effects of TGF1 signalling in cancer cells. 
 TGFβ ligands normally dimerize to associate and cluster receptors 
effectively.  A recent study substituted one of the dimerized TGFβ3 with TGFβ3 
WD (31). The TGF3 WD that was designed by the authors is a heteromeric 
TGFligand composed of one wild-type TGF3  and one TGF3 in which Arg25 
and Arg94 were substituted with glutamate, and Tyr90 was substituted with 
alanine (31), residues shown to be important for ligand binding. These residues 
are also missing in TGF2.  This TGFβ3 wild-type/ TGFβ3 WD dimer was found 
to associate with TβRII and recruited the TβRI with affinities similar to wild-type 
TGFβ3, but with one-half the stoichiometry (31). TGFβ3 WD was further shown 
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to retain approximately half the signaling activity of TGFβ3 in three TGFassays 
such as Smad3 phosphorylation and growth inhibition.  The authors also 
provided evidence that the two TβRI/TβRII heterodimers bind and signal in an 
independently of one another.  Taken together, these results and my 
observations suggest that TGF1 and TGF3 have different receptor clustering 
potential.  Future work comparing the amino acid sequences of the TGFβ1 vs. 
TGFβ3 ligands, which are >76% identical, may show specific regions of the 
ligands that are responsible for receptor binding and engagement.  
Another interesting consequence of my study was the observation that 
TRII membrane partitioning and trafficking is not influenced by isoform-specific 
ligand binding.  This is consistent with previous results which illustrated that the 
trafficking of TRII is not dependent on ligand association (20).  Indeed, the 
recruitment of TRI to the constitutively trafficking TRII may be the limiting factor 
in receptor signaling potential, where TRI must access the early endosome to 
phosphorylate Smad2 and initiate the signal transduction cascade.  Further 
studies on the effect of ligand specific trafficking of TRI may further elucidate 
this theory. 
Since the mechanism of TGFβ receptor endocytosis has a profound effect 
on TGFβ signaling, and a number of pathologies show aberrant TGFβ signaling, 
an in-depth study evaluating the mechanism through which TGFβ receptors are 
directed to internalize is warranted. 
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6 Chapter 6 
6.1 Summary and General Discussion 
The TGFsignalling pathway is a cell-type and context-dependent 
pathway which has pleiotropic effects. While it was initially thought that 
TGFsignal transduction simply occurred from the cell surface and was 
mediated by the Smad family of transcription factors, it is now understood that 
TGFreceptor internalization and trafficking play key roles in regulating signalling 
outcome. It has been shown that receptors internalized by clathrin-mediated 
endocytosis traffic to the early endosome where they can interact with SARA to 
propagate Smad-mediated transcription (1-3). However, receptors internalized by 
membrane raft-dependent, clathrin-independent mechanisms traffic to the 
caveolin-1 positive vesicle, are prevented from signal propagation and are 
targeted for degradation. While the role of endocytosis and trafficking in this 
pathway has now been established, the signal(s) directing the TGFreceptors to 
internalize via clathrin-dependent endocytosis or clathrin-independent 
endocytosis were not well understood. The overall purpose of my study was to 
evaluate factors directing TGFreceptor internalization. I evaluated the role of 
domains of TRII, the interaction of TRII with TRIII, the interaction of TRII 
with arrestin2, and the role of TGFligand isoforms on TGFreceptor trafficking 
and subsequent signal transduction. Therefore, in this body of work I have 
assessed both intracellular and extracellular factors which direct TGFreceptor 
trafficking and have direct effects on signalling outcome.   
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6.1.1 The extracellular domain of TRII directs entry into membrane-raft 
fractions 
 My work, presented in chapter 2, complemented a study I carried out with 
Valbona Luga to identify domains of TRII which may direct receptor 
internalization. We used truncation mutants of TRII and evaluated their ability to 
partition into membrane raft fractions. Previously very little work had been done 
on identifying motifs involved in TRII internalization. A study performed by 
Ehrlich and colleagues had identified a di-leucine motif in the cytoplasmic domain 
of TRII which regulated clathrin-mediated endocytosis (4); but no studies had 
attempted to evaluate the role of the extracellular domain in regulating TRII 
internalization.  In chapter 2, I showed that both the extracellular and intracellular 
truncation mutants of TRII were able to interact with TRI. This was an 
important parameter to assess as it has been shown that TRII and TRI form 
heterocomplexes at the cell surface (5) and it has been suggested that the 
binding ratio of TRII:TRI may also affect endocytic trafficking of the receptors 
(6). Upon analysis of TRII receptor partitioning, we found that the extracellular 
truncation mutant of TRII had a marked decrease in membrane-raft 
internalization. As TRII has several extracellular glycosylation sites (7) we 
assessed whether the glycosylation status of TRII affected its ability to partition 
into membrane rafts. We found that the glycosylation status of TRII itself did not 
affect its membrane raft partitioning, but the glycosylation status of the cell as a 
whole did affect the partitioning of TRII. Importantly, this was not due to a 
disruption in the ability of the cell to produce membrane rafts, as I illustrated that 
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treatment with nystatin did not disrupt membrane raft formation. Finally, I 
illustrated using a chimeric receptor composed of the GMCSF receptor 
extracellular domain and the intracellular domain of TRII that it is specifically the 
extracellular domain of TRII, and not a similarly glycosylated receptor, which 
directs entry of TRII into membrane rafts. 
6.1.2  TRIII increases clathrin-mediated endocytosis of TRII/TRI 
complexes and basal TGFsignalling 
 As shown in Chapter 2 that the extracellular domain of TRII and the 
glycosylation status of the cell as a whole affected membrane raft partitioning of 
TRII, I decided to assess the role of TRIII in directing TRII/TRI internalization 
and trafficking. Previously the role of TRIII in TGFsignal transduction had 
been thought to be simply involved in ligand-presentation to TRII. Since TRIII 
has a large, heavily glycosylated extracellular domain (7) and it has been shown 
to interact with TRII, I thought it could potentially be the signal regulating TRII 
trafficking based on my work from Chapter 2.  
 In Chapter 3, I demonstrated that TRIII was able to interact with both 
TRII and TRI in the absence of ligand. Furthermore, unlike TRII and TRI 
which were found primarily localized in membrane-raft fractions, TRIII was 
found enriched in non-membrane raft fractions. Interestingly, its association with 
TRII and TRI re-directed both receptor complexes into non-membrane raft 
fractions and subsequently into the early endosome (Figure 6.1). This altered  
 
Figure 6.1 TRIII increases clathrin-mediated endocytosis of TRII/TRI 
complexes 
In Chapter 3 of my thesis, I evaluated the ability of TRIII to direct internalization of 
TRII/TRI complexes. My work illustrated that TRIII could direct the TRII/TRI 
complex to increase its non-membrane raft partitioning, traffic to the early endosome, 
and increase its half-life and basal signalling potential.  
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Figure 6.1 
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internalization had effects on signal transduction as well, as the association of 
TRIII with the TRII/TRI receptor complex increased their half-life and basal 
TGFsignal transduction. As mentioned, while the role of TRIII had previously 
been thought to be in ligand-presentation, I showed in Chapter 3, that TRIII 
could alter the trafficking of the receptor complex thus supporting my model, that 
this altered receptor trafficking has direct implications in TGFsignalling 
potential.  
6.1.3  arrestin2 interacts with TRII to mediate Smad-dependent and 
Smad-independent signal transduction 
 I was interested in studying the role of arrestin2 in TGFsignal 
transduction, as Chen and colleagues had found a novel role for arrestin2 in 
mediating TRII/TRIII endocytosis through binding TRIII (8). Since they 
showed that arrestin2 promoted endocytosis of TRII/TRIII, I was interested in 
assessing whether this interaction directed membrane trafficking of the receptors. 
As arrestin2 bound to a phosphorylated threonine residue on TRIII, and TRII 
has multiple phosphorylated residues on its intracellular domain (7), I wanted to 
test the possibility that arrestin2 could bind TRII in the absence of TRIII. In 
Chapter 4, I illustrated that TRII and arrestin2 could interact in the absence of 
TRIII (Figure 6.2). Furthermore, this interaction had direct consequences on 
signalling. I used a cell line which has been shown to have very little endogenous 
TRIII (A549 cells) (9), and illustrated that loss of arrestin2 protein expression 
increased phosphorylation of both Smad2 and p38. Interestingly, the increased  
Figure 6.2 arrestin2 interacts with TRII to increase early endosomal trafficking 
of TRII and enhance Smad-dependent signal transduction    
In Chapter 4 of my thesis I evaluated the ability of arrestin2 to affect TGF signalling. 
My work illustrated that arrestin engages TRII and traffics with TRII to the early 
endosome. Here, its presence increases TRII-SARA interaction and Smad-dependent 
transcription. 
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phosphorylation of Smad2 did not translate into increased Smad signal 
transduction as arrestin2 increased TRII trafficking to the early endosome and 
mediated the interaction of TRII with SARA. However, increased 
phosphorylation of p38 in the absence of arrestin2 predisposed cells to 
apoptosis both in the presence and absence of TGF.  
 Therefore, in Chapter 4 I illustrated that arrestin2 associates with TRII 
and may direct Smad-dependent and Smad-independent responses to 
TGFstimulation.  
6.1.4 TGF3 is a less potent inducer of TGFsignalling than TGF1 in non-
small cell lung cancer cells  
 During my preparation for my comprehensive exam, I noticed that the 
majority of work done on TGFin cancer had been done with TGF1 ligand and 
very few research articles had evaluated the role of TGF2 or TGF3 in cancer. 
Furthermore, it was generally assumed that the role of TGF2 and TGF3 would 
be the same as TGF1 in TGFsignalling in cancer. Interestingly, in the wound 
microenvironment, TGF3 has opposite effects to TGF1 and TGF2 and 
promotes scar-free wound resolution, whereas TGF1 and TGF2 both cause 
scar formation  (10). Since many of the same cellular players are present in the 
wound microenvironment and the tumour microenvironment, I predicted that 
TGF3 would have different effects than TGF1 in TGFsignal transduction in 
cancer cells.  
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 In Chapter 5 I evaluated the signalling ability of TGF1 and TGF3 in 
A549 cells. In this chapter, I illustrated that TGF1 was a much more potent 
inducer of TGFsignal transduction than TGF3 and increased both Smad2 
phosphorylation and EMT to a greater extent than TGF3. Initially, I predicted 
that this difference in signal transduction would be due to an alteration of 
TGFreceptor partitioning and membrane trafficking, as was the case for my 
other studies. However, I found that both ligand treatments induced similar 
membrane-raft partitioning and trafficking of the receptor complex. Interestingly I 
did observe differences in cell-surface receptor complex formation with TGF3 
treatment compared to TGF1 treatment (Figure 6.3). I found that TGF3 
induced fewer TRI bound to TRII than TGF1 treatment. The generally 
accepted model of TGFcomplex formation is that at the cell surface TRII and 
TRI form a hetero-oligomeric complex composed of two TRII and two TRI  
(11). As TRI phosphorylates the downstream Smad transcription factors, having 
less TRI associated with TRII may cause less activated TRI available for 
activating the Smad pathway.  
6.2 Limitations and Future Studies 
 It is important to note that all of the studies performed in this thesis used 
immortalized cultured cell lines and purified ligands. The majority of my work is 
heavily mechanism-based and assesses TGFsignal transduction pathways. 
Using cell culture models that have been established for TGFsignalling assays 
allowed me to carry out my work in a simplified and well-characterized system.  
Figure 6.3 TGFligands cause altered TGFreceptor complex formation 
In Chapter 5 of my thesis I evaluated the role of TGF1 and TGF3 to induce Smad 
signal transduction in a non-small cell lung cancer cell line. I found that TGF3 induces 
less Smad-signal transduction than TGF1 and alters cell-surface TGFreceptor 
complex formation.   
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Furthermore, using these established cell lines where receptor levels and 
TGFsignalling capacity had been established allowed me to manipulate 
different protein-interactions to assess the effects on trafficking and signal 
transduction.  
In all of my data chapters I used HEK293T cells to assess TGFreceptor 
interactions and membrane raft partitioning. These cells are an ideal model 
system for this type of work, as HEK293T cells do not express high levels of 
endogenous TGF receptors and also have a high level of membrane raft 
content (1). This allowed me to assess receptor interactions in over-expression 
assays using tagged receptors for ease of detection. However, there are some 
issues regarding relying solely on over-expression studies to assess membrane 
raft partitioning. It is possible that the over-expression of a construct, such as 
TRIII may alter its distribution in the plasma membrane relative to endogenous 
levels of receptors. Ultimately, it would have been ideal to assess levels of 
endogenous TRIII in mediating the membrane partitioning of TRII/TRI 
complexes.  Unfortunately, there are few established antibodies available for the 
detection of endogenous TGFreceptors. Therefore, when possible, I attempted 
to evaluate endogenous TGFreceptors using 125I-TGFligand to bind 
receptors, as this method is highly sensitive and can allow for detection of 
receptors even in cell lines with low receptor levels. I used this method to detect 
endogenous levels of receptors in HepG2 cells in membrane raft partitioning 
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experiments in Chapter 3, and this method should be used to confirm membrane 
raft partitioning results in future studies.   
To confirm my membrane raft isolation experiments, I also used a well-
established cell line, Mv1Lu HAT cells, to evaluate receptor trafficking using 
immunofluorescence microscopy. This cell line is ideal for evaluating TRII 
trafficking, as it is stably transfected with a zinc-inducible HA-tagged TRII 
construct. These cells are also amenable to PEI transfection, which allowed me 
to evaluate the effects of TRIII and arrestin2 on TRII trafficking in Chapters 3 
and 4, respectively. While it would be ideal to assess the ability of endogenous 
receptors to traffic into different endosomal compartments, we do not currently 
have a sufficiently sensitive immunofluorescence approach to answer this 
question. 
Finally, to evaluate Smad-dependent transcription, I employed the use of 
luciferase assays under the control of a Smad-responsive promoter in HepG2 
cells in Chapters 3 and 4. HepG2 cells have been established for luciferase 
assays and are easily transfected using the calcium-phosphate precipitation 
method. Therefore, this approach allowed me to evaluate the role of different 
combinations of receptors and their interacting protein(s) on TGF-dependent 
transcription. When possible, I confirmed these results with signalling assays in 
non-small cell lung cancer cells, such as A549 and H1299 cells, which allowed 
me to assess the role of endogenous proteins on Smad-dependent and 
independent signal transduction.  
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Chapter 2 of this thesis provided evidence that the extracellular domain of 
TRII regulated the entrance of TRII into membrane raft fractions. Furthermore, 
it was shown that the glycosylation state of the cell as a whole, but not TRII 
itself, was involved in regulating its membrane partitioning. This suggests that 
there are cell-surface glycosylated TRII-interacting protein(s) which may direct 
the entrance of TRII into membrane rafts. I evaluated one of these candidate 
proteins, TRIII, in Chapter 3 of this thesis, but actually found that TRIII 
increased clathrin-dependent internalization of TRII, and not clathrin-
independent internalization, as was suggested in Chapter 2. This leads to the 
notion that there are likely other proteins directing TRII into membrane raft 
fractions.  One such protein is CD109, which is a glycoprotein with 17 potential 
N-linked glycosylation sites (12) and has been shown to enhance internalization 
of TGFreceptors into the caveolin-1 positive vesicle  (13). Future studies to 
identify other glycosylated cell-surface proteins directing TGFreceptor 
endocytosis may have important implications in TGFsignal capacity, and could 
potentially be performed by isolating membrane raft fractions, performing co-
immunoprecipitations to purify TRII and subjecting the immunoprecipitated 
proteins to mass spectroscopy to identify novel proteins.  
Though I initially thought that TRIII would promote clathin-independent 
internalization of TRII/TRI complexes, the finding that TRIII promotes clathrin-
dependent internalization of receptors has important implications in 
TGFreceptor biology. TRIII has been shown to be dysregulated in a number of 
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cancers (14-19), and the effect of its altered expression is similar to that of 
TGFsignalling as a whole: at times, loss of TRIII inhibits cancer progression 
and metastasis, while at other times it appears to increase tumorigenicity. While 
initially it could be thought that these discrepancies in the role of TRIII may be 
due to its role in ligand-presentation, my work suggests that the level of available 
TRIII may affect TGFsignal transduction through increasing the trafficking of 
the receptors to the early endosome and extending their half-life. Therefore, it 
would be interesting to evaluate the effect of knockdown of TRIII in cancer cell 
lines at different stages of tumorigenicity and evaluate the trafficking and receptor 
half-life of TRII. 
Chapter 4 of my thesis evaluated the role of arrestin2 in modulating 
TGFsignal transduction. While it had previously been shown that arrestin2 
could interact with TRIII, my work illustrating that arrestin2 can interact with 
TRII and affect Smad-dependent and Smad-independent signalling pathways 
suggests that it has a greater role than simply receptor internalization, as initially 
thought (8). I found it particularly interesting that arrestin2 caused such a 
marked increased in p38 phosphorylation resulting in apoptosis. It has been 
shown that Smad-independent pathways can have important effects in cancer 
progression such as through mediating EMT, cell survival and apoptosis 
(reviewed in (20)).Therefore, it would be interesting to see if loss of arrestin2 
could drive apoptosis in numerous cancer cell lines resistant to the growth-
inhibitory effects of TGF. Furthermore, it would be fascinating to evaluate the 
195 
 
 
 
role of arrestin2 in mediating metastasis of tumors in vivo. If loss of arrestin2 
was also able to induce apoptosis in vivo, this may represent a novel mechanism 
to disrupt TGF-dependent metastasis and tumor outgrowth.
Finally, in Chapter 5 of my thesis I attempted to assess the differences 
between TGF1 and TGF3 in TGFsignalling in a non-small cell lung cancer 
cell line, A549 cells. Overall, I showed that TGF3 was much less potent than 
TGF1 in inducing TGF-dependent signalling, especially in terms of EMT. Since 
EMT is a necessary step for epithelial-based tumors to escape the primary tumor 
site and metastasize, future studies should evaluate the role of TGF3 in cancer 
cell migration and invasion. Furthermore, it would be interesting to assess 
mechanistically how TGF3 induce less potent signalling even though both 
TGF1 and TGF3 bind to the same cell-surface receptors. Initial work in 
Chapter 5 of this thesis suggests that these ligands may induce different 
signalling capacities through TGFreceptor complex formation at the cell 
surface. However, as these ligands share 76% amino acid identity in their active 
forms (21), it may be important to identify differences in the amino acid sequence 
which could explain their differential ability to induce receptor complex formation. 
One important way in which these ligands differ is in terms of their post-
translational modifications. Upon comparison of the sequences of TGF1 and 
TGF3, it appears that TGF3 has a putative glycosylation site that is not found 
in TGF1. Therefore, manipulating the glycosylation state of TGF3 may affect 
its ability to bind to TRII and may change receptor complex formation. Overall, 
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the differences in the ability of TGF1 and TGF3 to induce signal transduction 
represent an exciting field of study applicable to numerous processes in addition 
to cancer, such as development and fibrotic conditions. 
6.3 Context of Findings in the Field of 
TGFSignalling Regulation 
 In this thesis I focus on the mechanisms whereby protein interactions with 
the TGF receptor complex can alter both membrane trafficking and signal 
transduction. However, there are many other mechanisms which regulate 
TGFsignal transduction.  
 For example, as suggested in the introduction, the bioavailability of 
TGFligand in the extracellular matrix may greatly regulate TGFsignalling. The 
latent TGFcomplex is composed of homodimeric TGF, latency associated 
peptides, and the latent TGFbinding protein (LTBP). Importantly, the LTBP is 
important for sequestering the TGFligand complex in the extracellular matrix 
and TGFin its latent form is unable to bind TGFreceptors (22).  Therefore, the 
ECM acts as a reservoir for latent TGF; however, TGFactivation can occur in 
several ways. For example, TGFcan be activated in vivo in low pH 
environments, such as in lacunae surrounding osteoclasts (23, 24). Furthermore, 
a number of proteases such as plasmin and thrombospondin can cleave latent 
TGFat the cell surface and at wound-healing sites, respectively (22). 
Interestingly, TRIII may regulate the bioavailability of active TGFthrough its 
ectodomain shedding. Soluble TRIII can be found naturally in serum and the 
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ECM and occurs as a protease cleavage of its extracellular, TGF-binding 
domain (25). It has been shown that soluble TRIII can bind and inhibit all three 
TGF ligands with relatively high affinity, but is best at binding and inhibiting the 
actions of TGF2 (25). The protease responsible for producing the soluble form 
of TRIII is still currently unknown (25). In chapter 3 of this thesis I examined the 
role of TRIII in regulating the trafficking and signalling of the TRII/TRI 
complex. In figure 3.11 I show that TRIII may increase the basal signalling of 
the TGFreceptor complex, but decreases Smad signalling in the presence of 
TGF1 ligand. One possible explanation for this finding is that the over-
expressed form of TRIII may be shed from the cell surface and therefore acting 
to sequester TGFligand from the TGFreceptor complex. Once the protease 
which is responsible for inducing the ectodomain shedding of TRIII is 
discovered, it will be possible to evaluate the potential for TRIII in negatively 
regulating TGFsignalling. 
 In many different receptor families, regulating the level of cell-surface 
receptors is an important mechanism for regulating signal transduction. Indeed, 
in the TGFreceptor family, this is also the case. For example, it has been 
shown that regulating the levels of endoglin can affect the ability of breast cancer 
cells to perform angiogenesis (26). Li and colleagues illustrated that decreasing 
the levels of endoglin in human vascular endothelial cells (HUVECs) inhibited in 
vitro angiogenesis and mAb to endoglin in a mouse model of breast cancer 
induced regression of breast cancer (26). Furthermore, the cell surface levels of 
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TGFreceptors can also be affected by glycosylation. It is thought that 
glycosylated receptors act as a network at the cell surface and delay 
internalization (27). It was shown that Mgat5, a Golgi enzyme involved in N-
glycan processing, sensitized cytokine receptors such as EGFR and 
TGFreceptors by keeping them at the cell surface (27). Indeed, loss of Mgat5 
decreased cytokine signalling and this effect could be rescued by treating with 
inhibitors of endocytosis (27). In chapter 4 of this thesis, I found that loss of 
arrestin2 expression appeared to increase steady-state levels of TRII at the 
cell-surface but did not appear to affect the half-life of the receptor. This increase 
in levels of receptor at the cell-surface may allow for the formation of more 
signalling complexes; however since receptor internalization is necessary for 
Smad signal transduction, this may preferentially activate Smad-independent 
pathways, such as the p38 pathway. 
 The main focus of this thesis was the role of receptor endocytosis on 
signal transduction. While the model that I propose in this thesis suggests that 
clathrin-mediated endocytosis enhances TGFsignalling and membrane-
raft/caveolae-dependent endocytosis decreases TGFsignalling, it is possible 
that membrane-rafts could function to compartmentalize other non-Smad 
signalling pathways. Zuo and Chen published an interesting article in which they 
illustrated that the membrane-raft localization of the TGF receptor complex was 
important for the activation of ERK and p38, but not Smad2/3 by TGF (28). 
Indeed, they illustrated that depleting cholesterol, which is an integral component 
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of membrane rafts, decreased TGF activation of ERK and p38 and also 
decreased the migration of HaCaT cells in response to TGF (28). Further 
supporting a role for caveolae in non-Smad signal transduction is a paper by 
Meyer et al. that showed that caveolae formation in hepatocytes was necessary 
for non-Smad mediated activation of the Akt pathway (29). In chapter 4 of this 
thesis, I found that decreasing levels of arrestin2 enhanced TGF-induced 
phosphorylation of p38. The mechanism of this enhanced phosphorylation could 
occur by several means. First of all, as I suggested in chapter 4, loss of 
arrestin2 also enhanced the levels of TRII at the cell surface which may 
increase the ability of the receptor complex to activate non-Smad signalling 
pathways. However, another possibility is that loss of arrestin2 may shift 
endogenous TRII into membrane raft fractions, which can then activate p38 
signalling as suggested by Zuo and Chen (28). While I found that over-
expressing arrestin2 did not further shift TRII into non-membrane raft fractions, 
it is essential to evaluate endogenous receptors and arrestin2 to completely 
discount the role of arrestin2 in membrane raft partitioning.  
  
6.4  Significance of Findings and Conclusion 
 In this thesis I provide evidence that TGFreceptor internalization and 
trafficking can have direct effects on TGF-dependent signalling. I have identified 
regions of TRII that are important in mediating its trafficking, as well as both 
cytoplasmic and extracellular interacting-proteins which direct TGFreceptor 
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trafficking. Furthermore, I have illustrated that the roles of TGFtrafficking in 
mediating signalling output are not limited to Smad-dependent pathways, as the 
Smad-independent p38 pathway is also affected by changes in TGFreceptor 
trafficking. 
 The TGFsignalling pathway is important in normal physiological 
conditions, such as development and cell differentiation, and pathological 
conditions such as cancer and fibrosis. As I have demonstrated that the 
trafficking of the receptors, and proteins which direct this trafficking, have 
implications in TGFsignal transduction, my work has implications in a number 
of fields. There is also support in the literature that perturbations in 
TGFreceptor trafficking can influence disease states such as cancer and 
fibrosis. For example, it has recently been shown that a mutation in TRII which 
disrupts its endocytosis promotes cancer cell migration and invasion in an oral 
squamous cell carcinoma (30). Similarly, in fibrotic conditions, such as systemic 
sclerosis which also show enhanced TGFsignalling, perturbations in 
TGFendocytosis have also been demonstrated. Patients with systemic 
sclerosis have decreased caveolin-1 expression in their lungs and studies have 
shown that decreased caveolin-1 expression increases collagen production (31). 
Therefore, identifying factors which promote and control TGFendocytosis will 
have significant effects in disease states in which TGFsignal transduction is 
deregulated.  
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